2026. Prchal, V. and Smythies, J. R., Temporal-lobe epilepsy presenting as fugue state, Lancet, 1034, 1977.

2027. Pull, I. and McIlwain, H., Centrally-acting drugs and related compounds examined for action on output of adenine derivatives from superfused tissues of the brain, Biochem. Pharmacol., 25: 293-7, 1976.

2028. Pulsinelli, W. A. and Rottenberg, D. A., Painful tic convulsif, J. Neurol. Neurosurg. Psychiatry, 40(2): 192-5, 1977.

2029. Racy, A., Osborn, M. A., Vern, B. A. and Molinari, G. F., Epileptic aphasia, Arch. Neurol., 37: 419-22, 1980.

2030. Raines, A., Phenytoin revisited, Epilepsia, 18(3): 297-8, 1977.

2031. Raines, A., Cohan, S. L., Panagakos, J. and Armitage, P., Utility of chlorpromazine (CPZ) and phenytoin (pH) in spasticity, Pharmacologist, 21(3): 183, 1979.

2032. Raines, A. and Niner, J. M., Blockade of a sympathetic nervous system reflex by diphenylhydantoin, Neuropharmacology, 14: 61-66, 1975.

2033. Ramsay, R. E., Wilder, B. J., Willmore, L. J. and Perchalski, R. J., Central nervous system penetration of anticonvulsant drugs, Abstract of Amer. Epilepsy Soc. Ann. Meeting, 1976.

2034. Rapport, R. L. and Ojemann, G. A., Prophylactically administered phenytoin, Arch. Neurol., 32(8): 539-48, 1975.

2035. Rapport, R. L. and Penry, J. K., A survey of attitudes toward the pharmacological prophylaxis of posttraumatic epilepsy, J. Neurosurg., 38: 159-166, 1973.

2036. Raskin, N. H. and Fishman, R. A., Neurologic disorders in renal failure, New England Journal of Medicine, 294(3): 143-8, 1976.

2037. Rau, J. H. and Green, R. S., Compulsive eating: a neuropsychologic approach to certain eating disorders, Compr. Psychiat., 16: 223-31, 1975.

2038. Rau, J. H. and Green, R. S., Soft neurological correlates of compulsive eaters, J. Nerv. Ment. Dis., 166(6): 435-7, 1978.

2039. Ravindran, M., Focal cerebral dysrhythmia-presenting as headache: report of a case, Clin. Electroencephalogr., 9(l): 29-31,1978.

2040. Reeback, J., Benton, S., Swash, M. and Schwartz, M. S., Penicillamine-induced neuromyotonia, Br. Med. J., 1464-5, 1979.

2041. Reidenberg, M. M., Drug metabolism in uremia, Clin. Nephrot., 4(3): 83-5, 1975.

2042. Reith, H., Availability of phenytoin infusion concentrate, Drug Intell. Clin. Pharm, 13(12): 783, 1979.

2043. Reynolds, E. H., Chronic antiepileptic toxicity: a review, Epilepsia, 16: 319-52, 1975.

2044. Reynolds, F., Ziroyanis, P. M., Jones, N. F. and Smith, S. E., Salivary phenytoin concentrations in epilepsy and in chronic renal failure, Lancet, 384-6, 1976.

2045. Richelson, E. and Tuttle, J. B., Diphenylhydantoin inhibits ionic excitation of mouse neuroblastoma cells, Brain Res., 99:209-12, 1975.

2046. Riddle, T. G., Mandel, L. J., Goldner, M. M., Dilantincalcium interaction and active Na transport in frog skin, Europ. J. Pharmacol., 33: 189-92, 1975.

2047. Riley, T. L. and Massey, E. W., The syndrome of aphasia, headaches, and left temporal spikes, Headache, 20(2): 90-2, 1980.

2048. Roberts, J. and Goldberg, P. B., Changes in responsiveness of the heart to drugs during aging, Fed. Proc., 38(5): 1927-32,1979.

2049. Robertson, S., Gibbs, M. E. and Ng, K. T., Sodium pump activity, amino acid transport and long-term memory, Brain Res. Bull., 3(l): 53-8, 1978.

2050. Rogers, H. J., Hasiam, R. A., Longstreth, J. and Lietman, P. S., Phenytoin intoxication during concurrent diazepam therapy, J. Neurol. Neurosurg. Psychiatry, 40: 890-5, 1977.

2051. Rootwelt, K., Ganes, T. and Johannessen, S. I., Effect of carbamazepine, phenytoin and phenobarbitone on serum levels of thyroid hormones and thyrotropin in humans, Scand. Clin. Lab. Invest., 38: 731-6, 1978.

2052. Rose, J. Q., Choi, H. K., Schentag, J. J., Krinkel, W. R. and jusko, W. J., Intoxication caused by interaction of chloramphenicol and phenytoin, JAMA, 237(24): 2630-1, 1977.

2053. Rose, M. and Johnson, I., Reinterpretation of the haematological effects of anticonvulsant treatment, Lancet, 1349-50, 1978.

2054. Rosen, M., Danilo, P., Alonso, M. and Pippenger, C., Effects of diphenylhydantoin on the electrophysiologic properties of blood-superfused Purkinje fibers, Fed. Proc., 34: 755 (Abstr. 3154), March 1975.

2055. Rosen, M. R., Danilo, P., Alonso, M. and Pippenger, C. E., Effects of therapeutic concentrations of diphenylhydantoin on transmembrane potentials of normal and depressed Purkinje fibers, J. Pharmacol. Exp. Ther., 197(3): 594-604, 1976.

2056. Rosenblatt, S., Schaeffer, D. and Rosenthal, J. S., Effects of diphenylhydantoin on child-abusing parents, Curr. Ther. Res., 19(3): 332-6, 1976.

2057. Roses, A. D., Butterfield, D. A., Appel, S. H. and Chestnut, D. B., Phenytoin and membrane fluidity in myotonic dystrophy, Arch. Neurol., 32 (8): 535-38, 1975.

2058. Rotmensch, H. H., Graff, E., Ayzenberg, O., Amir, C. and Laniado, S., Self-poisoning with digitalis glycosides-successful treatment of three cases, Israel J. Med. Sci., 13: 1109-13, 1977.

2059. Rowell, F. J. and Paxton, J. W., Conformational and chemical requirements for antibody recognition of diphenylhydantoin derivatives, Immunochen., 13: 891-4, 1976.

2060. Runge, M. and Rehpenning, W., Behaviour of salivary electrolytes potassium and calcium in digitalized patients after administration of diphenylhydantoin, Arzneim-Forsch, 24(10): 1696-9, 1974.

2061. Ruskin,]. N., Garan, H., Silver, T. S. and Powell, W. J., CNS-mediated effect of phenytoin in delaying the onset of digoxin-induced ventricular arrhythmias, Clin. Res., 26(3): 267, April 1975.

2062. Saad, S. F., Osman, 0. H., Mustafa, A. and Hussein, K. E., Possible involvement of gamma-aminobutyric acid in morphine abstinence in rats, IRCS Med. Sci., 5(7): 317, 1977.

2063. Sabai, Y., Kobayashi, K. and Iwata, M., Effects of an anabolic steroid and vitamin B complex upon myopathy induced by corticosteroids, Eur. J. Pharmacol., 52: 353-9, 1978.

2064. Sansom, L. N., O’Reilly, W. J., Wiseman, C. W., et al., Plasma phenytoin levels produced by various phenytoin preparations, Epilepsy Abstracts, 97: 249, 1976.

2065. Sastry, B. S. R. and Phillis, J. W., Antagonism of glutamate and acetylcholine excitation of rat cerebral cortical neurones by diphenylhydantoin, Gen. Pharmac., 7: 411-13, 1976.

2066. Sawaya, M. C. B., Horton, R. W. and Meldrum, B. S., Effects of anticonvulsant drugs on the cerebral enzymes metabolizing GABA, Epilepsia, 16: 649-55, 1975.

2067. Schlosser, W., Franco, S. and Sigg, E. B., Differential attenuation of somatovisceral and viscerosomatic reflexes by diazepam, phenobarbital and diphenylhydantoin, Neuropharmacol., 14: 525-31, 1975,

2068. Schmitz, I., janzik, H. H. and Mayer, K., The personality structure and sexual behavior of patients with epilepsy on long-term therapy with diphenylhydantoin, Epilepsia, 16: 412-3, 1975.

2069. Schneider, R. R., Bahler, A., Pincus, J. and Stimmel, B., Asymptomatic idiopathic syndrome of prolonged Q-T interval in a 45-year-old woman, Chest, 71: 210-3, 1977.

2070. Schwartz, P. A., Rhodes, C. T. and Cooper, J. W., Solubility and ionization characteristics of phenytoin, J. Pharm. Sci., 66(7): 994-7, 1977.

2071. Schwartz, P. J., Periti, M. and Malliani, A., The long Q-T syndrome, Am. Heart J., 89(3): 378-90, 1975.

2072. Schwarz, J. R. and Vogel, W., Diphenylhydantoin: excitability reducing action in single myelinated nerve fibres, Eur. J. Pharmacol., 44: 241-9, 1977.

2073. Selzer, M. E., The action of phenytoin on a composite electrical-chemical synapse in the lamprey spinal cord, Ann. Neurol., 3(3): 202-6, 1978.

2074. Selzer, M. E., The effect of phenytoin on the action potential of a vertebrate spinal neuron, Brain Research, 171: 511-21,1979.

2075. Selzer, M. E., Phenytoin blocks post-tetanic potentiation at a vertebrate CNS synapse, Trans. Am. Neurolqical Assoc., 102: 118-20, 1977.

2076. Shah, U. H., Jindal, M. N. anci Patel, V. K., Beta-adre noceptor blockade with diphenyihydantoin (DPH), Arzneim Forsch, 27: 2316-8, 1977.

2077. Shealy, C. N., Drug use in a pain rehabilitation center, Am. J. Hosp. Pharm., 32: 1083, 1975.

2078. Sherwin, A. L., Harvey, C. D., Leppik, I. E. and Gonda, A., Correlation between red cell and free plasma phenytoin levels in renal disease, Neurol., 26: 874-8, 1976.

2079. Sheth, K. J. and Bernhard, G. C., The arthropathy of Fabry disease, Arthritis Rheum., 22(7): 781-3, 1979.

2080. Shintomi, K., Effects of psychotropic drugs on meth amphetamine-induced behavioral excitation in grouped mice, Europ. J. Pharmacol., 31: 195-206, 1975.

2081. Silverman, H., Atwood, H. L. and Bloom, J. W., Phe nytoin application in murine muscular dystrophy; behavioral improvement with no change in the abnormal intracellular Na : K ratio in skeletal muscles, Exp. Neurol., 62: 618-27, 1978.

2082. Singh, B. N., Gaarder, T. D., Kanegae, T., Goldstein, M., Montgomerie, J. Z. and Mills, H., Liquid protein diets and torsade de pointes, JAMA, 240(2): 115-9, 1978.

2083. Sirohiya, M. K., Bhatnagar, H. N. S., Shah, D. R. and Narang, N. K., Phenytoin sodium in cardiac arrhythrnias, J. Indian Med. Assoc., 64(12): 329-34, 1975.

2084. Smith, I. M. and Burmeister, L. F., Biochemically assisted antibiotic treatment of lethal murine staphylococcus aureus septic shock, Am. J. Clin. Nutr., 30: 1364-8, 1977.

2085. Sneer, A., Colev, V., Dughir, E. and Sneer, I., The pro tective effect of diphenylhydantoin on the diabetogenic action of alloxan, Epilepsy Abstracts, 12(9): 421, 1979.

2086. Snider, S. R. and Snider, R. S., Phenytoin and cerebellar lesions: similar effects on cerebellar catecholamine metabolism, Arch. Neurol., 34: 162-7, 1977.

2087. Sohn, R. S. and Ferrendelli, J. A., Anticonvulsant drug mechanisms, phenytoin, phenobarbital, and ethosuximide and calcium flux in isolated presynaptic endings, Arch. Neurol, 33: 626-9,1976.

2088. Somerman, M. J., Au, W. Y. W. and Rifkin, B. R., Phenytoin inhibition of bone resorption in organ culture, J. Dent. Res., 56 (Special Issue B) Abstr. 579, 1977.

2089. Sordillo, P., Sagransky, D. M., Mercado, R. and Michelis, M. F., Carbamazepine-induced syndrome of inappropriate antidiuretic hormone secretion--reversal by concomitant phenytoin therapy, Arch. Intern. Med., 138: 299-301, 1978.

2090. Starkova, N. T., Marova, E. I., Lemesheva, S. N., Goncharova, V. N., Atamanova, T. M. and Sedykh, L. P., The effect of diphenin on functional condition of the adrenal cortex in patients with Itsenko-Cushing disease, Problemy Endokrinologii, 18: 35-8, Nov/Dec, 1972.

2091. Stavchansky, S. A., Tilbury, R. S., McDonald, J. M., Ting, C. T. and Kostenbauder, H. B., In thvo distribution of carbon II phenytoin and its major metabolite, and their use in scintigraphic imaging, J. Nucl. Med., 19(8): 936-41, 1978.

2092. St. Louis, E. L., McLoughlin, M. J. and Wortzman, Chronic damage to medium and large arteries following irradiation, J. Canad. Assoc. Radiol., 25: 94-104, 1974.

2093. Study, R. E., Phenytoin inhibition of cyclic guanosine 3 2:5 2-monophosphate (cGMP) accumulation in neuroblastoma cells by calcium channel blockade, J. Pharmacol. Exp. Ther., 215(3): 575-81, 1980.

2094. Suratt, P. M., Crampton, R. S. and Carpenter, M. A., Benign familial biventricular dysrhythmias with syncope limited to late childhood, adolescence and early youth, Circulation, 48 (Suppl. IV): 222, 1973.

2095. Swann, W. P., Swenson, H. M. and Shafer, W. G., Effects of Dilantin on the repair of gingival wounds, J. Periodont., 46(5): 302-5, 1975.

2096. Swanson, J. W. and Vick, N. A., Basilar artery migraine, Neurology, 28: 782-6, 1978.

2097. Swerdlow, M., The treatment of ‘shooting’ pain, Postgrad. Med. J., 56: 159-61, 1980.

2098. Swanson, P. D. and Crane, P. O., Diphenylhydantoin and movement of radioactive sodium into electrically stimulated cerebral slices. Biochem. Pharmcol., 21: 2899-905, 1972.

2099. Swift, T. R., Gross, J. A., Ward, L. C. and Flicek, B. O., Electrophysiologic study of patients receiving anticonvulsant drugs, Neurology, 29: 581, 1979.

2100. Szyper, M. S. and Mann, J. D., Anorexia nervosa as an interictal symptom of partial complex seizures, Neurology, 28(4): 335, 1978.

2101. Tanay, A., Yust, I., Peresecenschi, G., Abramov, A. L. and Avriam, A., Long-term treatment of the syndrome of inappropriate antidiuretic hormone secretion with phenytoin, Ann. Intern. Med., 90: 50-2, 1979.

2102. Taylor, P. H., Gray, K., Bicknell, P. G. and Rees, J. R., Glossopharyngeal neuralgia with syncope, J. Laryngol. Otol., 9 1: 859-68,1977.

2103. Thampi, N. S., Mader, M. M. and Earley, R. J., Effect of diphenythydantoin on levels of cyclic AMP and cyclic GMP in rat brain synaptasomes, Pharmacologist, 16: Abstr. 551, Fall, 1974.

2104. Tuttle, J. B., Intracellular recordings from a clonal, tis sue-cultured neuron: bioelectric differentiation of anti-metabo lite survivors and the action of diphenylhydantoin, Dissertation Abstracts International, Section B,38: 9 1 B-92B, 1977.

2105. Tuttle, J. B. and Richelson, E., Phenytoin action on the excitable membrane of mouse neuroblastoma, J. Pharmacol. Exp. Ther., 2(3): 632-7, 1979.

2106. Tyler, G. S., McNeely, H. E. and Dick, M. L., Vascular headache treatment update, Arizona Med., 36: 117-8, 1979.

2107. Vernillo, A. T. and Schwartz, N. B., Collagen and proteoglycan synthesis in 5,5 diphenylhydantoin (Dilantin) treated chondrocytes, J. Cell. Biol., 83(pt. 2): 116a, 1979.

2108. Vincent, T. S., When to use Dilantin in alcoholism, Resident and Staff Physician, 22: 50-1, 1976.

2109. von Albert, H. H., Treatment of acute trigeminal neuralgia with intravenous infusions of phenytoin, Munch. Med. Wsch., 120(15): 529-30, 1978.

2110. Wadell, M. C. and Chambers, D. A., Effect of diphe nylhydantoin on the cell cycle of a serum free mouse symphocyte system, Fed. Proc., 35(3): 749, March, 1976.

2111. Waller, D. A., Paroxysmal kinesigenic choreoathetosis or hysteria? Am. J. Psychiat., 134(12): 1439-40, 1977,

2112. Walson, P., Trinca, C. and Bressler, R., New uses for phenytoin, JAMA, 233(13): 1385-9, 1975.

2113. Walton, J. N., Muscular dystrophies and their manage ment, Br. Med. J., 3(671): 639-42, 1969.

2114. Wasserman, T. H., Phillips, T. L., Van Raalte, G., Urtasun, R., Partington, J., Koziol, D., Schwade, J. G., Gangji, D. and Strong, J. M., The neurotoxicity of misonidazole: potential modifying role by phenytoin sodium and dexamethasone, Br. J. Radiol., 53: 172-3, 1980.

2115. Weinberger, J., Nicklas, W. J. and Berl, S., Mechanism of action of anticonvulsants, Neurology 26: 162-166, 1976.

2116. Weiss, T. and Levitz, L., Diphenylhydantoin treatment of bulimia, Am. J. Psychiat., 133(9): 1093, 1976.

2117. Wermuth, B. M., Davis, L. K., Hollister, L. E. and Stunkard, A. J., Phenytoin treatment of the binge-eating syndrome, Am. J. Psychiat., 134(11): 1249-53, 1977.

2118. Wilson, J. T., Huff, J. G. and Kilroy, A. W., Brief clinical and laboratory observations, J. Pediatr., 95(l): 135-8, 1979.

2119. White, R. A. S. and Workman, P., Phenytoin sodium induced alterations in the pharmacokinctics of misonidazole in the dog, Cancer Treat. Rep., 64: 360-1, 1980.

2120. Wit, A. L., Rosen, M. R. and Hoffman, B. F., Electro physiology and pharmacology of cardiac arrhythmias, VIII. Car diac effects of diphenylhydantoin Part A., Am. Heart J., 90(3): 265-72,1975.

2121. Wit, A. L., Rosen, M. R. and Hoffman, B. F., Electro physiology and pharmacology of cardiac arrhythmias. VI II. Car diac effects of diphenylhydantoin Part B., Am. Heart J., 90(3): 397-404,1975.

2122. Wohns, R. N. W. and Wyler, A. R., Prophylactic phenytoin in severe head injuries, J. Neurosurg., 51: 507-8, 1979.

2123. Wolfe, G. W. and Schnell, R. C., Protection against al loxan-induced alterations in hepatic drug metabolism and plasma glucose levels in the male rat, Toxicol. App. Pharmacol., 48(Pt 2): A69, 1979.

2124. Wolter, M. and Brauer, D., Neuromyotonia syndrome, Foruchr. Neurol. Psychial., 45: 98-105, 1977.

2125. Woo, E. and Greenblatt, D. J., Choosing the right phenytoin dosage, Drug Therapy (Hospital Edition), 2: 35-41, Oct. 1977.

2126. Woodbury, D. M., Phenytoin: introduction and history, Antiepileptic Drugs: Mechanisim of Action, 305-13, Glaser, G. H., Penry, J. K. and Woodbury, D. M., Eds., Raven Press, New York, 1980.

2127. Woodbury, D. M., Phenytoin: Proposed mechanisms of anticonvulsant action, Antiepileptic Drugs: Mechanisms of Action, 447-7 1, Glaser, G. H., Penry, J. K. and Woodbury, D. M., Eds., Raven Press, New York, 1980.

2128. Workman, P., Effects of pretreatment with phenobarbitone and phenytoin on the pharmacokinetics and toxicity of misonidazole in mice, Br. J. Cancer, 40; 335-53, 1979.

2129. Workman, P., Bleehen, N. M. and Wiltshire, C. R., Phenytoin shortens the half-life of the hypoxic cell radiosensitizer misonidazole in man: implications for possible reduced toxicity, Br. J. Cancer, 41: 302-4, 1980.

2130. Yaari, Y., Pincus, J. H., Argov, Z., Phenytoin and transmitter release at the neuromuscular junction of the frog, Brain Res., 160: 479-87, 1979.

2131. Yaari, Y., Rahamimoff, H. and Pincus, J. H., Action of diphenylhydantoin at the frog neuromuscular junction, Israel J. Med. Sci., 12(2): 171-2, 1976.

2132. York, G. K., Gabor, A. J. and Dreyfus, P. M., Paroxysmal genital pain: an unusual manifestation of epilepsy,Neurology, 29: 516-9, 1979.

2133. Yeh, J. Z., Quandt, F. N. and Kirsch, G. E., Comparative studies of phenytoin action on ionic channels in excitable membranes, Fed. Proc., 40(3): 240, 1981.

2134. Young, B., Rapp, R., Brooks, W. H., Madauss, W. and Norton, J. A., Posttraumatic epilepsy prophylaxis, Epilepsia, 20: 671-81,1979.

2135. Young, R. F., Facial pain, The Practitioner, 219: 731-7, 1977.

2136. Zapadnyuk, V. I., Zaika, M. U., The therapeutic efficacy of diphenine, Klin. Med., 1: 128-31, 1975.

2137. Zenteno Vacheron, J. S., Carrasco Zanini, J. and Ramos Ramirez, R., Paroxysmal dystonic choreoathetosis. A form of reflex epilepsy (two sporadic cases), Epilepsy Abstracts, 10(3): 84, 1977.

2138. Zhiping, Q., Chuanzhen, L., Iiyun, Y., Hanbai, C. and Yue, D., Limb-pain epilepsyè:è:report of  9 cases, Chin. Med. J. 93(4): 265-8, 1980.

2139. Ziegler, B., Hahn, H. J., Ziegler, M. and Fiedler, H., Successful cultivation of isolated islets of Langerhans without attachment: relationship between glucose and theophylline-induced insulin release and insulin content in rat islets after cultivation, Endocrinologie, 69(l): 103-11, 1977.

2140. Zweibel, P. C., Insulinoma: review of seven cases at the Mount Sinai Hospital in light of the current literature, Mount Sinai J. Med., 43(5): 637-56, 1976.

2141. Adams, H.P., Diphenylhydantoin in the treatment of alcohol withdrawal, JAMA, 218(4): 598, 1971.

2142. Aldrete, J. A., Romo Salas, F., Mazzia, V. D. B. and Tan, S.L., Phenytoin for brain resuscitation after cardiac arrest, Critical Care Medicine, 9(6): 474-7, 1981.

2143. Almotrefi, A. A. and Baker, J. B. E., Investigation of the antifibrillatory activity of some anticonvulsant -y-aminobutyric acid-transarninase inhibitors in the rabbit isolated heart: comparison with phenytoin and mexiletine, Br. J. Pharynac., 71(2): 635-9,1980.

2144. Artru, A. A. and Michenfelder, J. D., Anoxic cerebral Potassium accumulation reduced by phenytoin: mechanism of cerebral protection?, Anesth. Analg., 60: 41-5,1981.

2145. Artru, A .A. and Michenfelder, J. D., Influence of hypothermia or hyperthermia alone or in combination.with pentobarbital and phenytoin on survival time in hypoxic mice, Anesth. Analg., 60: 867-70,1981.

2146. Ashizawa, T., Butler, Ij., Harati, Y. and Marshall, R.N. Autosomat dominant form of continuous motor neuron dis charge, Neurology, 31(2): 59, 1981.

2147. Askanas, V., Engel, W.K., Berginer, V.M., Odenwald, W.F. and Galdi, A., Lysosomal abnormalities in cultured Schwann cells from a patient with peripheral neuropathy and continuous muscle fiber activity, Ann. Neurol., 10: 238-42, 1981.

2148. Austin, G., Ed., The Spinal Cord: Basic Aspects and Consideration, Charles C. Thomas, Illinois, 1972.

2149. AvRuskin, T.W., Tio, S.L. and Juan, C.S., Modulating effects of acute and chronic Dilantin administration on the hyperglucagonemia of type-1 diabetes mellitus, Clin. Res., 27(4): 625A, 1979.

2150. Bashour, F.A., ]ones, E. and Edmonson, R., Cardiac arrhythmias in acute myocardial infarction: 11. Incidence of the common arrhythmias with special reference to ventricular tachycardia, Dis. Chest, 51: 520-9, 1967.

2151. Bashour, F.A., Lehmann, J. and Prati, R., Prophylactic use of Dilantin in acute myocardial infarction, J. Lab. Clin. Med., 70(5): 893,1967.

2152. Baskin, S.I. and Finney, C.M., The Effects of Taurine on Excitable Tissues, 405-18, Spectrum Publications, 1981. 

2153. Bauer, E.A. and Cooper, T.W., Therapeutic considerations in recessive dystrophic epidermolysis bullosa, Arch. Dermatol., 117: 529, 1981.

2154. Behrens, J.M., Postmotor status epilepticus masking as a stroke, Postgrad. Med., 68(5): 223-6,1980.

2155. Bergenholtz, A. and Hanstrom, L., The effect of diphenythydantoin upon the biosynthesis and degradation of collagen in cat palatal mucosa in organ culture, Biochem. Pharmacol., 28:2653-9, 1979.

2156. Blank, H., Treatment of pachyonychia congenita with phenytoin, Br. J. Dermatol., 106(l): 123, 1982.

2157. Bremer, A. M., Yamada, K. and West, C. R., Ischemic cerebral edema in primates: effects of acetazolamide, phenytoin, sorbitol, dexamethasone, and methylprednisolone on brain water and electrolytes, Neurosurgery, 6(2): 149-54, 1980.

2158. Bücking, P.H. and Regli, F., The short periodicity of paroxysmal complex waves in electroencephalographic and clinical course of Creutzfeldt-Jakob disease, Z. EEG-EMG., 10: 80-7, 1979.

2159. Cadnapaphornchai, P., Ponies, C. and McDonald, F.D., Mechanism of effect of phenytoin sodium on renin release, Fed. Proc., 41(4): 1232, 1982.

2160. Cahill, D.W., Knipp, H. and Mosser J., Intracranial hemorrhage with amphetamine abuse, Neurology, 31: 1058-9, 1981.

2161. Chase, T.N., Katz, R.I. and Kopin, I. J., Effect of anticonvulsants on brain serotonin, Trans. Am. Neurol. Assoc., 94: 236-8, 1969.

2162. Check, W.A., ‘A remarkable medicine’ raises HDL levels, JAMA, 247(12): 1686-7, 1982.

2163. Chung, D.C., Anaesthetic problems associated with the treatment of cardiovascular disease: I. Digitalis toxicity, Can. Anaesth. Soc. J., 28(l): 6-16, 1981.

2164. Cisson, C.M., Entrikin, R.K. and Wilson, B.W., Actions of phenytoin on AChE synthesis in cultured chick embryo muscle treated with paraoxon, Soc. Neurosci. Abstr., 310: 986, 1977.

2165. Cisson, C.M., Entrikin, R.K. and Wilson, B.W., Effects of phenytoin on acetylcholinesterase activity and cell protein in cultured chick embryonic skeletal muscle, Can. J. Physiol. Pharmacol., 56(2): 287-93,1978.

2166. Clark, R.W. and Malarkey, W.B., Seizures and sleep-associated ventilatory dysfunction findings and treatment in 18 cases, Neurology, 31(2): 113, 1981.

2167. Craviso, G.L. and Musacchio, J.M., Penytoin (diphenylhydantoin) enhances the binding of dextromethorphan to guinea pig brain, Fed. Proc., 40(3): 324, 1981.

2168. Delini-Stula, A., Radeke, E., Schlicht, G. and Hedwall, P.R., Detection of CNS-depressant properties of antihypertensives: validity of various methods in rodents and estimation of therapeutic margin in hypertensive rats, Pharmac. Ther., 5: 43144, 1979.

2169. DeLorenzo, R. J., Emple, G. P., and Glaser, G. H., Regulation of the level of endogenous phosphorylation of specific brain proteins by diphenylhydantoin,J. Neurochem., 28: 21-30,1977.

2170. DeSousa, R.C. and Grosso, A., Interactions of diphenylhydantoin with norepinephrine, theophylline and cyclic AMP in frog skin, Experientia, 29: 748-9, 1973.

2171. Deupree, J.D., The role or non-role of ATPase activation by phenytoin in the stabilization of excitable membranes, Epilepsia, 18(3): 309-15, 1977.

2172. Dinner, D.S., Lueders, H., Lederman, R. and Gretter, T.E., Aphasic status epilepticus: a case report, Neurology 31: 888-91, 1981.

2173. Donoff, R.B., The effect of diphenylhydantoin on open wound healingin guinea pigs, J. Surg. Res., 24: 41-4,1978.

2174. Dtachman, D.A. and Kapen, S., Sleep disturbance, JAMA, 246(2): 163-4, 1981.

2175. Dungan, W.T., Garson, Jr., A. and Gillette, P.C., Arrhythmogenic right ventricular dysplasia: a cause of ventricular tachycardia in children with apparently normal hearts, Am. Heart J., 745-50,1981.

2176. Eisenberg, M., Williams, J.F., Stevens, L. and Schofield, P.J., Mammalian collagenase and peptidase estimation in normal skin and in the skin of patients suffering from epidermolysis bullosa, IRCS, 2: 1732, 1974.

2177. Emerson, G. A., Drug prophylaxis against lethal effects of severe anoxia: VI. Neostigmine bromide and diphenylhydantoin, Proc. Soc. Exp. Biol. Med., 54: 252-4, 1943.

2178. Entrikin, R. K. and Bryant, S. H., Membrane electrical effects of phenytoin on skeletal muscle of dystrophic chickens, Epilepsy Abstracts, 11(7): 277, 1978.

2179. Entrikin, R. K. and Bryant, S. H., Suppression of myotonia in dystrophic chicken muscle by phenytoin, Am. J. Physiol., 237(3): C13-6,1979.

2180. Entrikin, R. K., Patterson, G. T. and Wilson, B. W., Phenytoin, methysergide, and penicillamine in hereditary muscular dystrophy of the chicken, Exper. Neurol., 72: 82-90,1981.

2181. Ferro, J.M. and Castro-Caidas, A., Palatal myoclonus and carbamazepine, Ann. Neurol., 10(4): 402, 1981.

2182. Finer, M.J., Diphenylhydantoin for treatment of alcohol withdrawal syndromes, JAMA, 215(1): 119, 1971.

2183. Flacke, W., Mulke, G. and Schulz, R., Contribution to the effect of drugs on negative-pressure tolerance, Arch. Exper. Path. u. Pharmakol., 220: 469-76,1953.

2184. Fleckman, A., Erlichman, J., Schubart, U.K. and Fleischer, N., Effect of trifluoperazine, D600, and phenytoin on depolarization and thyrotropin-releasing hormone-induced thyrotropin release from rat pituitary tissue, Endocrinology, 108: 2072-7,1981.

2185. Flick, M. F., Hoeffel, J. and Webster, R. O., Phenytoin attenuates increased lung microvascular permeability in sheep, Fed. Proc., 41(5): 1500, 1982.

2186. Foley, K.M. and Rogers, A., The Rational Use of analgesics in the Managevwnt of Cancer Painè:Vol. II, Roche Laboratories, Nutley, NJ, 1981.

2187. Frank-Piskor!;ka, A., Bogoniowgka, Z., Baranska, H. and Donicowa, K., Insulin secretion in obese patients treated with diphenylhydantoin (DPH), Pol. Tyg. Lek., 33(2): 41-3, 1978.

2188. Epilepsy drug decreases blistering due to a genetic disease, NIH Research Resources Reporter, V(l 2): 1981.

2189. Friis, M.L., Broeng-Nielson, B., Sindrup, E.H., Lund, M., Fogh-Anderson, P. and Hauge, M., Facial clefts among epileptic patients, Arch. Neurol., 38: 227-9, 1981.

2190. Fromm, G.H., Terrence, C.F., Chattha, A.S. and Glass, J.D., Baclofen in trigeminal neuralgia: a pilot study, Arch. Neurol., 37: 768-71, 1980.

2191. Fry, B.W. and Ciarione, A.E., Effects of phenytoin on mouse cerebellar 5-hydroxytryptamine and norepinephrine, Neuropharmacology 20: 623-5, 1981.

2192. Fukuda, A., Tabuse, H., Fujii, C. and Kohama, A., Experirnental studies on total cerebral ischemia in dogs: II. The effect of phenytoin on electrocorticogram, Epilepsy Abstracts, 15(3): 98, 1982.

2193. Fukuda, A., Tabuse, H., Fujii, C. and Kohama, A., Experimental studies on total cerebral ischemia in dogs: I. The effect of phenytoin on regional cerebral blood flow, Epilepsy Abstracts, 15(3): 108, 1982.

2194. Gambert, S. R. and Garthwaite, T. L., The effect of diphenylhydantoin on basal and stimulated thyroid stimulating hormone (TSH) and prolactin secretion in euthyroid and hypothyroid rats, Horm. Metab. Res., 12:636-7, 1980.

2195. Gerber, A.M., Olson, W.L. and Harris, J.H., Effect of phenytoin on functional recovery after experimental spinal cord injury in dogs, Neurosurgery, 7(5): 472-6, 1980.

2196. Gibbs, M.E. and Ng, K.T., Counteractive effects of notepinephrine and amphetamine on ouabain-induced amnesia, Pharmac. Biochem. Behav., 6(5): 533-7, 1977.

2197. Gillis, R.A., McClellan, J.R., Sauer, TS. and Standaert, F.G., Depression of cardiac sympathetic nerve activity by diphenylhydantoin, J. Pharmacol. Exp. Ther., 179: 599-600, 1971.

2198. Gilmore, R.L. and Heilman, K.M., Speech arrest in partial seizures: evidence of an associated language disorder, Neurology, 31: 1016-9, 1981.

2199. Goncharov, N.P., The effect of substances stimulating and depressing the central nervous system on the quantity and quality of corticosteroids in the blood of dogs and guinea pigs, Biull. Eksp. Biol. Med., 52: 1295-7, 1962.

2200. Gordon, A. S., Goldsmith, E. D. and Charipper, H. A., Effects of thiouracil and sodium 5,5-diphenylhydantoinate (Dilantin sodium) on resistance to lowered barometric pressures, Proc. Soc. Exp. Biol. Med., 56: 202-3, 1944.

2201. Gordon, A.S., Milfay, D. and Diamond, I., Phosphorylation of the membrane-bound acetylcholine receptor: inhibition by diphenylhydantoin, Ann. Neurol., 5(2): 201-3, 1979.

2202. Grafova, V. N. and Danilova, E. I., Action of antiepileptic drugs on myoclonia of spinal origin, Bull. Exp. Biol. Med., 90(11): 1503-6, 1980.

2203. Greene, C.A., Rao, V.S., Maragos, G.D. and Mitchell, J.R., On the relationship migraine-epilepsy, Nebraska Med. J., 56(4): 136-8,1971.

2204. Gupta, D. N., Vollmer, V., Bashour,. F. A. and Webb, W. R., Effect of Dilantin on the excitability of the experimentally infarcted heart, Fed. Proc., 26: 381, 1967.

2205. Hanstrom, L., Lerner, U. and Gustafson, G.T., The effect of diphenylhydantoin upon enzyme release in relation to coliagen degradation in cat palatal mucosa during organ culture, Med. Biol., 57: 171-6, 1979.

2206. Holmes, G. L., McKeever, M. and Saunders, Z., Epileptiforrn activity in aphasia of childhood: an epiphenomenon, Epilepsia, 22: 631-9, 1981.

2207, Hudecki, M. S., Pollina, C. M., Heffner, R. R. and Bhargava, A. K., Enhanced functional ability in drug-treated dystrophic chickens: trial results with indomethacin, diphenylhydantoin and prednisolone, Exp. Neurol., 73: 173-85, 1981.

2208. Jordan, L.S., Receptive and expressive language problems occurring in combination with a seizure disorder: a case report, J. Commun. Disord., 13: 295-303, 1980.

2209. Jubiz, W., Bigler, A.H., Kumagai, L.F. and West, C.D., Estimation of thyroxine production rates in non-steady states, J. Clin. Endoctinol. Metab., 34: 1009-15, 1972.

2210. Jorgenson, J.G. and Brennan, R.W., Stimulus-related rnyokymia as a manifestation of mild peripheral neuropathy, Neurology, 32(2): A204, 1982.

2211. Kaplan, M.M., Breitbart, R., Larsen, P.R., Tatro,J.B. and Appiah, A., Effects of phenytoin (DPH) on thyroxine (T4) 5’-deiodinase in rat liver and anterior pituitary, Clin. Res., 28(2): 261A, 1980.

2212. Kendig, J., Courtney, K.R. and Cohen, E.N., Anesthetics: molecular correlates of voltage and frequency-dependent sodium channel block in nerve, J. Pharmacol. Exp. Ther., 210(3): 446-52, 1979.

2213. Kogure, K., Scheinberg, R., Kishikawa, H. and Busto, R., The role of monoamines and cyclic AMP in ischemic brain edema, Dynamics of Brain Edema, Pappius, H. M. and Feindel, W., Eds., Springer, NY, 1976.

2214. Kong, Y., Heyman, A., Entman, M.L. and McIntosh, H.D., Glossopharyngeal neuralgia associated with bradycardia, syncope, and seizures, Circulation, 30: 109-13, 1964.

2215. Krone, Rj., Miller, J.P., Kleiger, R.E., Clark, K.W. and Oliver, G.C., The effectiveness of antiarrhythmic agents on earlycycle premature ventricular complexes, Circulation, 63(3): 664-9, 1981.

2216. Kuhn, E., Douwes, 0. and Kern R., The action of hydantoin derivatives on the experimental myotonia induced in the isolated rat diaphragm by 2,4-dichlorophenoxyacetate, Klin. Wschr., 47: 278-80,1969.

2217. Lambert, J. R., Byrick, Rj. and Hammeke, M. D., Management of acute strychnine poisoning, Can. Med. Assoc. J., 124: 1268-70,1981.

2218. Lang, T. W., Bazika, V., Pappelbaum, S., Gold, H., Bernstein, H., Herrold, G. and Corday, E., Autotransplanted heartlung and cerebral venous shunt preparations: two new techniques for pharmacologic assay of cardiovascular drugs, Amer. J. Cardiol., 16:695-700,1965.

2219. Lazar, M.L., Current treatment of tic douloureux, Oral Surg. Oral Med. Oral Pathol., 50(6): 504-8, 1980.

2220. Levin, H.S. and Grossman, R.G., Behavioral sequelae of closed head injury, Arch. Neurol., 35: 720-7, 1978,

2221. Levin, S.R., Driessen, J., Pehlavanian, M., Adachi, R. and Kasson, B., Do “electrolyte pump” enzymes have a role in islet cell function?, Clin. Res., 24: 118A, 1976.

2222. Liewendahl, K., Helenius, T., Majuri, H., Ebeling, P. and Ahlfors, U. G., Effect of anticonvulsant and antidepressant drugs on iodothyronines in serum, Scand. J. Clin. Lab. Invest., 40: 767-74, 1980.

2223. Lipp, H., Pitt, A., Anderson, S.T. and Zimmett, R., Recurrent ventricular tachyarrhythmias in a patient with a prolonged Q-T interval, Med. J. Aust., 1296-9, 1970.

2224. Loh, C. K., Effects of diphenylhydantoin (DPH) on potassium exchange kinetics and transmembrane potentials in amphibian atrium, Fed. Proc., 33: 445, 1974.

2225. Lucchesi, B.R., Cardiovascular Pharmacology, Antonaccio, M., Ed., Raven Press, New York, 1977.

2226. Marshall, J. S. and Levy, R. P., Polyacrylanide electrophoretic study of thyroxine binding to human serum, J. Clin. Endocr., 26: 87-98, 1966.

2227. Matsuki, N., Quandt, F. N., Yeh, ].Z. and Eick, R. T., Sodium channel blocking action of phenytoinin mammal neurons in tissue cultures, Soc. Neurosci. Abstr., 7: 811, 1981.

2228. Mayeux, R., Alexander, M.P., Benson, D.E, Brandt, and Rosen, J., Poriornania, Neurology, 29: 1616-9, 1979.

2229. McCandless, D. W., Feussner, G. K., Lust, W. D. and Passonneau, J. V., Metabolite levels in brain following experimental seizures: the effects of maximal electroshock and phenytoin in cerebellar layers, J. Neurochem., 32: 743-53, 1979.

2230. Melmon, K. L., Ed., Cardiovascular Drug Therapy, F. A. Davis, Co., Philadelphia, 1974.

2231. Michalski, F. J., Gala, H. K. and Chen, J., The effect of diphenylhydantoin (Dilantin) on replication of Herpes simplex virus in human fibroblasts in vitro, Presentedat2Oih Interscience Conference an Antimicrobial Agents and Chemotherapy, New Orleans, 1980.

2232. Moses, L., Postoperative trigeminal neuralgia-case report, Opthalamic Surg., 11: 131-2, 1980.

2233. Nosek, T.M., How valproate and phenytoin affect the ionic conductances and active transport characteristics of the crayfish giant axon, Epilepsia, 22: 651-65, 1981.

2234. Neufeld, M.Y., Swanson, J.W. and Klass, D.W., Localized EEG abnormalities in acute carbon monoxide poisoning, Arch. Neurol., 38: 524-7, 1981.

2235. O’Neill, B., Callaghan, N., Stapleton, M. and Molloy, W., Serum elevation of high density lipoprotein (HDL) cholesterol in epileptic patients taking carbamazepine or phenytoin, Acta Neurol. Scand., 65: 104-9, 1982.

2236. Palmer, G.C., Palmer, S.J. and Legendre, J.L., Guanylate cyclase-cyclic GMP in mouse cerebral cortex and cerebellum: modification by anticonvulsants, Exp. Neurol., 71: 601-14, 1981.

2237. Patmas, M.A., Colton, J.S. and Colton, C.A., Modulation of mitochondrial calcium flux by convulsant (diamide) and antironvulsant (diphenylhydantoin) agents, Clin. Res., 29(l): 62A, 1981.

2238. Pfeiffer, C.C., Observations on the therapy of the schizophrenias, J. Appl. Nutr., 26: 29-36, 1974.

2239. Pincus, J.H., Presynaptic actions of phenytoin and barbiturates, Neurology, 31(2): 15 7, 1981.

2240. Pincus, J. H. and Hsiao, K., Calcium uptake mechanisms affected by some convulsant anticonvulsant drugs, Brain Res, 217: 119-27, 1981.

2241. Pincus, J. H. and Hsiao, K., Phenytoin inhibits both synaptosomal 45Ca uptake and efflux, Exp. Neurol., 74; 293-8, 1981.

2242. Prevot,H.,Andrien,J.M.,Bounameaux,Y.andSpitaels, J.M., Oral diphenylhydantoin support therapy in arrhythmias, Rev. Med. de Liege., 22(23): 683-7, 1967.

2243. Pritchard, III, P.B. and Gross, J.A., Ictal aphasia, Electroencephalogr. Clin. Neurophysiol., 51: 75P, 1981.

2244. Rall, TW. And Schleifer, L.S., The Pharmacological Basis of Therapeutics, 6th Ed., 454-5, Goodman, L.S. and Gilinan, A., Eds., Macmillan, New York, 1980.

2245. Rautio, A., Sotaniemi, E.A., Pelkonen, R.O. and Luoma, P. V., Treatment of alcoholic cirrhosis with enzyme inducers, Clin. Pharmacol. Ther., 28(5): 629-37, 1980.

2246. Reid, C. and Chanarin, I., Effect of phenytoin on DNA synthesis by human bone marrow, Scand. J. Haematol., 20: 237-40, 1978,

2247. Reinckens, W., New drug treatment reported for rare, blistering skin disease, NIH News & Features, March, 1981.

2248. Remmer, H., The acceleration of liver regeneration after hepatectomy by phenobarbital and diphenylhydantoin, Presented at Int. Congress of Gastroenterology, Prague, July 13, 1968.

2249. Reynolds, E.H., Drug treatment for epilepsy, Lancet, 2:721-5,1978.

2250. Rhee, H., Antiarrhythmic action of phenytoin (DPH) in dogs: inhibition of Ca + + -ATPase and Ca + + transport, Fed. Proc., 40(3): 645, 1981.

2251. Rocchini, A. P., Chun, P. O., and Dick, M., Ventricular tachyeardia in children, Amer. J. Cardiol., 47: 1091-7,1981.

2252. Rogers, M. P., Gittes, R. F., Dawson, D. M. and Reich, P., Giggle incontinence, JAMA, 274(10): 1446-8, 1982.

2253. Rushton, J. G., Stevens, C. and Miller, R. H., Glossopharyngeal (vagoglossopharyngeal) neuralgia-a study of 217 cases, Arch. Neurol., 38: 201-5, 1981.

2254. Sato ‘h, K., Narimatsu, A. and Taira, N., Effects of antiarrhythrnic drugs on AV nodal and intraventricular conduction as assessed in the isolated, blood-perfused AV node preparation of the dog, J. Cardiovasc. Pharmacol., 3(4): 75368,1981.

2255. Seelig, J. M., Becker, D. P., Miller, D., Greenberg, ft. P., Warcl, J. D., and Choi, S. C., Traumatic acute subdural hematoma-major mortality reduction in comatose patients treated within four hours, New Eng. J. Med., 304(25): 1511-9, 1981.

2256. Servitz, Z. and Muzil, F., Prophylactic treatment of post-traumatic epilepsy: results of a long-term follow-up in Czechoslovakia, Epilepsia, 22: 315-20, 1981.

2257. Stannard, M. and Caplan, H. L., Cardiac arrest due to imipramine hydrochloride, Med. J. Aust., 2(1): 22-4, 1967.

2258. Staple, P. H. and Nakeeb, S.J., Effect of diphenylhydantoin (phenytoin) on dermal allograft survival in rats, J. Dent. Res., 57:291, 1978.

2259. Stjernholm, M.R., Alsever, R.N. and Rudolph, M.C., Thyroid-function tests in diphenylhydantoin-treated patients, Clin. Chem., 21(10): 1388-92, 1975.

2260. Swerdlow, M. and Cundill, J.G., Anticonvulsant drugs used in the treatment of lancinating pain. A comparison, Anaesthesia,36: 1129-32,1981.

2261. Terrence, C.F. and Fromm, G.H., Complications of baclofen withdrawal, Arch. Neurol., 38: 588-9, 1981.

2262. Trascasa, M.L., Egido, J., Sancho, J. and Hernando, L., Evidence of high polymeric IgA levels in serum of patients with Berger’s disease and its modification with phenytoin treatment, Proc. Eur. Dial Transplant Assoc., 16: 513-9, 1979.

2263. Vedernikov, Y. P., Shinskaya, N. E. and Strelkov, R. B., Role of the central monoaminergic structures in the tolerance of animals to extreme hypoxic hypoxia, Patol. Fiziol. Eksp. Ter., 6: 1825,1978.

2264. Voorhies, R. and Patterson, R.H., Management of trigeminal neuralgia (tic douloureux), JAMA, 245(24); 2521-3, 1981.

2265. Wagner, P. and Bader, H., Effect ofalcohols, chlorpromazinc and diphenylhydantoin on (Ca2+)-ATPase of human red blood cells, Naunyn-Schtnied. Arch. Phartnacol., 282: RI 03, 1974.

2266. Walker, M.D. and Strike, T.A., Misonidazole peripheral neuropathy: its relationship to plasma concentration and other drugs, Cancer Clin. Trials, 3: 105-9, 1980.

2267. Watson, E.L. and Siegel, I.A., Diphenylhydantoin effects on salivary secretion and microsomal calcium accumulation and release, Europ. J. Pharmacol., 37: 207-11, 1976.

2268. Willow, M., Kuenzel, E. A., Catterall, W. A., Inhibition of voltage-sensitive sodium channels in neuroblastoma cells and synaptosomes by the anticonvulsant drugs diphenylhydantoin and carbamazepine, Molec. Pharmacol., 25 (2): 228.35, 1984.

2269. Wohns, R. N. W. and Kerstein, M. D., The role of Dilantin in the prevention of pulmonary edema associated with cerebral hypoxia, Crit. Care Med., 10(7): 436-43, 1982.

2270. Zaidi, S.M.M., Satsangi, R.K., Nasir, P.K.M., Agarwal, R. and Tiwari, S.S., New anti-myobacterial hydantoins, Pharmazie, 35(12): 755-6,1980.

2271. Aanderud, S., Aarbakke, J., Sundsfjord, J., Metabolism of thyroid hormones in isolated rat hepatocytes: studies on the influences of carbamazepine and phenytoin, Acta. Endocrinol., 104(4): 479-84, 1983.

2272. Abiko, H., Suzuki, J., Mizoi, K., Oba, M., Yoshimoto, T., Protective effect of phenytoin and enhancement of its action by combined administration of mannitol and vitamin E in cerebral ischemia, Brain Nerve, 38(4); 328-35, 1986.

2273. Abdul-Ghani, A. S., Goutinho-Neito, J., Druce, D., Bradford, H. F., Effects of anticonvulsants on the in vivo and in vitro release of GABA, Biochem. Pharmacol., 30(4): 363-8, 1981.

2274. Adams, P. R., Constanti, A., Banks, F. W., Voltage clamp analyisis of inhibitory synaptic action in crayfish stretch receptor neurons, Fed. Proc., 40(11): 2637-41, 1981.

2275. Adler, E., Yaari, Y., David, C., Selzer, M. E., Use- and frequency-dependent action of phenytoin on the action potential of lamprey spinal axons,Neurology, 35(Sup 1): 126, 1985.

2276. Adler, E. M., Yaari, Y., David, G., Selzer, M. E., Frequency-dependent action of phenytoin on lamprey spinal axons, Brain Research, 362(2): 271-80, 1986.

2277. Ahmad, S. N., Jailkhani, B. L., Jaffery, N. F., A rapid method for separation and estimation of free phenytoin in serum, Indian J. Exp. Biol., 22(11): 605-7, 1984.

2278. Aichele, R., Paik, H., Heller, A. H., Efficacy of phenytoin, procainamide, and tocainide in murine genetic myotonia, Exp. Neurol., 87: 377-81, 1985.

2279. Aldrete, J. A., Cubillos, P., Protection against anoxia by phenytoin and thiopentone in rabbits, Sixth Eur. Congress of Anaesthesiology, 248, Sept. 8-15, 1982.

2280. Aldrete, J. A., Cubillos, P., Phenytoin improves hemodynarnic tolerance and survival after severe hypoxia, Anesth. Analg., 63: 1021-4, 1984.

2281. Ali, N. N., Harvey, W., Harris, M., Bone matrix turnover and anticonvulsant drugs, J. Dent. Res., 61: 548, 1982.

2282. Allen, J. K., Whitfield, J. B., Hensley, W. J., The effects of diphenylhydantoin on the relationship between high-density lipoprotein cholesterol and several biochemical assays, Clin. Chim. Acta, 102: 111-14, 1980.

2283. Alps, B. J., Hass, W. K., Nicarclipine -and phenytoin prevention of cerebral ischemic cell change in a new rat survival model of brief four-vessel occlusion, Neurology, 35(Sup 1): 141, 1985.

2284. Alvin, J. D., Bush, M. T., Physiological disposition of anticonvulsants, Anticonvulsants, Vida, J. A., Ed., Academic Press, New York, 113-50, 1977.

2285. Aly, M. I., Abdel-Latif, A. A., Studies on the effects of acetylcholine and antiepileptic drugs on 32Pi, incorporation into phospholipids of rat brain synaptosomes, Neurochem. Res., 7(2): 159-69, 1982.

2286. Aman, M. C., Paxton, J. W., Werry, J. S., Fluctuations in steady-state phenytoin concentrations as measured in saliva in children, Pediatr. Pharmacol., 3: 87-94, IM.

2287. American Medical Association, Drugs used in disorders affecting skeletal muscle, AMA Drug Evaluations, 6th Edition, AMA, Chicago, 221-37, 1986.

2288. American Medical Association, Antiepileptic drugs, AMA Drug Evaluations, 6th Edition, AMA, Chicago, 169-95, 1986.

2289. American Medical Association, Antiarrhythmic Agents, AMA Drug Evaluations, 6th Edition, AMA, Chicago, 435-61,1986.

2290. American Medical Association, Drugs used to treat neuralgias, AMA Drug Evaluations, 6th Edition, AMA, Chicago, 197-202,1986.

2291. Amy, B., LeGrand, P., Levitzky, M., Welsh, R. A., Schechter, F. C., Suppression of centrineurogenic shock lung by dilantin (DPH) administered early in established hemorrhagic shock, J. Trauma, 21(9) 7628, 1981.

2292. Andoh, B., Idle, J. R., Sloan, T. P., Smith, R. L., Woolhouse, N., Interethnic and inter-phenotype differences among Ghanaians and Caucasians in the metabolic hydroxylation of phenytoin, Br. J. Clin. Pharmacol., 9: 282-83, 1979.

2293. Anisimov, V. N., The effect of buformin and diphenine on the lifetime, estral function, and frequency of spontaneous tumors in rats, Vopr. Onkol., 26(6): 42-8, 1980.

2294. Anisimov, V. N., Ostroumova, M. N., Dilman, V. N., Inhibition of the carcinogenic effect of 7,12-dirnethylbenz (a) anthracene in fernale rats by buforynin, phenytoin, pineal polypeptide extract, and L-dopa, Bull. Exp. Biol. Med., 89(6): 81922, 1980.

2295. Apple, F. S., Walker, F. C., Dietzler, D. N., Serum creatinine concentration and the discrepancy between EMIT and GLC phenytoin levels, Clin. Chem., 28(7): 1589, 1982.

2296. Aronson, J. K., Digitalis intoxication, Clin. Sci., 64:253-8, 1983.

2297. Asboe-Hansen, G., Treatment of generalized scleroderma with inhibitors of collagen synthesis, Int. J. Dermatol., 21(3): 159-61, 1982.

2298. Ashizawa, T., Butler, 1. J., Harati, Y., Ftoongta, S. M., A dominantly inherited syndrome with continuous motor neuron discharges, Ann. Neurol., 13: 285-90, 1983.

2299. Bachmann, K., Forney, R. B., Voeller, K., Monitoring phenytoin in salivary and plasma ultrafiltrates of pediatric patients, Ther, Drug Monit., 5(3): 325-9, 1983.

2300. Bachmann, K., Schwartz, J., Forney Jr., R., Jauregui, L., Phenytoin as a probe of drug metabolism: predicting clearance with a salivary sample, Pharmacologist, 26(3): 207, 1984.

2301. Bachmann, K., Voeller, K., Forney, B., Use of plasma unbound drug concentrations in adjusting phenytoin doses, Ther. Drug Monit., 6(2): 173-8, 1984.

2302. Bady, B., Girard, P. F., Jallade, S., Gaillard, L., A case of pseudomyotonia cured by carbamazepine, Rev. Neurol., 120: 277-86, 1969.

2303. Bailey, E., Farmer, P. B., Hoskins, J. A., Lamb, J. H., Peal, J. A., Determination of Plasma phenytoin by capillary gas chromatography with nitrogen-phosphorus detection and with selective ion monitoring, J. Chromatogr., 310(l): 199-203, 1984.

2304. Balboa De Paz, F., Campos Castello, J., Olivan Palacios, J., Espino Hurtado, P., Vela Bueno, A., Anoretic syndrome associated with convulsive seizures, Psiquis, 2(5); 56-61, 1981.

2305. Balogh, E., Mattyus, A., Nemeth, C., Szabadosne, N. M., Transient lowering of the IgA level during diphedan therapy, Orv. Hetil., 120: 2179-82,1979.

2306. Bandmann, H. J., Perwein, E., Phenytoin in treatment of epidermolysis bullosa hereditaria dystrophica partim inversa (Gedde-Dahl), Z. Hautkr., 57(21): 1587-98, 1982.

2307. Banerjee, A., Turner, A. J., Guha, S. R., GABA dehydrogenase activity in rat brain, Biochem. Pharmacol., 31(20): 3219-23,1982.

2308. Barba Rubio, J., Diphenylhydantoin in leprosy. Its topical application in ulcers and plantar trophic ulcers, Presented to XII Mexican Congress of Dermatology, Oaxaca, Oct. 9-12, 1985.

2309. Barker, J. L., Owen, D. C., Segal, M., Clinically important drugs have opposing actions on the excitability of cultured mammalian neurons, Neurotransmitters, Seizures, and Epilepsy II, Fariello, R. G., et al., Eds., Raven Press, New York, 153-66,1984.

2310. Baron, J. C., Roeda, D., Munari, C., Crouzel, C., Chodkiewics, J. P., Comar, D., Brain regional pharmacokinctics of 11C-labeled diphenylhydantoin: positron emission tomography in humans, Neurology, 3-3: 580-5, 1983.

2311. Barratt, E. S., Faulk, D. M., Brandt, M. E., Bryant, S. C., Effects of phenytoin on N100 augmenting/reducing and the late positive complex of the event-related potential: a topographic analysis, Neuropsychobiology, 15: 201-7, 1986.

2312. Barron, S. A., Heffner, B. R., Continuous muscle fiber activity a case with unusual clinical features, Arch. Neurol., 36: 520-1, 1979.

2313. Bartels, H., Cutber, E., Wallis, S., Monitoring therapy by analysis of drug concentration in saliva, Monatsschr. Kinderheilkd., 131(1): 13-16, 1983.

2314. Baruah, J. K., Confusional episode a seizure phenomenon in the elderly, Epilepsia, 24: 246, IW.

2315. Bauer, L. A., Edwards, W. A., Dellinger, E. P., Raisys, V. A., Brennan, C., Importance of unbound phenytoin serum levels in head trauma patients, J. Trauma, 23: 1058-60, 1983.

2316. Bechtereva, N. P., Nikitina, L. I., Iliuchina, V. A., Dambinova, S. A., Denisova, V. V., Dilantin: clinical and scientific experience of application, Eur. J. Clin. Invest., 14: 36, 1984.

2317. Behan, P., Migraine: a rational approach to therapy, Br. J. Clin. Pract., 36(10): 359-62, 1982.

2318. Bell, H. H., Dittmeier, G. E., Comparative effects of gemfibrozil, phenytoin, and nicotinic acid on serum HDL, Arteriosclerosis, 5(5): 514A, 1985.

2319. Bell, H. H., Dittmeier, G. E., Increase in HDL2 cholesterol with phenytoin therapy, Arteriosclerosis, 5(5): 514A, 1985.

2320. Bellak, L., A possible subgroup of the schizophrenic syndrome and implications for treatment, Am. J. Psychother., 30: 194-205, 1976.

2321. Benet, L. Z., Massoud, N., Cambertoglio, J. C., Pharmacokinetic basis and therapeutic concentrations, Pharmacokinetic Basis for Drug Treatment, Raven Press, New York, 425-440,1984.

2322. Berger, J. R., Sheremata, W. A., Melamed, E., Paroxysmal dystonia as the initial manifestation of multiple sclerosis., Arch. Neurol., 4 1; 747-50, 1984.

2323. Berlit, P., Krause, K. H., Heuck, C. C., Schellenberg, B., Serum lipids and anticonvulsants, Acta Neurol. Scand., 66: 328-34, 1982.

2324. Bernard, P., Wilson, D., Paster, G., Brown, W., Glenn, T. M., Possible involvement of adenosine receptors in the electroshock anticonvulsant effects of carbamazepine, diphenylhydantoin, phenobarbital and diazepam, Pharmacologist, 25 (3): 164, 1983.

2325. Bertch, K. E., Norton, J. A., Young, A. B., Rapp, B. P., Tibbs, P. A., A comparative study of laboratory parameters in head-injured patients receiving either phenytoin or placebo for 24 months, Drug Intell. Clin. Pharm., 19: 561-6, 1985.

2326. Besser, R., Schuster, C. J., Possibility of influencing sharp alpha waves in coma by means of drugs: a clinical contribution, Z. EEG-EMG, 10: 158-60, 1979.

2327. Bezchlibnyk-Butler, K., New treatment of psychiatric disorders, On. Contin. Pract., 11(2): 13-18,1984.

2328. Bhandari, A. K., Shapiro, W. A., Morady, F. S., Shen, E. N., Mason, J., Scheinman, M. M., Electrophysiologic testing in patients with the long QT syndrome, Circulation, 71(t): 6371, 1985.

2329. Bhattacharya, S. K., Bhattacharya, D., Effect of restraint stress on anticonvulsant actions of phenobarbitone and diphenylhydantoin in rats, Indian J. Exp. Biol., 20: 406-8, 1982.

2330. Bhise, S. B., Subrahmanyam, C. V., Malhotra, A. K., Srivastava, B. C., Liquid membrane phenomenon in antiepileptic drugs, Int. J. Pharyn., 24(2/3): 297-305, 1985.

2331. Bielak, J., Pokora, J., The effect of  hydantoinal on cardiac arrhythmias, Pol. Tyg. Lek., 25: 967-9, 1970.

2332. Bigger, J. T., Dresdale, R. J., Heissenbuttel, R. H., Weld, F. M., Wit, A. L., Ventricular arrhythmias in ischemic heart disease: mechanism prevalence significance and management, Prog. Cardiovase. Dis., 19(4): 255-300, 1977.

2333. Bigger, J. T., Hoffman, B. F., Antiarrythmic drugs, The Pharmacological Basis of Therapeutics, 7th edition, Gilman, A. G., Goodman, L. S., Hall, T. W., Murad, F., Eds., Macmillan Publishing Co., New York, 748-83,1985.

2334. Billings, R. E., Interactions between folate metabolism, phenytoin metabolism and liver microsomal cytochrome P450, Drug. Nutr. Interact., 3(l); 21-32, 1984.

2335. Billings, R. E., Fischer, L. J., Oxygen-18 incorporation studies of the metabolism of phenytoin to the catechol, Drug Metab. Dispos., 13(3): 312-17, 1985.

2336. Billings, R. E., Hansen, D. K., Species differences in phenytoin induction of cytochrome P450 due to pharmacokinetic differences, Proc. West Pharmacol. Soc., 27: 539-42, 1984.

2337. Billings, R. E., Milton, S. G., Chemical nature of reactive metabolites formed with phenytoin in rat liver microsomes, Fed. Proc., 44(4): 1114, 1985.

2338. Bint, A. J., Burtt, I., Adverse antibiotic drug interactions, Drugs, 20: 57-68, 1980.

2339. Bird, T. D. Carlson, C. B., Horning, M., Ten year follow-up of paroxysmal choreoathetosis: a sporadic case becomes familial, Epilepsia, 19: 129-32, 1978.

2340. Birkmayer, W., Die behandlung der traumatischen epilepsie, Wein. Klin. Wochenschr., 63: 606-9, 1951.

2341. Bittar, E. E., Nwoga, J., Some further observations on the stimulation by high external potassium of the sodium efflux in barnacle muscle fibers, Pflugers Arch., 395: 318-25, 1982.

2342. Bleehen, N. M., The Cambridge glioma trial of misonidazole and radiation therapy with associated pharmacokinetic studies, Cancer Clin., 3: 267-73, 1980.

2343. Block, P. J., Winkle, R. A., Hemodynamic effects of antiarrhythmic drugs, Amer. J. Cardiol., 52: 14c-23c, 1983.

2344. Blom, S., Trigeminal neuralgia: its treatment with a new anticonvulsant drug (G-32883), Lancet, 1: 839-40, 1962.

2345. Bobrove, A. M., Possible beneficial effects of phenytoin for rheumatoid arthritis, Arthritis Rheum., 26 (1): 118-19, 1983.

2346. Bock, J. L., Ben-Ezra, J., Rapid measurement of free anticonvulsant drugs by direct liquid chromatography of serum ultrafiltrates, Clin. Chem., 31(11): 1884-7, 1985.

2347. Bodewei, R., Hering, S., Schubert, B., Winkler, Wollenberger, A., Calcium channel block by phenytoin in neuroblastoma X glioma hybrid cells, Biomed. Biochim. Acta, 7/8: 1229-37,1985.

2348. Boehnert, M., Lovejoy, F. H., The effect of phenytoin on cardiac conduction and ventricular arrhythmias in acute tricyclic antidepressant (TCA) overdose, Vet. Hum. Toxicol., 27: 297, Abst. 32, 1985.

2349. Bowles, A. M., Raines, A., Dretchen, K. L., Protection by phenytoin and verapamil against organophosphate poisoning in the mouse, Fed. Proc., 43(3): 553, 1984.

2350. Bowling, A. C., De Lorenzo, R. J., Anticonvulsant receptors; identification and characterization in brain, Neurology, 32 (2): A224, 1982.

2351. Bowling, A. C., De Lorenzo, R. J., Micromolar affinity benzodiazepine receptors: indentification and characterization in central nervous system, Science, 216: 1247-50, 1982.

2352. Brady, R. O., King, F. M., Fabry’s disease, Peripheral Neuropathy, Vol. 2, Dyck, P. J., et al., Eds., W. B. Saunders Co., Philadelphia, 914-27, 1975.

2353. Brandt, L., Ljunggren, B., Andersson, K. E., Hindfelt, B., Uski, T., Effects of indometbacin and prostacylin on isolated human pial arteries contracted by CSF from patients with aneurysmal SAH, J. Neurosurg., 55: 877-83, 1981.

2354. Braun, C. W., Goldstone, J. M., Increased clearance of phenytoin as the presenting feature of infectious mononucleosis, Ther. Drug. Monit., 2(4); 355-57, 1980.

2355. Brodie, M. J., Muir, S. E., Agnew, E., Macphee, C. Volo, C., Teasdale, E., Macpherson, P., Protein binding and CSF penetration of phenytoin following acute oral dosing in man, Br. J. Clin. Pharmac., 19(2): 161-8, 1985.

2356. Brodsky, L., Shah, A., Casenas, E., Two distinct “paradoxical” reactions to neuroleptics, Psychiatr. J. Univ. Ottawa, 9: 61-4, 1984.

2357. Brodsky, L., Zuniga, J. S., Casenas, E. R., Ernstoff, R., Sachdev, H. S., Refractory anxiety: a masked epileptiform disorder?, Psychiatr. J. Univ. Ottawa, 8: 42-5, 1983.

2358. Brown, B. S., Akera, T., Brody, T. M., Mechanism of grayanotoxin III-induced afterpotentials in feline cardiac Purkinje fibers, Europ. J. Pharmacol., 75: 271-81, 1981.

2359. Brown, H., Tetanus, JAMA, 204(7) 614-16, 1968.

2360. Brown, J. J., Murphy, M. J., Transverse myelopathy in progressive systemic sclerosis, Ann. Neurol., 17: 615-17, 1958.

2361. Brown, M., Liberthson, R. R., Ali, H. H., Lowenstein, E., Perioperative anesthetic management of a patient with long Q-T syndrome (LQTS), Anesthesiology, 55: 586-9, 1981.

2362. Brown, S. B., Garcia-Mullin, R., Murai, Y., The Schwartz-Jampel syndrome (myotonic chondrodystrophy) in the adult, Neurology, 4 (25): 366, 1975.

2363. Brown, T. J., Isaacs syndrome, Arch. Phys. Med. Rehabil., 65(l): 27-9, 1984.

2364. Browne, T. R., Pharmacologic principles of antiepileptic drug administration, Epilepsy, Diagnosis and Management, Browne, T. R., Feldman, R. G., Eds., Little, Brown & Co., Boston, 145-60, 1983.

2365. Bryson, S. M., Kelly, J. C., Kelman, A. W., Whiting, B., Therapeutic free phenytoin monitoring, Clin. Pharmacokinet., 9 (sup 1): 90, 1984.

2366. Burger, L. J., Lopez, R. I., Elliott, F. A., Tonic seizures induced by movement, Neurology, 22: 656-9, 1972.

2367. Burke, B. E., De Lorenzo, R. J., Ca2+ and calmodulin-dependent phospborylation of endogenous synaptic vesicle tubulin by a vesicle-bound calmodulin kinase system, J. Neurochem., 38(5): 1205-18, 1982.

2368. Burke, B. E., De Lorenzo, R. J., Ca2+  and calmodulinregulated endogenous tubulin kinase activity in presynaptic nerve terminal preparations, Brain Res., 236: 393-415, 1982.

2369. Burnham, W. N., Spero, L., Okazaki, M. M., Madras, B. K., Saturable binding of [3H]-phenytoin to rat brain membrane fraction, Can. J. Physiol. Pharmacol., 59(4): 402-7,1981.

2370. Butt, H., QT-syndrome includes two symptom complexes, Med. Klin., 76 (6) 38-41, 1981.

2371. Cadnapaphornchai, P., Kellner, D., McDonald, F., Role of adrenoceptor in diphenylhydantoin (D)-stimulated renal renin release, Fed. Proc., 44(5): 1570, 1985.

2372. Cadnapaphornchai, P., Kellner, D., McDonald, F. D., Inhibition of renal alpha adrenoceptor by diphenylhydantoin, Fed. Proc., 45(4): 1033, 1986.

2373. Cadnapaphornchai, P., Pontes, C., McDonald, F. D., Mechanisms of effect of diphenylhydantoin on renal renin release, Am. J. Physiol., 247(3): F418-22, 1984.

2374. Caldwell, K. K., Harris, R. A., Effects of anesthetic and anticonvulsant drugs on calcium dependent efflux of potassium from human erythrocytes, Europ. J. Pharmacol., 107(2): 119-25, 1985.

2375. Calixto, J. B., De-Lima, T. C., Diphenylhydantoin inhibition of drug-induced contractions of isolated rat vas deferens: additional evidence for a calcium-blocking action, Braz. J. Med. Biol. Res., 16: 327-31, 1983.

2376. Campbell, J. W., Frisse, M., Manual of Medical Therapeutics, 24th Edition, Little, Brown & Co., Boston, 79 passim 422, 1983.

2377. Cantrill, V., Prophylactic phenytoin in tricyclic overdose, J. Emerg. Med., 1: 169-77, 1983.

2378. Capuano, V., Capobianco, S., Romano, A., Therapeutic approach to arrhythmias in pediatric age, Osp. Ital. Pediatr., 18(5): 769-80,1983.

2379. Catterall, W. A., Inhibition of voltage-senisitive sodium channels in neuroblastoma cells by antiarrhythmic drugs. Molec. Pharmacol., 20: 356-62, 1981.

2380. Chadda, V. S., Joshi, K. G., Chadda, S., A double-blind crossover study of diphenylhydantoin in irritable bowel syndrome, J. Assoc. Physicians India, 31 (7): 425-7, 1983.

2381. Chalfie, M., Hoadley, D., Pastan, S., Perlman, R. L., Calcium uptake into rat pheochromocytoma cells, J. Neurochem., 27: 1405-9, 1976.

2382. Chalk, J. B., Ridgeway, K., Brophy, T. R., Yelland, J. D., Eadie, M. J., Phenytoin impairs the bioavailability of dexamethasone neurological and neurosurgical patients, J. Neurol. Neurolsurg. Psychiatry, 47(10): 1087-90, 1984.

2383. Chalmers, R. J., Johnson, R. H., The effect of diphenylhydantoin on metabolic and growth hormones during and after exercise., J. Neurol. Neurosurg. Psychiatry, 46(7): 662-65,1983.

2384. Chambers, D. A., Cohen, B. L., The direct effects of biological response modifiers on epidermal cells, Br. J. Derma tot., 3: 114-22, 1984.

2385. Chang, T., Glasko, A. J., Phenytoin: Biotransformation, Antiepileptic Drugs, Woodbury, D. M., et al., Eds., Raven Press, New York, 209-26, 1982.

2386. Chapman, A. G., Meldrum, B. S., Effects of anticonvulsant drugs on brain amino acid metabolism, Epilepsy: An Update on Research and Therapy, Nistico, G., et al., Eds., Alan R. Liss Inc., New York, 63-76, 1983.

2387. Chapman, J. R., Roberts, D. W., Schol, H. M., Bagwell, C. B., Hudson, J. L., Flow cytometric analysis of the effects of phenytoin and its major metabolite on mitogen stimulated mouse spleen cells, Int. J. Immunopharmacol., 5(5): 471-8, 1983.

2388. Cheigh, J. S., Reidenberg, M. M., Drug metabolism and dose adjustment in patients with renal failure, Developments in Nephrology, Vol. 1, Manual of Clinical Nephrology of the Rogosin Kidney Center, Cheigh, J. S., et al., Eds., Martinus Nijhoff, Boston, 428-52,1981.

2389. Cheng, S. C., Brunner, E. A., Effects of anesthetic agents on synaptosomal GABA disposal, Anesthesiology, 55: 34-40,1981.

2390. Chiche, P., Benaim, R., Chesnais, F., Phenytoin: Clinical pharmacology. Use in various arrhythmias in 86 cases, Ann. Cardiol. Angeiol., 2: 231-42, 1971.

2391. Chien, C. P., Keegan, D., Diazepam as an oral longterm anticonvulsant for epileptic mental patients, Dis. Nerv. Syst., 33: 100-04, 1972.

2392. Cbong-Cheng, X., Occurrence of spontaneous channel sensation in epileptic patients with intracranial damage, Chin. Med. J., 96(l): 33-6, 1983.

2393. Chung, E. K., Unusual form of digitalis-induced triple A-V nodal rhythm, Am. Heart. J., 79(2): 250-53, 1970.

2394. Churchill, P. C., McDonald, F. D., Churchill, M. C., Phenytoin stimulates renin secretion from rat kidney slices, J Pharmacol., Exp. Ther., 211: 615-19,1979.

2395. Claesen, M., Moustafa, M. A., Adline, J., Vandervorst, D., Poupaert, J. H., Evidence for an arene oxide-NIH shift pathway in the metabolic conversion of phenytoin to 5-(4-hydroxyphenyl)-5-Phenylhydantoin in the rat and in man, Drug Metab. Dispos., 10(6): 667-71, 1982.

2396. Clifford, D. B., Trotter, J. L., Pain in multiple sclerosis, Arch. Neurol., 41: 1270-2, 1984.

2397. Coers, C., Telerman-Toppet, N., Durdu, J., Neurogenic benign fasciculations, pseudomyotonia and pseudotetany: A disease in search of a name, Arch. Neurol. 38: 282-7, 1981.

2398. Cohn, D. F., Avrahami, E., Dalos, E., Thermal epilepsy manifest as fever attacks, Ann. Intern. Med., 101(4): 56970,1984.

2399. Connors, B. W., A comparison of the effects of pentobarbital and diphenylhydantoin on the GABA sensitivity and excitability of adult sensory ganglion cells, Brain Res., 207: 357-69,1981.

2400. Cook, C. E., Christensen, H. D., Amerson, E. W., Kepler, J. A., Tallent, C. B., Taylor, C. F., Radioimmunoassay of anticonvulsant drugs: Phenytoin, phenobarbital, and primidone, Quantitative Analytic Studies in Epilepsy, Kellaway, P. and Petersen, I., Eds., Raven Press, New York, 39-58, 1976.

2401. Coodley, E. L., Ofstein, M., Rick, J., Cardiac arrhythmias-an update on identification and therapy, Postgrad. Med., 80(3): 38-55,1986.

2402. Cook, C. E., Kepler, J. A., Christiansen, H. D., Antiserum to diphenylhydantoin: preparation and characterization, Res. Commun. Chem. Pathol. Pharm., 5(3): 767-74,1973.

2403. Coombes, E. J., Phenytoin assay on dried blood spots, Neurology, 34: 703, 1984.

2404. Coombes, E. J., Camlen, T. R., Batstone, G. F., Leigh, P. N., A phenytoin assay using dried blood spot samples suitable for domiciliary therapeutic drug monitoring, Ann. Clin. Biochem., 21(6): 519-22, 1984.

2405. Cooper, R. L., Constable, 1. J., Davidson, L., Aqueous humor catecholamines, Curr. Eye Res., 3(6): 809-13, 1984.

2406. Cooper, T. W., Bauer, E. A., Therapeutic efficacy of phenytoin in recessive dystropic epidermolysis, Arch. Dermatol., 120 (4): 490-5, 1984.

2407. Cordonnier, M., Delwaide, P. J., Malignant and benign fasciculations. Apropos of a case of neuromyotonia, Rev. Med. Liege., 34: 839-45, 1979.

2408. Cosofret, V. V., Buck, R. P., A poly(vinylehloride) membrane electrode for determination of phenytoin in pharmaceutical formulations, J. Pharm. Biomed. Anal., 4(l): 45-52, 1986.

2409. Cotrufo, R., Di forio, G., Arnmendola, A., Bravaccio, F., Continuous muscle fiber activity associated with denervation atrophy, Eur. Neurol., 21: 375-9, 1982.

2410. Courtney, K. R., Interval-dependent effects of small antiarrhythmic drugs on excitability of guinea-pig myocardiurn, Mol. Cardiol., 12: 1273-86,1980.

2411. Courtney, K. R., Depressant effects of drugs used in inyotonia therapy, Proc. West Phannacol. Soc., 25: 159-61, 1982.

2412. Courtney, K. R., Etter, E. F., Modulated anticonvulsant block of sodium channels in nerve and muscle, Europ. J. Clin. Pharmacol., 88; 1-9, 1983.

2413. Cramer, J., Mattson, R., Gallagher, B., King, D. W., Wannamaker, B., Denio, L., Shellenberger, M. K., Haidukewych, D., Splane, M. L., Whole blood/plasma ratio and clinical performance of a non-instr-umented assay for phenytoin., Neurology, 36: 84, 1986.

2414. Cranford, R. E., Leppik, 1. E., Intravenous administration of pbenytoin, Neurology, 29: 754, 1979.

2415. Cranford, R. E., Leppik, 1. E., Patrick, B., Anderson, C. B., Kostick, B., Intravenous phenytoin: Clinical and pharmacokinetic aspects, Neurology, 27(4): 376, 1977.

2416. Cranford, R. E., Leppik, 1. E., Patrick, B. K., Anderson, B. B., Kostick, B., Intravenous phenytoin in acute seizure disorders, Neurology, 28(4): 351-52, 1978.

2417. Crooks, J., O’Malley, K., Stevenson, I. H., Pharmacokinetics in the elderly, Handbook of Clinical Pharmacokinetics, Gibaldi, M., Prescott, L., Eds., ADIS Health Science Press, New York, 169-87,1983.

2418. Cruz Martinez, A., Arpa, J., Perez Conde, M. C., Ferrer, M. T., Bilateral carpal tunnel in childhood associated with Schwartz-Jampel syndrome, Muscle Nerve, 7: 66-72, 1984.

2419. Curcie, M., Preoperative considerations and anesthetic management, University Hospital, Zurich, Switzerland, Int. Anesthesiol. Clin., 20(2): 227-33, 1982.

2420. Curran, A. E., El-Mofty, S. K., Protection of irradiated parotid by phenytoin (DPH), J. Dent. Res., 62: 232, 1983.

2421. Czuczwar, S. J., Turski, L., Kleinrok, Z., Effects of combined treatment with diphenylhydantoin and different benzodiazepines on pentylenetetrazol- and bicuculline-induced seizures in mice, Neuropharmacology, 21(6): 563-7, 1982.

2422. D’Arcy, P. F., Drug interactions with new drugs, Pharm. Int., 4: 285-91, 1983.

2423. Dam, M., Phenytoin toxicity, Antiepileptic Drugs, Woodbury P. M., Penry, J. K., Pippinger, C. E., Eds., New York, Raven Press, 247-56, 1982.

2424. Dam, M., Summing up of the success so far gained through choice of drugs orcombinations ofdrugs, Acta Neurol. Scand., 69(99): 19-22, 1984.

2425. Dana-Haeri, J., Oxley, J., Richens, A., Pituitary responsiveness to gonadotrophin-releasing and thyrotrophinreleasing hormones in epileptic patients receiving carbamazepine or phenytoin, Clin. Endocrinol., 20: 163-8, 1984.

2426. Danhof, M., Breimer, D. D., Therapeutic drug monitoring in saliva, Handbook of Clinical Pharmacokinetics, Gibaldi, M., Prescott, L., Eds., New York, ADIS Health Science Press, 207-27,1983. 

2427. Danielson, D. A., Douglas, S. W., Herzog, P., Jick, H., Porter, J. B., Drug-induced blood disorders, JAMA, 252: 325760,1984.

2428. Danilenko, M. V., Ivaniv, Y. A., Corrections of hypoalphacholesterolemia in patients with atherosclerosis by means of diphenine, Vrach. Delo, 7: 72-75, 1983.

2429. David, G., Selzer, M. E., Yaari, Y., Suppression by phenytoin of convulsant-induced after-discharges at presynaptic nerve terminals, Brain Res., 330(1): 57-66, 1985.

2430. David, G., Selzer, M. E., Yaari, Y., Activity-dependent depression of nerve action potential by pbenytoin, Neurosci. Lett., 66(2): 163-8, 1986.

2431. Davies, J. E., Edmundson, W. F., The effects of phenytoin on human residues of DDT and dieldrin-a compendium, Epidemiology of DDT. Davies, J. E., Edmundson, W. F., Eds., Futura Publishing Co., 109-23,1979.

2432. Davies-Jones, G. A., Antiepileptic medication during pregnancy, Side Effects of Drugs Annual, Vol. 4, A Worldwide Yearly Survey of New Data and Trends, Dukes M.N., Ed., Excerpta Medica, Amsterdam, 42-6, 1980.

2433. Davis, C. M., Fenimore, D. C., Rapid microanalysis of anticonvulsants by high performance thin-layer chromatography, J. Chromatogr., 222: 265-270, 1981.

2434. Davis, J. R., Lynam, T. C., Franklyn, J. A., Docherty, K., Sheppard, M. C., Tri-iodothyronine and phenytoin reduce prolactin messenger RNA levels in cultured rat pituitary cells, J. Endocr., 109: 359-64, 1986.

2435. De Belleroche, J., Dick, A., Wyrley-Birch, A., Anticonvulsants and trifluoperazine inhibit the evoked release of GABA from cerebral cortex of rat at different sites, Life Sci., 31: 2875-82,1982.

2436. De Boer, T., Stoof, J. C., Van Duijn, H., The effects of convulsant and anticonvulsant drugs on the release of radiolabeled GABA, glutamate, noradrenaline, sertonin and acetylcholine from rat cortical slices, Brain Res., 253: 153-60, 1982.

2437. de la Torre, R., Navarro, J. L., Aldrete, J. A., Comparison between phenytoin and conventional treatment for irritable bowel syndrome, Curr. Ther. Res., 38(4): 661-9, 1985.

2438. De Lorenzo, R. J., Antagonistic action of diphenylhydantoin and calcium on the endogenous phosphorylation of specific brain proteins, Neurology, 26: 386, 1976.

2439. De Lorenzo, R. J., Calmodulin in neurotransmitter release and synaptic function, Fed. Proc., 41(7): 2265-72, 1982.

2440. De Lorenzo, R. J., Calcium calmodulin protein phosphorylation in neuronal transmission: A molecular approach to neuronal excitability and anticonvulsant drug action, Advances in Neurology. Status Epilepticus, Delgado-Escueta, A. V., et al., Eds., Raven Press, New York, 325-38, 1983.

2441. De Lorenzo, R. J., Calmodulin systems in neuronal excitability: a molecular approach to epilepsy, Ann. Neurol., 16: S104-S114, 1984.

2442. De Vane, P. J., Kelly, J. C., Macpherson, P., Whiting, B., Phenytoin prophylaxis in radiological contrast studies, Br. J. Clin. Pharmacol., 17(5): 643p, 1984.

2443. De Wolff, F. A., Vermeii, P., Ferrari, M. D., Buruma, S., Breimer, D. D., Impairment of phenytoin parahydiroxylation as a cause of severe intoxication. Ther. Drug Monit., 5(2): 213-15,1983.

2444. Dearden, N. M., Ischaemic brain, Lancet, 2: 255-9, Aug 3, 1985.

2445. Declerek, A. C., Martens, W. L., Wauquier, A., Evaluation of the effects of antiepileptic drugs on sleep-wakefulness patterns following one night total sleep deprivation in epileptic patients, Neuropsychobiology, 13: 201-05,1985.

2446. Delandsheer, E., Guieu, J. D., Bouchez, B., Reant, O., Effect of intravenous diphenylhydantoin on myotonia in myotonic dystrophy, Lyon Med., 252: 279-84, 1984.

2447. Delgado Escueta, A. V., Wasterlain, C., Treiman, D. M., Porter, R. J., Status epilepticus: Summary, Advances in Neurology. Status Epilepticus, Delgado-Escueta, A. V., et al., Eds., New York, Raven Press, 537-41, 1983.

2448. Den Hartog Jager, W. A., Hootsmans, W. J., Isaacs’ Disease (continuous muscle fiber activity), Ned. Tijdschr. Geneeskd., 122: 1917-20, 1978.

2449. Deutschman, C. S., Haines, S. J., Anticonvulsant prophylaxis in neurological surgery, Neurosurgery, 17: 510-7, 1985. 2450. De Vane, P. J., Macpherson, P., Teasdale, E., Volo, G., Casey, M., Kelly, J. C., Whiting, B., The prophylactic use of phenytoin during iopamidol contrast studies of the subarachnoid space, Europ. J. Clin. Pharmacol., 29: 747-9, 1986.

2451. Diamond, I., Gordon, A. S., Davis, C. G., Milfay, D., Phenytoin and phosphorylation of nicotinic receptors, Advances in Neurology. Status Epilepticus, Delgado-Escueta, A. V., et al., Eds., Raven Press, New York, 339-44, 1983.

2452. Digregorio, G. J., Barbieri, E. J., Pharmacologic management of pain, Am. Fam. Physician, 27: 185-8, 1983.

2453. Dikrnen, S., Matthews, C. G., Effect of major motor seizure frequency upon cognitive-intellectual functions in adults, Epilepsia, 18(1); 21-9, 1977.

2454. Dilman, V. D., Therapy for aging and diseases ofcompensation in light of the elevating mechanism of their development, Diseases of Aging, Wright, J., Ed., PSG, Inc., Boston, 283-302, 1981.

2455. Dilman, V. M., Cancer susceptibility. Diseases of Aging, Wright, J., Ed., PSG, Inc., Boston, 205-33, 1981.

2456. Ding-Cuo, S., Investigation in electrophysiology of neuromyotonia, Electroencephalogr. Clin. Neurophysiol., 56(3): S70, 1983.

2457. Dodrill, C. B., Correlates of generalized tonic-clonic seizures with intellectual, neuropsychological, emotional, and social function in patients with epilepsy, Epilepsia, 27(4): 399-411,1986.

2458. Doemer, D., Partridge, L. D., Effects of convulsant and anticonvulsant drugs on potassium inactivation, Soc. Neurosei. Abstracts, 9 PT 1: 396, 1983.

2459. Doster, S. K., Me Kinney, L. C., Ferrendelli, J. A., Anticonvulsant specificity and ability to block sodium channels are determined by 5-substitution of hydantoins and alphasubstitution of suceinimides, Soc. Neurosei. Abstracts, 10: 184, 1984.

2460. Dougherty, R. J., Office management of chronic pain, Postgrad. Med., 76(2): 215-18, 1984.

2461. Drake, Jr., M. E., Coffey, C. E., Complex partial status epilepticus simulating psychogenic unresponsiveness, Am. J. Psychiat., 140: 800-01, 1983.

2462. Dreifus, L. S., Soffer, J., Drug-induced ventricular arrhythmias: prolonged QT interval, Ann. Emerg. Med., 11(10): 597-8, 1982.

2463. Dreifuss, F. E., Adverse effects of antiepileptic drugs, Epilepsy, Ward, A. A., et al., Eds., Raven Press, New York, 249-66,1983.

2464. Dretchen, K. L., Bowles, A. M., Raines, A., Protection by phenytoin and calcium channel blocking agents against the toxicity of diisopropylfluorophosphate, Toxicol. Appl. Pharmacol., 83: 584-9, 1986.

2465. Drew, J. H., Kitchen, W. H., The effect of maternally administered drugs on bilirubin concentrations in the newborn infant, J. Pediatr., 89(4): 657-61, 1976.

2466. Dreyfus, J., A Remarkable Medicine Has Been Overlooked, lst Ed. Simon and Schuster, Inc., New York, 1981; 2nd Ed. Pocket Books, New York, 1982 (Available through Dreyfus Medical Foundation).

2467. Drug Side Effects Bulletin, A review of side effects of antiepileptic drugs over the last eleven years, Lakartidningen, 79(28-9): 2646-50, 1982.

2468. Dubick, M. A., Keen, C. L., Alterations in tissue trace element and ascorbic acid metabolism in phenytoin-fed rats and mice, J. Nutr., 115(11): 1481-7, 1985. 

2469. Durelli, L., Mutani, R., Sechi, G. P., Traccis, S., Monaco, F., Glorioso, N., Treatment of human myotonia. Double-blind trial carbamazepine and diphenylhydantoin, Electroencephalogr. Clin. Neurophysiol., 54: 5p, 1982.

2470. Dworkin, S. F., Benign chronic orofacial pain. Clinical criteria and therapeutic approaches, Postgrad. Med., 74(3): 239-48, 1983.

2471. Eadie, M. J., Lander, C. M., Tyrer, J. H., Plasma drug level monitoring in pregnancy, Handbook of Clinical Pharmacokinetics, Gibaidi, M., Prescott, L., Eds., ADIS Health Science Press, New York, 52-62, 1983.

2472. Editor, Management of trigeminal neuralgia, Lancet, 662-3, Mar 24, 1984.

2473. Editor, Antiepileptic drug may enhance attentiveness, FASEB News, 1-2, 1984.

2474. Edwards, W. T., Approaches to managing chronic pain, Med. Times, 110: 3s-11s, 1982.

2475. Egido, J., Rivera, F., Sanebo, J., Barat, A., Hemado, L., Phenytoin in IgA nephropathy: a long-term controlled trial, Nephron., 38: 30-9,1984.

2476. Eichelbaum, K. M., Polymorphic drug oxidation in burnans, Fed. Proc., 43: 2298-2302, 1984.

2477. Eichelbaum, M., Genetic polymorphism of oxidative drug metabolism. Therapeutic and toxicologic implications, Internist, 24: 117-127, 1983.

2478. Eidar, M., Motro, M., Yahini, J. H., Neufeld, H. N., Atypical torsade de pointes, Am. Heart J., 106(2): 420-1, 1983.

2479. Elliot, F. A., Neurological factors in violent behavior (the dyscontrol syndrome), Violence and Responsibility, the Individual, the Family and Society, Sadoff, R. L., Ed., SP Medical & Scientific Books, New York, 59-86, 1978.

2480. Ellis, D., Effects of stimulation and diphenylhydantoin on the intracellular sodium activity in Purkinje fibres of sheep heart, J. Physiol., 362: 331-48, 1985.

2481. Elwes, R. D., Dellaportas, C., Reynolds, E. H., Robinson, W., Butt, W. B., London, D. R., Prolactin and growth hormone dynamics in epileptic patients receiving phenytoin, Clin. Endocrinol., 23: 263-70, 1985.

2482. Essman, W. B., Essman, E. J., Anticonvulsant effects upon regional synaptosomal GABA uptake: differences in convulsed rats, Brain Res. Bull., 5(2): 821-4, 1980.

2483. Evans, D. E., Gillis, R. A., Effect of diphenylhydantoin and lidocaine on cardiac arrhythrnias induced by hypothalamic stimulation,J. Pharmacol. Exp. Ther., 191(3): 506-17, 1974.

2484. Evans, D. E., Gillis, R. A., Effect of ouabain and its interaction with diphenylhydantoin on cardiac arrhythmias induced by hypothalamic stimulation, J. Pharmacol. Exp. Ther., 195:577-86, 1975.

2485. Evans, P. J., Walker, R. F., Peters, J. R., Dyas, J., RiadFahmy, D., Thomas, J. P., Rimmer, E., Tsanaclis, L., Scanlon, M. F., Anticonvulsant therapy and cortisol elimination, Br. J. Clin. Pharmac., 20: 129-32, 1985.

2486. Faber, J., Lumhltz, 1. B., Kirkegaard, C., Friis, T., Turnover studies of T4, T3 and rT3 in L-T4 treated hypothyroid subjects receiving phenytoin, Ann. Endocrinol., 44(4): 63a, 1983.

2487. Feldman, M. S., Helfant, R. H., Antiarrhythmic agents. Bellet’s Essentials of Cardiac Arrhythmias, Helfant, R. H., Ed., W. B. Saunders Company, Philadelphia, 308-29, 1980.

2488. Feldman, R. C., Pippinger, C. E., Florence, M. L., The relation of anticonvulsant drug levels to complete seizure control, Epilepsia, 16(l): 203-4, 1975.

2489. Fenimore, D. C., Davis, C. M., Simultaneous determination of phenobarbital and diphenylhydantoin in blood plasma by high performance thin layer chromatography, J. High. Resolut. Chroinatogr, Commun., 1: 105-106, 1978.

2490. Ferrendelli, J. A., Daniels-McQueen, S., Comparative actions of phenytoin and other anticonvulsant drugs on potassium- and veratridine-stimulated calcium uptake in synaptosomes, J. Pharm. Exp. Ther., 220(1): 29-34, 1982.

2491. Feurle, G. E., Weidauer, H., Baldauf, G., Schulte-Braucks, T., Anton-Lamprecht, I., Management of esophageal stenosis in recessive dystrophic epidermolysis bullosa, Gastroenterology, 87: 1376-80, 1984.

2492. Fields, H. L., Raskin, N. H., Anticonvulsants and pain, Clinical Neuropharmacology, Klawans, H. L., Ed., Raven Press, New York, 173-83, 1976.

2493. File, S. E., Lister, R. G., The anxiogenic action of Ro 5-4864 is reversed by phenytoin, Neurosci. Lett., 35: 93-6, 1983.

2494. File, S. E., Pellow, S., RO 5-4864, a ligand for benzodiazepine micromolar and peripheral binding sites: antagonism and enhancement of behavioral effects., Psychopharinacology, 80(2): 166-70, 1983.

2495. Fine, A. S., Person, P., Biochemistry of gingival oxidative metabolism: A Review, J. Oral. Pathol., 13: 191-212, 1984.

2496. Fine, W., Post-hemiplegic epilepsy in the elderly,Br. Med. J., 199-201, 1967.

2497. Finkel, M. J., Phenytoin revisited, Clin. Ther., 6(5): 577-91, 1984.

2498. Finn, A. L., Anticonvulsants, Applied Clinical Pharmacokinetics, Mungall, D., Ed., Haven Press, New York, 10326,1983.

2499. Finucane, J. F., Griffiths, R. S., Effect of phenytoin therapy on thyroid function, Br. J. Clin. Pharmacol., 3, 1041-4, 1976.

2500. Fitzgerald, D. C., Palatal myoclonous. Case report, Laryngoscope, 94(2): 217-19, 1984. 2501. Fogoros, B. N., Elson, J. J., Fiedler, S. B., Relative efficacy of phenytoin in suppressing inducible ventricular tachyarrhythmias, Circulation, 74(4): 11-105, 1986.

2502. Folbergrova, J., Cyclic GMP and cyclic AMP in the cerebral cortex of mice during seizures induced by 3-mercaptopropionic acid: effect of anticonvulsant agents, Neurosci. Lett., 16: 291-6, 1980.

2503. Foong, F. W., Satoh, M., Takagi, H., A newly devised reliable method for evaluating analgesic potencies of drugs on trigeminal pain, J. Pharmacol. Methods, 7: 271-78, 1982.

2504. Fortman, C. S., Witte, D. L., Serum 5’-nucleotidase in patients receiving antiepileptic drugs, Am. J. Clin. Pathol., 84(2); 197-201, 1985.

2505. Franceschi, M., Perego, L., Cavagnini, F., Cattaneo, A. G., Invitti, C., Caviezel, F., Strambi, L. F., Smirne, S., Effects of long-term antiepileptic therapy on the hypothalamicpituitary axis in man, Epitepsia, 25(l): 46-52, 1984.

2506. Franklyn, J. A., Davis, J. B., Ramsden, D. B., Sheppard, M. C., Phenytoin and thyroid hormone action, J. Endocrinol., 104: 201-04, 1985.

2507. Franklyn, J. A., Sheppard, M. C., Ramsden, D. B., Measurement of free thyroid hormones in patients on long-term phenytoin therapy, Europ. J. Clin. Pharmacol., 26(5): 6334, 1984.

2508. Franssen, H., Fortgens, C., Wattendorff, A. R., Van Woerkom, C. A., Paroxysmal kinesigenic choreoathetosis and abnormal contingent negative variation, Arch. Neurol., 40: 381-5, 1983.

2509. Freed, C. R., Cal, J., Manchester, D. K., Increased pbenytoin requirement during pregnancy results from an increase in drug metabolism, Clin. Res., 33(1): 91A, 1985.

2510. Frenkel, G. M., Safronova, N. A., Marova, E. I., Lemesheva, S. N., A change in electrical activity of the brain under the effect of diphenylhydantoin in patients with Itsenko-Cushing disease, Probl. Endokrinol., 1: 19-22, 1976.

2511. Friedman, 1. M., Litt, I. F., Henson, R. E., Saliva phenobarbital and phenytoin concentrations in epileptic adolescents, J. Pediatr., 98(4): 645-7, 1981.

2512. Friend, D. C., Addiction, psychedelic experimentation and abuse of drugs by the concerned generation, Md. State Med. J., 18: 59-66, 1969.

2513. Frigyesi, T. L., Lombardini, J. B., Augmentation of thalamo-motor cortico-cerebellar epileptogenesis by taurine and its antagonism by diphenlyhydantoin, Life Sci., 24: 125160,1979.

2514. Frisk-Holmberg, M., Hellstrom, L., Holmstrom, M., Dahlberg, E., Jakobsson, A. K., Utilization of blood drug level determinations for therapy monitoring, Lakartidningen, 77: 1316-7, 1980.

2515. Fromm, G. H., Chattha, A. S., Terrence, C. F., Glass, J. D., Do phenytoin and carbamazepine depress excitation and/or facilitate inhibition?, Europ. J. Pharmacol., 78: 403-9, 1982.

2516. Fukuda, A., Tabuse, H., Ihara, N., Tanabe, J., Ikeda, H., Kohama, A., Effects of phenytoin on regional cerebral blood flow, electroencephalogram, and electrolyte contents in cerebral blood and cerebral cortex following total cerebral ischemia in dogs, Circulatory Shock, 10: 341-50, 1983.

2517. Gaffey, C. M., Chun, B., Harvey, J. C., Manz, H. J., Phenytoin-induced systemic granulomatous vasculitis, Arch. Pathol. Lab. Med., 110: 131-5, 1986.

2518. Gallager, D. W., Mallorga, P., Tallman, J. F., Interaction of diphenylhydantoin and benzodiazepines in the CNS, Brain Res., 189: 209-20, 1980.

2519. Gallagher, J. P., lnokuchi, H., Nakamura, J., Shinnick-Gallagher, P., Effects of anticonvulsants on excitability and GABA sensitivity of cat dorsal root ganglion cells, Neuropharmacology, 20: 427-33, 1981.

2520. Gallagher, J. P., Inokuchi, H., Shinnick-Gallagher, P., Actions of anti-convulsants on GABA-depolarizations and action potentials recorded from a mammalian sensory neuron, Soc. Neurosci. Abstr., 5; 588, 1970.

2521, Galvan, M., Actions of 4-aminopyridine on neurones, Fortschr. Med., 101(3), 1983.

2522. Gambertoglio, J. G., Effects of renal disease: altered pharmacokineties, Pharmacokinetic basis for drug treatment, Benet, L. Z., Ed., Raven Press, New York, 149-71, 1984.

2523. Gangarosa, L. P., Mahan, P. E., Pharmacologic management of TMJ-MPDS, Ear Nose Throat J., 61: 670-8, 1982.

2524. Gankina, E. M., Avdulov, N. A., Maisov, N. I., Effects of different psychotropic drugs on 14C-glutamate uptake by rat brain synaptosormes, Farmakol. Toksikol., 45(6): 17-20, 1982.

2525. Garan, H., Ruskin, J. N., Powell, W. J., Centrally mediated effect of phenytoin on digoxin-induced ventricular arrhythmias, Am. J. Physiol., 241: h67-h72, l981.

2526. Garcia-Bengoehea, F., Collins, C. H., Monstrocellular sarcoma of the brain: 6-year postoperative survival, J. Neurosurg., 31: 686-9, 1969.

2527. Garson, A., Ventricular dysrhythmias, Pediatric Cardiac Dysrhythtnias, Gillette, P. C., Carson, A., Eds., Grune & Stratton, New York, 295-360, 1981.

2528. Garson, A., Gillette, P. C., Treatment of chronic ventricular dysrhythmias in the young, Pace, 4: 658-69, 1981.

2529. Garson, A., Kugler, J. D., Gillette, P. C., Simonelli, A., McNamara, D. G., Control of late postoperative ventricular arrhythmias with phenytoin in young patients, Amer. J. Cardiol., 46(2): 290-4, 1980.

2530. Garson, A., Randall, D. C., Gillette, P. C., Smith, R. T., Moak, J. P., Me Vey, P., Me Namara, D. G., Prevention of sudden death after repair of tetralogy of Fallot: treatment of ventricular arrhythmias, J. Am. Coll. Cardiol., 6: 221-7,1985.

2531. Gayet-Hallion, T., On the temperature-reducing properties of diphenylhydantoin, Compt. Rend. Soc. Biol., 153: 760-1, 1959.

2532. Gedde-Dahl, T., Sixteen types of epidermolysis bullosa: on the clinical discrimination, therapy and prenatal diagnosis, Acta Derm. Venerol., 95: 74-87, 1981.

2533. Gedik, O., Sayek, I., Raucan, S., Telatar, F., Adalar, N., Usman, A., Akalin, S., Insulinoma. (Clinical, diagnostic and therapeutic features of 3 cases), Hacettepe Bull. Med. Surg., 15: 13-9, 1982.

2534. Geraidini, C., Sideri, G., EMG and nerve conduction velocity in patients treated with antiepileptic drugs, Electroencephalogr. Clin. Neurophysiol., 55(1): 9p, 1983.

2535. Gerson, W. T., Fine, S. P., Sensenbrenner, L. L., Anticonvulsant-induced aplastic anemia: increased susceptibility to toxic drug metabolites in vitro, Blood, 61(5): 889-93, 1983.

2536. Gilbert, J. C., Wyllie, M. G., Effects of anticonvulsants at the nerve terminal, Advances in Epileptology, Meinardi, H., Rowan, A. J., Swets & Zeitlinger, Amsterdam, 172-75, 1978.

2537. Gill, M. W., Connors, M. B., Schaiz, R. A., The effects of diazepam and phenytoin on phospholipid metabolism and ATPase activity: possible correlation with anticonvulsant activity, Pharmacologist, 27(3): 230, 1985.

2538. Gillis, R. A., Quest, J. A., The nervous system as an important site of action for drugs affecting cardiovascular function, Cardiac Pharmacology, Wilkerson, B. D., Ed., New York, Academic Press, 25-50, 1981.

2539. Gilman, A. G., Goodman, L. S., Rail, T. W., Murad, F., The Pharmacological Basis of Therapeutics, 7th Edition, Macmillan Publishing Co., New York, 1985.

2540. Gingrich, S. A., Smith, P. J., Shapiro, L. E., Surks, M. I., 5,5 2-diphenylhydantoin (phenytoin) attenuates the action of 3,5,3 2-triiodo-l-thyronine in cultured GC cells, Endocrinology, 116(6): 2306-13, 1985.

2541. Ginsberg, J., Chen, H. J., Walfish, P. G., Multiple sites of action of diphenylhydantoin on rat thyroid regulation, Ann. Endocrinol., 49a, 1979.

2542. Glueek, C. J., Nonpharmacologic and pharmacologic alteration of high-density lipoprotein cholesterol: therapeutic approaches to prevention of atherosclerosis, Am. Heart J., 110: 1107, 1985.

2543. Gobernado, J. M., Ortin, A., Rodriguez De Castro, A. R., Gimeno, A., Stiffman syndrome, Prensa Med. Argent., 68(15): 613-6, 1981.

2544. Godfrey, J. W., Roberts, M. A., Caird, F. I., Epileptic seizures in the elderly: 11. Diagnostic problems, Age and Ageing, 11: 29-34, 1982.

2545. Godolphin, W., Trepanier, J., Gas chromatography versus irnrnunoassay (EMIT) for analysis of free phenytoin in serum ultrafiltrate, Ther. Drug Monit., 6(3): 374-5, 1984.

2546. Goerz, G., Merk, H., Progress in dermatology: new biochemical aspects, Fortschr. Med., 100: 1467-71, 1982.

2547. Goldberg, M. A., The Pharmacology of Phenytoin, H. Houston Merritt Memorial Volume, Yahr, M.D., Ed., Raven Press, New York, 81-99, 1983.

2548. Goldman, A.S., Biochemical mechanism of glueocorticoidand phenytoin-induced cleft palate, Curr. Top. Dev. Biol., 19: 217-39,1984.

2549. Goldman, A. S., Baker, M. K., Piddington, R., Herold, R., Inhibition of programmed cell death in mouse embryonic palate in vitro by cortisol and phenytoin: receptor involvernent and requirement of protein synthesis, Proc. Soc. Exp. Biol. Med., 174(2): 239-43,1983.

2550. Grafova, V. N., Danilova, E. I., Kryzhanovskii, C. N., Analgesic effects of antiopileptic agents in pain of spinal origin, Bull. Exp. Biol. Med., 88(8): 147-51, 1979.

2551. Gram, L., Bentsen, K. D., Hepatic toxicity of antiepileptic drugs: A Review, Acta Neurol. Scand., 68 (sup97): 8190,1983.

2552. Grarnmaticos, P., Mirtsu-Fidant, V., Suslous, C., Paradellis, A., Observations of the action of diphonylhydantoiri on the neuromuscular preparation of the rat diaphragm, Drugs Expti. Clin. Res., 10(4): 235-9, 1984.

2553. Grassa, C., Figa-Talamanca, L., LoRusso, F., Giacanelli, M., Pontesilli, B., Syndrome of continuous muscle fiber activity, Ital. J. Neurol. Sci., 4: 415-8, 1981.

2554. Green, A. R., Grahame-Smith, D. G., The effect of diphenylhydantoin on brain 5-hydroxytryptamine metabolism and function, Neuropharmacology, 14: 107-13, 1975.

2555. Greenberg, D. A., Cooper, E. C., Carpenter, C. L., Phenytoin interacts with calcium channels in brain membranes,Ann. Neurol., 16: 616-17, 1984.

2556. Greenway, F. L., Dahms, W. T., Bray, G. A., Phenytoin as a treatment of obesity associated with compulsive eating, Curr. Ther. Res., 21(3): 338-42, 1977.

2557. Grenader, A. K., Ponomareva, V. M., Zurabishvili, G. G., Vasiev, B. N., Changes in the refractoriness of cardiac tissue as a result of a decrease in the fast inward sodium current. Comparison of the atrium and ventricle, Biofizika, 27(5): 911-14,1982.

2558. Griggs, R. C., Davis, B. J., Anderson, D. C., Dove, J. T., Cardiac conduction in myotonic dystrophy, Am. J. Med., 59: 37-42, 1975.

2559. Grindulis, K. A., Nichol, F. E., Oldham, R., Phenytoin in rheumatoid arthritis, J. Rheumatol., 13: 1035-9, 1986.

2560. Guill, M. F., Wray, B. B., Rogers, R. B., Yancey, K. B., Allen, B. S., Junctional epidermolysis bullosa: treatment with phenytoin, Am. J. Dis. Child., 137: 992-4, 1983.

2561. Gupta, C., Katsurnata, M., Goldman, A. S., H-2 histocompatibility region influences the inhibition of arachidonic acid cascade by dexamethasone and phenytoin in mouse embryonic palates, J. Craniofac. Genet. Dev. Biol., 5: 277-85, 1985.

2562. Gurevich, V. S., Matveeva, I. M., Ogurechnikov, V. I., Korovkina, G. V., Effect of diphenylhydantoin on taurine binding by subcellular fractions of nerve cells, Farmakol. Toksikol. 47(6): 74-7,1984.

2563. Gurevich, V. S., Razumovskaya, N. I., Molecular mechanisms of the interaction of diphenylhydantoin with biological membranes, Farmakol. Toksiko., 47(l): 114-19, 1984.

2564. Gut, I., Becker, B. A., Diphenylhydantoin stimulation of various pathways of hepatic microsomal drug metabolism in rabbits, Acta Univ. Carol. Med., 26(1-2): 105-14, 1980.

2565. Hagerman, G. A., Hanashiro, P. K., Reversal of tricyclic-antidepressant-induced cardiac conduction abnormalities by phenytoin, Ann. Emerg. Med., 10(2): 82-6, 1981.

2566. Haidukewych, D., Splane, M. L., Vasos, B., Enzyme immunochromatographic assay of phenytoin in capillary and venous blood compared with fluorescence polarization irnmunoassay of plasma from epileptic patients, Clin. Chem., 32(l): 204, 1986.

2567. Halmos, P., Molnar, L., Kormos, M., Experiences with anticonvulsants in the treatment of tinnitus, HNO Praxis, 7(l): 59-61,1982.

2568. Hamilton, N. G., Matthew, T., Aphasia: the sole manifestation of focal status epilepticus, Neurology, 29: 745-48, 1978.

2569. Hansen, H. W., The treatment of digitalis induced cardiac arrhythmia with diphenylhydantoin, Med. Klin., 65: 101-4, 1970.

2570. Hanson, J. W., Myrianthopoulos, N. C., Harvey, M. A., Smith, D. W., Risks to the offspring of women treated with hydantoins during pregnancy, Pediatr. Res., 10(4): 449, 1976.

2571. Hanstrom, L., The effect of diphenylhydantoin on the metabolism of connective tissue macromolecules in oral mucosa and bone in vitro, University of UMEA, Dissertation, 1981.

2572. Harik, S. I., Baraka, A. S., Tomeh, C. J., Mire Salmari, Kronfulk, Z., Afifi, A. K., Autonomous peripheral nerve activity causing generalized muscle stiffness and fasciculations: report of a case with physiological, pharmacological, and morphological observations, Johns Hopkins Med. J., 139: 60, 1976.

2573. Harned, C. L., Nerland, D. E., Sonnenfeld, G., Effects of passive transfer and induction of gamma (type II immune) interferon preparation on metabolism of diphenylhydantoin by murine cytochrome p-450, J. Interferon Res., 2(l): 5-10, 1982.

2574. Harris, M., Goldhaber, P., Root abnormalities in epileptics and the inhibition of parathyroid hormone induced bone resorption by diphenylhydantoin in tissue culture, Archs. Oral Biol., 19; 981-84, 1974.

2575. Harris, R. A., Differential effects of membrane perturbants on voltage-activated sodium and calcium-dependent potassium channels, Biophys. J., 45: 132-4, 1984.

2576. Hartman, G. S., Flamengo, S. A., Riker, W. F., Succinylcholine: mechanism of fasciculations and their prevention by d-tubocurarine or diphenylhydantoin, Anesthesiology, 65(4): 405-13, 1986.

2577. Hashimoto, K., Ishii, M., Komori, S., Mitsuhashi, H., Canine digitalis arrhythmia as a model for detecting Na-channel blocking antiarrhythmic drugs: a comparative study using other canine arrhythmia models and the new antiarrhythmic drugs, propafenone, tocainide, and SUN 1165, Heart Vessels, 1: 29-35,1985.

2578. Hashimoto, K., Satoh, H., Shibuya, T., Imai, S., Canine-effective plasma concentrations of antiarrhythmic drugs on the two-stage coronary ligation arrhythmia, J. Pharmacol. Exp. Ther., 223(3): 801-10, 1982.

2579. Hashimoto, K., Shibuys, T., Satoh, H., Imai, S., Quantitative analysis of the antiarrhythmic effect of drugs on canine ventricular affhythmias by the determination of minimum effective plasma concentrations., Jpn. Circ. J., 47: 92-97,1983.

2580. Hassell, T., O’Donnell, J., Pearlman, J., Salivary phenytoin levels in institutionalized epileptics, J. Chronic Dis., 36(12): 899-9W, 1983.

2581. Hassell, T. M., Evidence for production of an inactive collagenase by fibroblasts from phenytoin-enlarged human gingivae, J. Oral Pathol., 11: 310-17, 1982.

2582. Hawk, G. L., Franconi, L. C., High-pressure liquid chromatography in quantitation of antiepileptic drugs, Antiepileptic Drugs: Quantitative Analysis and Interpretation, Pipponger, C. E., et al., Eds., Raven Press, New York, 153-62, 1978.

2583. Hayashi, K., Takemura, N., Inhibition of PCB accumulation in liver and fat of rats by administration of diphenylhydantoin, Jpn. J. Ind. Health, 17: 242-3, 1975.

2584. Hayes, M. J., Langman, M. J., Short, A. H., Changes in drugs metabolism with increasing age; phenytoin clearance and protein binding, Br. J. Clin. Pharmac., 2: 72-9, 1975.

2585. Hegedus, L., Hansen, J. M., Luhdorf, K., Perrild, H., Feldt-Rasmussen, U., Karnpmann, J. P., increased frequency of goitre in epileptic patients on long-term pbenytoin or carbamazepine treatment, Clin. Endocrinol. (Oxford), 23(4): 4239,1985.

2586. Heinemann, U., Franceschetti, S., Hamon, B., Konnerth, A., Yaari, Y., Effects of anticonvulsants on spontaneous epileptiform activity which develops in the absence of chemical synaptic transmission in hippocampal slices, Brain Res., 325: 349-52, 1985.

2587. Heinicke, R. J., Stobs, S. J., Al-Turk, W., Lemon, H. M., Chronic phenytoin administration and the hepatic mixed function oxidase system in female rats, Gen. Pharmacol., 15(2): 85-9, 1984.

2588. Heller, F., Hepatotokicity caused by antituberculous and antiepileptic drugs, Louvain Med., 101(3): 159-65, 1982.

2589. Herchuelz, A., Lebrun, P., Sener, A., Malaisse, W. J., Ionic mechanism of diphenylhydantoin action on glucose-induced insulin release, Europ. J. Pharmacol., 73 (2-3): 189-97, 1981.

2590. Hernandez, J., Serrano, J. S., Experimental automaticity induced by mechanical lesion in rat isolated right ventricle; the effects of quinidine, phenytoin, and propranolol, J. Pharmacol. Methods, 7: 255-61, 1982.

2591. Herschkowitz, N., Mahany, T. M., Baizer, L., Raines, A., Phenytoin reduction of extensor tone and gamma motorneuron activity in the decerebrate cat, Neurosci. Abstr., 4: 297, 1978.

2592. Heuser, D., Possibilities and limitations of brain protections: general survey, Anasth. Intensivmed, 23(8): 315-24, 1982.

2593. Hier, D. B., Headache, Manual of Neurologic Therapeutics, 2nd Edition, Samuels, M. A., Ed., Little, Brown & Co., Boston, 15-29, 1982.

2594. Himmelhocb, J. M., Major mood disorders related to epileptic changes, Psychiatric Aspects of Epilepsy, Blumer, D., Ed., American Psychiatric Press Inc., Washington D.C., 271-94,1984.

2595. Hinds, J. A., Pincombe, C. F., Smith, S., Duffy, P., The use of a monosaccharide linkage group in a heterologous solid-phase enzyme immunoassay for phenytoin, J. Immunol. Methods, 80: 239-53, 1985.

2596. Hinds, J. A., Pincornbe, C. F., Smith, S., Duffy, P., Ligand displacement immunoassay-demonstration of its use for the measurement of serum phenobarbital and phenytoin, Clin. Chim. Acta, 149(2-3): 105-15, 1985.

2597. Hitchcock, E., Teixeira, M., Anticonvulsant activation of pain-suppressive systems, Appl. Neurophysiol., 45: 582-93, 1982.

2598. Hodson, A. K., Sanders, D. B., Isaac syndrome: a cause of infantile tetany and tremor during sleep, Neurology, 33: 74, 1983.

2599. Hoff, H., Hoff, H., Advances in the treatment of epilepsy, Monatsschr. Psychiatr. Neurol., 114: 105-18, 1947.

2600. Hoffman. B. F., Bigger, J. T., Digitalis and allied cardiac glycosides, The Pharmacological Basis of Therapeutics, 7th Edition, Gilman, G. A., et al., Eds., Macmillan Publishing Co., New York, 716-747, 1985.

2601. Holland, N. J., Wiesel-Levison, P., McDonnel, M., Nursing care, Multiple Sclerosis, A Guide for Patients and Their Families, Scheinberg, L. C., Ed., Raven Press, New York, 111-28, 1984.

2602. Hollander, A., What’s new in American dermatology?, Hautarzt., 130-37, 1982.

2603. Hou, H., Chen, D., A report of 25 cases of myotonic congenital, China Medical Abstracts, 2(4): 2.34-5, 1985.

2604. Howrie, D. L., Crumrine, P. K., Phenytoin-induced movement disorder associated with intravenous administration for status epilepticus, Clin. Pediatr., 24(8): 467-9, 1985.

2605, Hrazdira, C. L., Zouhar, A., Hrazdirova, V., Skalova, M., Dynamics of the serum levels of phenytoin and associated EEG changes after a single intravenous dose, Cesk. Neurol. Neurochir., 42: 185-94, 1979.

2606. Hsu, R., Turndorf, H., Mangiardi, J., Fischer, M., Preoperative management and anesthetic considerations, N.Y.U. Med. Center, Int. Anesthesiol. Clin., 20(2): 215-20, 1982.

2607. Iivanainen, M., Savolainen, H., Side effects of phenobarbital and phenytoin during long-term treatment of epilepsy, Acta Neurol. Scand., 68(97): 49-67, 1983.

2608. Ikeda, H., Pharmacologic studies on the central nervous system function of first generation rats of dams administered phenytoin during pregnancy, Nihon Yakurigaku Zasshi, 79:65-76,1982.

2609. Imaizumi, S., Suzuki, J., Kinouchi, H., Yoshimoto, T., Superior protective activity of phenytoin against hypoxia-pharmacological evaluation in a screening test, Brain Nerve, 38(2): 135-43, 1986.

2610. Imanaka, S., Matsuda, S., Ito, K., Matsuoka, T., Okada, Y., Studies of pharmacotherapy of inoperable insulinoma. Effectiveness of the combined use of diphenylhydantoin and calcium antagonists, Nippon Naika Gakkai Zasshi, 74: 590-6, 1985.

2611. Irace, P., Lesser, R. P., Kutt, H., Winkelman, E., Terrentine, S., Gardner, M., Altered phenytoin clearance in a patient with Crohn’s disease, Neurology, 33: 232, 1983.

2612. Isaacs, H., Heffron, J. J., The syndrome of continuous muscle-fibre activity cured: further studies, J. Neurol. Neurosurg. Psychiatry, 37: MI-5, 1974.

2613. Ivic, M., Klisic, L., Influence of diphenylhydantoin on the sodium, potassium ATPase activity in thyroid parafollicular cells and on the sodium, potassium-ATPase activity in parathyroid glands, Stereol. lugosl., 3(l): 593-8, 1981.

2614. Izumi, K., Kishita, C., Nakagawa, K., Huxtable, R. J., Shimizu, T., Koja, T., Fukuda, T., Reduced taurine contents and modification of anticonvulsive effects of phenobarbital and phenytoin by guanidinoethane sultanate in mice, Prog. Clin. Biol. Res., 179: 425-34, 1985.

2615. Izumi, K., Kishita, C., Nakagawa, K., Huxtable, R. J., Shimizu, T., Koja, T., Fukuda, T., Modification of the antiepileptic actions of phenobarbital and phenytoin by the taurine transport inhibitor, guanidinoethane sultonate, Europ. J. Pharmacol., 110: 219-24, 1985.

2616. Jacknowitz, A. I., Possible effect of viral infections on drug metabolism, JAMA, 251(16): 2084-5, 1984.

2617. Jacobs, A. H., What’s new in pediatric dermatology?, Acta Derm., 95: 91-5, 1981.

2618. Jailkhani, B. L., Jaffery, N. F., Comparison of colorimetric, spectrophotometric, and EMIT methods for estimation of phenytoin., Indian J. Med. Res., 79: 679-683, 1984.

2619. Jannetta, P. J., Medical treatment of trigeminal neuralgia, Neurological Surgery of the Ear and Skull Base, Brackmann, D. E., Ed., Raven Press, New York, 145-8, 1982.

2620. Januskevicius, Z., Disturbances of cardiac rhythm produced by use of cardiac glycosides, Kardiologiya, 10(2): 35-42, 1970.

2621. Janz, D., Pregnancy and development of the embryo in epileptic women, Geburtshilfe Fraunheilkd., 44(7): 428-34, 1984.

2622. Jay, G. W., Epilepsy, migraine, and EEG abnorrnalities in children: A review and hypothesis, Headache, 22: 11014, 1982.

2623. Jenkins, M. V., Harris, M., Wills, M. R., The effect of phenytoin on parathyroid extract and 25-hydroxycholecalciferol-induced bone resorption: adenosine 3’, 5’ cyclic rnonophosphate production, Calcif. Tissue Res., 16: 163-7, 1974.

2624. jenner, P., Marsden, D., Pratt, J., Actions of benzodiazepines and other anticonvulsants on 5HT turnover in mouse brain, Br. J. Pharmacol., 74: 812-3p, 1981.

2625. Johnson, C., Stuckey, M., Mitchell, J., Psychopharmacological treatment of anorexia nervosa and bulimia. Review and synthesis, J. Nerv. Ment. Dis., 524-.34, 1983.

2626. Johnson, L. C., Effects of anticonvulsant medication on sleep patterns, Sleep and Epilepsy, Sterman, M. B., Shouse, M. N., Passouant, P., Eds., Academic Press, New York, 381-94, 1982.

2627. Johnson, S. W., Riker, W. K., Relationships between the antagonism of electrically-induced maximal seizures by phenytoin (PHT) and central nervous system (CNS) levels of adenosine 3’,5-monophosphate (cAMP) and guanosine 3’,5monophosphate (cGMP) in frogs and mice, Soc. Neurosci. Abstr., 7, 1981.

2628. Johnson, S. W., Riker, W. K., Phenytoin antagonism of electrically induced maximal seizure in frogs and mice and effects on central nervous system levels of adenosine 3’,5’monophosphate and guanosine 3’,5’-monophosphate, J. Pharmacol. Exp. Ther., 221(l): 139-45, 1982.

2629. Jones, G. L., Kemp, J. W., Characteristics of the hydrogen bonding interactions of substituted hydantoins with 9-ethyladentine, Molec. Pharmacol., 10: 48-56, 1974.

2630. Jones, G. L., Wimbish, C. H., Hydantoins, Handbook of Experimental Pharmacology-Antiepileptic Drugs, Frey, H. H. and Janz, D., Eds., Springer-Verlag, Berlin, 74: 351-419, 1985.

2631. Jones, C. L., Wimbish, G. H., McIntosh, W. E., Phenytoin: Basic and clinical pharmacology, Med. Res. Rev., 3(4): 383-434, 1983.

2632. Jones, C. L., Woodbury, D. M., Biochemistry, Handbook of Experimental Pharmacology-Antiepileptic Drugs, Frey, H. H. and Janz, D., Eds., Springer-Verlag, Berlin, 74: 245-263, 1985.

2633. Jubiz, W., Meikle, A. W., Alterations of glueocorticoid actions by other drugs and disease states, Drugs, 18: 113-21, 1979.

2634. Juergens, U., Routine determination of eight common anti-epileptic drugs and metabolites by high performance liquid chromatography using a column-switching system for direct injection of serum samples, J. Chromatogr., 310(l): 97-106, 1984.

2635. Juma, I., Electrophysiological effects of antiepileptic drugs, Handbook of Experimental Pharmacology-Antiepileptic Drugs, Frey, H. H., and Janz, D., Eds., Springer-Veriag, Berlin, 74: 611-9, 645-58, 1985.

2636. Juma, I., Lanzer, G., Inhibition of the effect of reserpine on motor control by drugs which influence reserpine rigidity, Naunyn-Schmiedebergs Arch Pharmakcol., 262: 309-24,1969.

2637. Kadar, D., Fecycz, T. D., Kalow, W., The fate of orally administered (4-14 C) phenytoin in two healthy male volunteers, Can. J. Physiol. Pharinacol., 61: 403-7, 1982.

2638. Kaeser, H. E., Drug-induced myasthenic syndromes, Acta Neurol. Scand., 70 (Sup. 100): 39-47, 1984. 2639. Kaeser, H. E., Corbat, F., Neuromytonia or the malady of fasoiculations, Rev. Neurol., 120: 430-2, 1969.

2640. Kalff, R., Houtkooper, M. A., Meyer, J. W., Goedhart, D. M., Augusteijn, R., Meinardi, H., Carbamazepine and serum sodium levels, Epilepsia, 25(3): 390-7, 1984.

2641. Kallen, B., A register study of matemal epilepsy and delivery outcome with special reference to drug use, Acta Neurol. Scand., 73: 253-9,1986.

2642. Kalra, V., Transitory IgA deficiency in phenytoin treated epileptics, Neurology India, 31(3): 15-17, 1983.

2643. Kaluza, C., Kennedy, B. J., Harman, L., Head and neck complications of epidermolysis bullosa, Laryngoscope, 95: 599-600, 1985.

2644. Kaneko, S., Otani, K., Fukushima, Y., Sato, T., Narita, S., Kurahashi, K., Ogawa, Y., Nomura, Y., Shinagawa, S., Effects of antiepileptic drugs on hGH, TSH, and thyroid bormone concentrations during pregnancy, Int. J. Biol. Res. Pregnancy, 3(4): 148-51, 1982.

2645. Kaneko, S., Sato, T., Kirahashi, K., Hill, R. G., Taberner, P. V., Effect of carbamazepine on primary afferent depolarization and gamma-aminobutyric acid metabolism comparison with phenytoin, Igaku No. Ayumi, 121(12): 1030-2,1982.

2646. Karp, M., Lerman, P., Doron, M., Laron, Z., Effect of diphenylhydantoin on insulin response in the oral glucose tolerance test in children and adolescents, Helv. Paediatr. Acta, 28: 617-20,1973.

2647. Kasai, S., Hachimine, K., Effect of 5,5-diphenylbydantoin sodium on the synthesis of collagen by some fibroblastic cell lines including gingiva derived cells, Bull. Tokyo Dent. Coll., 15: 53-62, 1974.

2648. Kassai, Y., Okishic, Y., Kida, T., Ebisu, S., Okada, H., Immunopathological studies of phenytoin-induced gingival hyperplasia, Nippon Shishubyo Gakkai Kaishi, 27: 197-205, 1985.

2649. Kaste, M., Muuronen, A., Nikkila, E. A., Neuvonen, P. J., Increase of low serum concentrations of high-density lipoprotein (HDL) cholesterol in TIA patients treated with phenytoin, Stroke, 13: 123,1982.

2650. Kaste, M., Muuronen, A., Nikkila, E. A., Neuvonen, P. J., Increase of low serum concentrations of high-density lipoproteins (HDL) cholesterol in tia-patients treated with phenytoin, Stroke, 14(4); 525-30, 1983.

2651. Katsumata, M., Gupta, C., Baker, M. K., Sussdorf, C. E., Goldman, A. S., Diphenylhydantoin: an alternative ligand of a glucocorticoid receptor affecting prostaglandin generation in A/j mice, Science, 218: 1313-15, 1982.

2652. Kaukola, S., Manninen, V., Neuvonen, P. J., Malkonen, M., Ehnoholm, C., Effect of phenytoin on serum lipoproteins in middle-aged men, J. Cardiovase. Pharmacol., 3: 207-14,1981.

2653. Kauppinen, K., Stubb, S., Drug eruptions: causative agents and clinical types. A series of in-patients during a 10 year period, Acta Derm. Venereol., 64(4): 320-4, 1984.

2654. Kavey, R. E., Blackman, M. S., Sondheimer, H. M., Phenytoin therapy for ventricular arrhythmias occurring late after surgery for congenital heart disease, Am. Heart J., 104: 794-8, 1982.

2655. Kelly, T. E., Teratogenicity of anticonvulsant drugs. I: Review of the literature, Am. J. Med. Genet., 19: 413-434, 1984.

2656. Kennedy, S., Garfinkel, P. E., Anorexia nervosa, American Psychiatric Association Annual Review, Vol. 4, Hales, R. E. and Frances, A. J., Eds., American Psychiatric Press, Washington, D.C., 438-63, 1985.

2657. Kepes, E. R., Management of pain, Fundamentals of Geriatric Medicine, Cape, R. D., et al., Eds., Raven Press, New York, 247-57, 1983.

2658. Kero, M., Palotie, A., Peltonen, L., Collagen metabolism in two rare forms of epidermolysis bullosa, Br. J. Dermatol., 110: 177-84, 1984.

2659. Khan, M. T., The effect of diphenylhydantoin on liver regeneration in partially hepatectomized and on liver growth in normal rats, Garyounis Med. J., 2: 49-53, 1979.

2660. Khan, M. T., Studies on the uterine inhibitory actions of diphenylhydantoins, Arch. Int. Pharmacodyti. Ther., 260: 265-73,1982.

2661. Kilpatrick, C. J., Wanwimolruk, S., Wing, L. M., Plasma concentrations of unbound phenytoin in the management of epilepsy, Br. J. Clin. Pharmacol., 17(5): 539-46, 1984.

2662. King, R. B., Barnett, J. C., Studies of trigeminal nerve potentials, J. Neurosurg., 14: 617-27, 1957.

2663. Knott, C., Reynolds, F., The place of saliva in anti-epileptic drug monitoring, Ther. Drug Monit., 6(l): 35-41, 1984.

2664. Ko, P. T., Culamhusein, S., Kostuk, W. J., Torsades de pointes, a common arrhythmia induced by medication, Ann. Emerg. Med., 338: 3, 1983.

2665. Koizumi, F., Kumai, M., Ishimori, A., Comparison of i-PiT, TDX and EMIT measurement of serum phenytoin and digoxin levels, Rinsho Byori, 33(7): 761-770, 1985.

2666. Koppe, V. I., Klepel, H., Prenatal care and delivery of women having epileptic fits, Gynakol., 105(15): 955-60, 1983.

2667. Kotia, K. C., Haidia, S. S., Gupta, V., Role of oral diphenylhydantoin in angina pectoris, Clinician, 44(12): 510-14, 1980.

2668. Kotovskaya, E. S., Erina, E. V., Experiment in the use of neurotropic preparations (diphenylhydantoin and pyrroxan) for the purpose of the crisis-preventive treatment of hypertensive patients, Biull. Vsesoiuznogo Kardiol. Nauchn. Tsentra AMN SSSR, 5(l): 75-9, 1982.

2669. Krause, K. H., Rascher, W., Berlit, P., Plasma arginine vasopressin concentrations in epileptics under monotherapy, J. Neurol., 230(3): 193-6, 1983.

2670. Krnjevic, K., GABA-mediated inhibitory mechanisms in relation to epileptic discharges, Basic Mechanisms of Neuronal Hyperexcitability, Jasper, H. H. and Van Gelder, N. M., Eds., Alan R. Liss, Inc, New York, 249-80, 1983.

2671. Kruse, K., Kracht, U., Inhibition of calcitonin secretion/synthesis by anticonvulsant drugs, Acta Endocrinol., 96: 38-9,1981.

2672. Kruse, K., Kracht, U., Gopfert, G., Response of kidney and bone to parathyroid hormone in children receiving anticonvulsant drugs, Neuropediatrics, 13(l): 3-9, 1982.

2673. Kugler, J. D., Cheatham, J. P., Gumbiner, C. H., Hofschire, P. J., Latson, L. A., Results of phenytoin and propranolol drug electrophysiology studies for ventriculay tachyeardia in patients having repaired lesions with tetralogy of Fallot physiology, Circulation, 72(4): iii-341, 1985.

2674. Kulig, K., Baror, D., Marx, J., Wythe, E., Rumack, B. H., Phenytoin as treatment for tricyclic antidepressant cardiotoxicity in a canine model, Vet. Hum. Toxicol., 26(5): A-2, 1984.

2675. Kulig, K., Baror, D., Marx, J., Wythe, E., Rumack, B. H., Phenytoin as treatment of the cardiotoxicity of tricyclic antidepressant overdose in experimental animals, Vet. Hum. Toxicol., 25: 285, 1983.

2676. Kulkarni, S. K., Mehta, A. K., Possible mechanism of digoxin-induced convulsions, Psychopharmacology, 79(2-3) 287-9, 1983.

2677. Kulpmann, W. R., Gey, S., Beneking, M., Kohl, B., Oellerich, M., Determination of total and free phenytoin in serum by non-isotopic immunoassays and gas chromatography, J. Clin. Chem. Clin. Biochem., 22(11): 773-9, 1984.

2678. Kumps, A., Genin-Ramakers, J., Mardens, Y., Simultaneous determination of anticonvulsant drugs and metabolites in plasma by high-performance liquid chromatography, J. Chroinatogr., 342(2): 469-471, 1985.

2679. Kupersmith, J., Monitoring of antiarrhythmic drug levels: values and pitfalls, Clinical Pharmacology of Cardiac Antiarrhythmic Agents: Classical and Current Concepts Reevaluated, Carfein, 0. B., Ed., N.Y. Acad. Sci., 432: 138-54, 1984.

2680. Kutt, H., Phenytoin: interaction with other drugs, Antiepileptic Drugs, Woodbury, D. M., et al., Eds., Haven Press, New York, 227-40, 1982.

2681. Kutt, H., Interactions between anticonvulsants and other commonly prescribed drugs, Epilepsia, 25: s118-sl3l, 1984.

2682. Kwiecinski, H., Myotonia induced with clofibrate in rats, J. Neurol., 219: 107-16, 1978.

2683. Kwiecinski, H., The antimyotonic effect of diphenylhydantoin, Eur. J. Clin. Invest., 14: 37, 1984.

2684. Lai, M. L., Hung, T. P., Pharmacokineties of a large single dose phenytoin, J. Formosan Med. Assoc., 82: 370-80, 1983.

2685. Lalonde, R., Botez, M. I., Chronic phenytoin and the stereotyped motor response induced by 5-methoxy-N, N-dimethyltryptamine in rats, Brain Res., 326: 388-91, 1985.

2686. Lalonde, R., Botez, M. I., Subsensitivity to muscimolinduced catalepsy after long-term administration of phenytoin in rats, Psychopharmacology, 86: 77-80, 1985.

2687. Lamy, P. P., Prescribing for the Elderly, PSG Publishing Co., Littleton, Mass., 1980.

2688. Lander, C. M., Smith, M. T., Chalk, J. B., Bioavailability and pharmacokineties of phenytoin during pregnancy, Europ. J. Clin. Pharmacol., 27(l): 105-10, 1984.

2689. Langer, P., The effects of salicylates and similar acting substances, (diphenylhydantoin, dinitropbenol, etc.) on the bypophyseal-thyroid gland axis, Vnitr. Lek., 30: 48-54, 1984.

2690. Lasker, S. E., Lee, B. Y., Madden, R. E., Jetter, R. B., Topical use of 5,5-diphenyl-2,4-imidazolidinedione (diphenylhydantoin) inducing rapid granulation of chronic skin ulcers, Clin. Res., 31(3): 677a, 1983.

2691. Lason, W., Przewlocka, B., Przewlocki, R., The effect of Gamma-hydroxybutyrate and anticonvulsants on opioid peptide content in the rat brain, Life Sci., 33(l): 599-602, 1983.

2692. Laterza, A., Paolella, P., Valassi, F., Myotonia-like deforming stiffness (a new myo-oculo-skeletal disease sensitive to diphenylhydantoin, Rev. Otoneuroophtalmol., 42 (1); 5170, 1967.

2693. Lauxerois, M., Pechardre, J. C., Bonnard, M., Colnet, C., Gibert, J., Chabannes, J., Early preand postoperative epileptic seizures during operations on osteomeningeal breaches, value of preventive treatment with hydantoins, Neurochirurgie, 30(4): 241-4, 1983.

2694. Lazarev, A. V., Chernokhvostov, V. V., Kokoz, Y. M., Calmodulin-dependent regulation of calcium-activated outward current in frog atrial membrane, Adv. Myocardial., 3: 95-105,1982.

2695. Lazzara, R., Anomalous atrioventricular conduction and the pre-excitation syndromes, Bellet's Essentials of Cardiac Arrhythmias, Helfant, R. H., Ed., W. B. Saunders Co., Philadelphia, 182-96, 1980.

2696. Le Quesne, P. M., Neuropathy due to drugs, Peripheral Neuropathy by 78 Authorities, Vol. 2, Dyck, P. J., et al., Eds., W. B. Saunders Co., Philadelphia, 1263-80,1975.

2697. Lebrun, L. H., Villeneuve, J. P., Hypermetabolism of phenytoin as a cause of treatment failure, Can. J. Neurol. Sci., 9: 277,1982.

2698. Lee, K. S., Sancesario, L. G., Tetzlaff, W., Kreutzberg, C. W., Post-anoxic treatment with anticonvulsants: electrophysiological and anatomical studies of CAI pyramidal cells, Soc. Neurosci. Abstr., 12 (Pt 2): 869, 1986.

2699. Lehr, H. A., Zimmer, J. P., Kern, W., Diphonylhydantoin in AIDS, Dtsch. Med. Wschr., 111(44): 1701, 1986.

2700. Lehr, H. A., Zimmer, J. P., Diphenylhydantoin in the prevention and treatment of AIDS?, Dtsch. Med. Wochenschr., 111(25): 1001-2, 1986.

2701. Lemon, H. M., Stohs, S. J., Heinicke, R., Pfeiffer, R., Campbell, J. L., Anti-mammary carcinogenic activity of phenytoin (5,5' diphenylhydantoin), Proc. Am. Assoc. Cancer Res., 25: 128, 1984.

2702. Lennard, M. S., Ramsay, L. E., Silas, J. H., Tucker, C. T., Wood, H. F., Protecting the poor metabolizers: clinical consequences of genetic polymorphism of drug oxidation, Pharm. Int., 4: 53-7 Mar. 1983.

2703. Lepore, V., Di Reda, N., Defazio, C., Pedone, D., Giovine, A., Lanzi, C., Tartaglione, B., Livrea, P., Dopaminomimetic action of diphenylhydantoin in rat striatum: effect on homovanillic acid and cyclic AMP levels, Psychopharmacology, 86: 27-30, 1985.

2704. Leppik, I. E., Fisher, J., Kriel, R., Sawchuck, R., Altered phenytoin clearance during febrile illnesses, Neurology, 31(2): 158, 1981.

2705. Leppik, I. E., Patrick, B. W., Cranford, R. E., Treatment ofacute seizures and status epilepticus with intravenous phenytoin, Advances in Neurology. Status Epilepticus, Delgado-Escueta, A. V., Ed., Raven Press, New York, 447-51, 1983.

2706. Leppik, I. E., Ramani, V., Sawchuk, R. J., Cummit, R. J., Seizures and altered phenytoin metabolism in mononucleosis. Advances in Epileptology: The 10th Epilepsy International Symposium. Wada, J. A., Penry, J. K., Eds., Raven Press, New York, 506-7, 1980.

2707. Lemer, U., Fredholm, B. B., Hanstrom, L., Diphenylhydantoin inhibits parathyroid hormone and prostaglandin E2-stimulated bone resorption in mouse calvaria without affecting cyclic AMP formation, J. Oral. Pathol., 14: 644-53, 1985.

2708. Lemer, U., Hanstrom, L., Influence of diphenylhydantoin on lysosomal enzyme release during bone resorption -in vitro, Acta Pharmacol. Toxicol., 47: 144-50, 1980.

2709. Levin, R., Lee, S. I., Nonconvulsive status epilepticus following metrizamide myelogram, Ann. Neurol., 17(5): 518-19, 1985.

2710. Levine, D. N., Finklestein, S., Delayed psychosis after right temporoparietal stroke or trauma; relation to epilepsy, Neurology, 32: 267-73, 1982.

2711. Levine, M., Toxic reaction to phenytoin following a viral infection, Can. Med. Assoc. J., 128: 1270, 1983.

2712. Levy, G., Protein binding of drugs in the maternal-fetal unit and its potential clinical significance, Drugs and Pregnancy. Maternal Drug Handling-Fetal Drug Exposure, Krauer, B., et al., Eds., Academic Press, Orlando, 29-44, 1984.

2713. Levy, R. H., Moreland, T. A., Rationale for monitoring free drug levels, Clin. Pharmacokinet., 9 (sup 1): 1-9, 1984.

2714. Levy, R. H., Schmidt, D., Utility of free level monitoring of antiepileptic drugs, Epilepsia, 26(3): 199-205, 1985.

2715. Levy, R. H., Yerby, M. S., Effects of pregnancy of antiepileptic drug utilization, Epilepsia, 26(supl): s52-7, 1985.

2716. Lewin, E., Bleck, V., Electroshock seizures in mice: effect on brain adenosine and its metabolites,Epilepsia, 577-81, 1981.

2717. Lewis, D. V., Diphenylhydantoin reduces the outward current of the action potential in Aplasia, Brain Res., 207: 234-8,1981.

2718. Liedtke, B., Kerschensteiner, M., Manifestation of myotonic disturbances of muscle function under continuous intravenous drip treatment with the beta-adrenergic Th 1165a (fenoterolhydrobromide), Z. Geburtshilfe. Perinatol., 178(4): 297-303,1974.

2719. Liponi, D. F., Winter, M. E., Tozer, T. N., Renal function and therapeutic concentrations of phenytoin, Neurology, 34: 395-7, 1984.

2720. Lisander, B., Jaju, B., Wang, S. C., CNS site of antiarrhythmic action of diphenylhydantoin (DPH) in the cat, Eur. Pharinacol., 31(1): 53-62, 1975.

2721. Lishman, W. A., Symonds, C. P., Whitty, C. W., Willison, R. G., Seizures induced by movement, Brain, 85: 93-108, 1962.

2722, Liskow, B. I., Psychiatric disorders, Conn’s Current Therapy, Rakel, R. E., Ed., W. B. Saunders Company, Philadelphia, 899-902, 1986.

2723. Lisso, C., Mortari, A., Sioli, C., Marked antiarrhythmic activity of diphenylhydantoin, Atti Accad. Med. Lombarda, 22; 385-90, 1967.

2724. Lloyd, K. G., Worms, P., GABA agonists: their potential as anticonvulsant drugs, Br. Assoc. Psychopharmacol, Monogr., 2: 54-61, 1982.

2725. Loh, C. K., MeElhinney, A. J., Litwak, R., Peirce, E. C., Effects of antiarrhythmic agents on digitalis and hypoxia induced myocardial K loss, Fed. Proc., 41(4): 1107, 1982.

2726. Loiseau, P., Strube, E., Broustet, D., Battellochi, S., Gomeni, C., Morselli, P. L., Learning impairment in epileptic patients, Epilepsia, 24: 183-92, 1983.

2727. Lothman, E. W., Geary, W. A., Wooten, C. F., Perlin, B., Absence of specific binding of phenytoin to brain sections in vitro, Neurology, 36(4): 85, 1986.

2728. Lucchesi, B. R., Patterson, E. S., Antiarrhythmic drugs, Cardiovascular Pharmacology, 2nd Edition, Antonaecio, M. J., Ed., Raven Press, New York, 329-414,1984.

2729. Luckmann, E., Hossmann, H., Dorner, V., Rothenberger, W., Wichert, P. V., Clinical experience with diphenylhydantoin in ventricular and supraventricular extrasystoles, Aktuelter Stand der Pathosphysiologie, Diagnostik und Therapie von Herzrhythmusstorungen, Haan, D., Runge, M., Eds., Desitin Werk, Hamburg, 165-73, 1973.

2730. Ludewig, R., Otto, G., Therapeutic effect of topical phenytoin application, Russian Pharmacol. Toxicol., 45(3): 101-3, 1982.

2731. Luhdorf, K., Nielsen, C. J., Oy-baek, K., Hammerberg, P. E., Motor and sensory conduction velocities and electromyographic findings in man before and after carbarnazepine treatment, Acta Neurol. Scand., 67: 103-7,1983.

2732. Luoma, P. V., Sotaniemi, E. A., Pelkonen, R. O., Arranto, A., Ehnholm, C., Plasma high-density lipoproteins and hepatic microsomal enzyme induction: relation to histological changes in the liver, Europ. J. Clin. Pharmacol., 23: 275-82, 1982.

2733. Luoma, P. V., Myllyla, V. V., Sotaniemi, E. A., Hokkanen, T. E., Plasma HDL cholesterol and growth hormone in epileptics treated with anticonvulsants, Acta Pharmacol. Toxicol., 47: 249-251, 1980.

2734. Luoma, P. V., Myllyla, V. V., Sotaniemi, E. A., Lehtinen, I. A., Hokkanen, E. J., Plasma high-density lipoprotein cholesterol in epileptics treated with various anticonvulsants, Eur. Neurol., 19; 67-72,1980.

2735. Luoma, P. V., Pelkonen, R. O., Sotaniemi, E. A., Plasma high-density lipoprotein cholesterol and hepatic drug metabolizing enzyme activity in man, Acta Physiol. Scand., 226: 71, 1979.

2736. Luoma, P. V., Reunanen, M. I., Sotaniemi, E. A., Serum lipid levels during long-ten-n therapy with anticonvulsants, Clin. Pharmacol. Ther., 23: 119-20, 1978.

2737. Luoma, P. V., Reunanen, M. I., Sotaniemi, E. A., Changes in serum triglyceride and cholesterol levels during long-term phenytoin treatment for epilepsy, Acta Med. Scand., 206:229-31,1979.

2738. Luoma, P. V., Savolainen, M. J., Sotaniem, E. A., Pelkonen, B. O., Arranto, A. J., Enholm, C., Plasma high-density lipoproteins and liver lipids and proteins in man, Acta Med. Scand., 214: 103-9, 1983.

2739. Luoma, P. V., Sotaniemi, E. A., Arranto, A. J., Serum LDL cholesterol, the LDL/HDL cholesterol ratio and liver microsomal enzyme induction evaluated by antipyrine kinetics, Scand. J. Clin. Lab. Invest., 43; 671-75, 1983.

2740. Luoma, P. V., Sotaniemi, E. A., Pelkonen, R. O., Myllyla, V. V., Plasma high-density lipoprotein cholesterol and hepatic cytochrome P-450 concentrations in epileptics undergoing anticonvulsant treatment, Scand. J. Clin. Lab. Invest., 40: 163-67, 1980.

2741. Luoma, P. V., Sotaniemi, E. A., Pelkonen, R. O., Savolainen, M. J., Arranto, A., Enholm, C., Enzyme-inducers reduce the risk of atherosclerotic vascular disease?, Br. J. Clin. Pharmacol., 14(4): 606P, 1982.

2742. Luoma, P. V., Sotaniemi, E. A., Pelkonen, R. O., Inverse relationship of serum LDL cholesterol and the LDL/HDL cholesterol ratio to liver microsomal enzyme induction in man, Res. Commun. Chem. Pathol. Pharmacol., 42(l): 173-6, 1983.

2743. Lust, W. D., Fuessner, G. K., Passonneau, J. V., McCandless, D. W., Biochemical mechanisms of anticonvulsants: studies on cyclic neucleotide systems in brain, Neuropharmacology of Central Nervous System and Behavioral Disorders, Palmer, G. C., Ed., Academic Press, New York, 407-31, 1980.

2744. MacDonald, J. T., Childhood migraine-differential diagnosis and treatment, Postgrad. Med., 80(5): 301-6, 1986.

2745. Macdonald, R. L., Barbiturate and hydantoin anticonvulsant mechanisms of action, Basic Mechanisms of Neuronal Hyperexcitability, Jasper, H. H. and Van Gelder, N. M., Eds., Alan R. Liss, Inc., New York, 361-87, 1983.

2746. Macdonald, B. L., Anticonvulsant and convulsant drug actions on vertebrate neurones in primary dissociated cell culture, Electrophysiology of Epilepsy, Schwartzkroin, P.A. and Wheal, H. V., Eds., Academic Press, London, 353-87, 1984.

2747. Macdonald, R. L., McLean, M. J., Skerritt, J. H., Anticonvulsant drug mechanisms of action, Fed. Proc., 44: 2634-9, 1985.

2748. Macdonald, R. L., Skerritt, J. H., McLean, M. J., Anticonvulsant drug cations on GABA responses and sustained repetitive firing neurons in cell culture, Neuropharmacology, 23(7): 843-4, 1984.

2749. Macfarlane, D. C., Clark, B., Panayi, G. S., Pilot study of phenytoin in rheumatoid arthritis, Ann. Rheum. Dis., 45: 954-6,1986.

2750. MacKinney, A. A., Vyas, R., Lee, S. S., The effect of parahydroxylation of diphenylhydantoin on metaphase accumulation, Proc. Soc. Exp. Biol. Med., 149: 371-5, 1975.

2751. MacKinney, A. A., Vyas, B., Mueller, C., Corder, C., A comparison of potency of bydantoins in metaphase arrest and inhibition of microtubulay polymerization, Molec. Pharmacol., 17: 275-8, 1980.

2752. MacKinney, A. A., Vyas, R., Mueller, C., I-acetyl-3acetoxy-5’5-diphenylbydantoin has coichicine-like activity against microtubular protein, Res. Commun. Chem. Pathol. Pharmacol., 44(2): 251-64, 1984.

2753. MacKinney, A. A., Vyas, R., Powers, K., Morphologic effect of hydantoin drugs on mitosis and rnicrotubules of cultured human lymphocytes, J. Pharmacol. Exp. Ther., 204: 195202,1978.

2754. MacKinney, A. A., Vyas, R. S., Walker, D., Hydantoin drugs inhibit polymerization of pure microtubular protein, Pharmacol. Exp. Ther., 204(l): 189-94, 1978.

2755. Mace, P. F., Hughes, J., The Ames Seralyzer Reagent Strip System evaluated for measuring serum phenytoin, Clin. Chem., 32(2): 391, 1986.

2756. Maciewicz, R., Bouckoms, A., Martin, J. B., Drug therapy of neuropathic pain, Clin. J. Pain, l(l): 1-10, 1985.

2757. Maguire, J. H., Murthy, A. R., Hall, 1. H., Hypolipidemic activity of antiepileptic 5-phenylhydantoins in mice, Eur. J. Phamacol., 117; 135-8, 1985.

2758. Magyarosi, G. H., Therapeutic value of intravenous diphenylhydantoin in digitalis arrhythmia, Rev. Med. Intern., 37(l): 61-6,1985.

2759. Maitre, M. J., Coltart, J., Diagnosis of digitalis intoxication, International Symposium on Diagnosis and Treatment of Cardiac Arrhythmias, Bayes, A. and Cosin, J., Ed., Pergamon Press, New York, 701-24, 1980.

2760. Mann, D. N., Kumara-Siri, M. H., Surks, M. I., Effect of 5,5-diphenylhydantoin on the activities of hepatic cytosol malic enzyme and mitocbondrial alpha-glycerophosphate dehydrogenase in athyreotic rats, Endocrinology, 112(5): 1732-8, 1983.

2761. Mann, D. N., Surks, M. I., 5,5-diphenylhydantoin decreases specific 3,5,3’-triiodothyronine (T3) binding by rat hepatic nuclear T3 receptors, Endocrinology, 112(5): 1723-31, 1983.

2762. Marcoli, M., Gatti, G., Ippoliti, C., Lombardi, M., Crema, A., Zoechi, M. T., DePonti, F., Leechini, S., Frigo, G. M., Effect of chronic anticonvulsant monotherapy on lymphocyte subpopulations in adult epileptic patients, Hum. Toxicol., 4(2): 147-57,1985.

2763. Maria, G., Pisanelli, S., A case of neuromyotoniaconsiderations ofpathogenesis, Riv. Neurot., 53:400-09,1983.

2764. Marshall, J. B., Forker, A. D., Cardiovascular effects of tricyclic antidepressant drugs: therapeutic usage, overdose, and management of complications, Am. Heart J., 103 (3): 401-14, 1982.

2765. Martin, M. L., Pharmacologic therapeutic modalities: phenytoin, dimethyl sulfoxide, and calcium channel blockers, Crit. Care Quart., 5: 72-81, 1983.

2766. Marx, K. A., Anastasi, N. C., Hernandez, Y. M., Fivozinsky, K. B., Protection by phenytoin against the toxic effects of organophosphate on central respiratory centers, Soc. Neurosci. Abstracts, 10: 709, 1984.

2767. Mason, D. T., Zeiis, R., Lee, G., Hughes, J. L., Spann, J. F., Amsterdam, E. A., Current concepts and treatment of digitalis toxicity, Amer. J. Cardiol., 27: 546-59, 1971.

2768. Massei, R., DeSilva, E., Grosso, P., Robbiati, B. R., Infuso, L., Ravagnati, L., Altamura, C. A., Cerebral protection with diphenylhydantoin during disobliterating surgery of the sovra-aortic branches, J. Neurosurg. Sci., 27(2): 107-10, 1983.

2769. Mathur, K. S., Wahal, P. K., Seth, H. C., Intermittent anomalous atrioventricular excitation (W.P.W. aberation)-an unusual manifestation of digitalis toxicity, Indian Heart J., 21: 249-52,1969.

2770. Matsuki, N., Quandt, F. N., Ten Eich, R. E., Yeh, J. Z., Characterization of the block of sodium channels by phenytoin in mouse neuroblastoma cells, J. Pharmacol. Exp. Ther., 22,8(2): 523-30, 1984.

2771. Matsumoto, Y., Hiramatsu, M., Mori, A., Effects of phenytoin on convulsions and brain 5-hydroxytryptamine levels in E1 mice, IRCS Med. Sci. Biochem., 11(9): 837, 1983.

2772. Matsumoto, Y., Hiramatsu, M., Mori, A., Effects of chronic administration of phenytoin on its metabolism and brain monoamine level, Neurosciences (Kobe, Jpn), 10: 183-9, 1984.

2773. Matsuo, A., Yajima, T., Cell proliferation and collagen fibrogenesis of cultured fibroblasts, Jpn. J. Oral Biol., 27: 53-63, 1985.

2774. Matthews, W. D., McCafferty, C. P., Anticonvulsant activity of muscimol against seizures induced by impairment of GABA-mediated neurotransmission, Neuropharmacology, IS: 885-9, 1979.

2775. Mattson, R. H., Cramer, J. A., Epilepsy, sex hormones, and antiepileptic drugs, Epilepsia, 26(supi): S40-51, 1985.

2776. Maurya, A. K., Boyle, S., Mutagenic potential of anticonvulsant diphenylbydantoin (DPH) on human lymphocytes in vitro, Meth. Find. Exp. Clin. Pharmacol., 7(3): 109-12, 1985.

2777. Maxion, H., Jacobi, P., Schneider, E., Kohler, M., Effect of the anticonvulsant drugs primidone and diphenylhydantoin on night sleep in healthy volunteers and epileptic patients, Sleep 1974. 2nd Europ. Congr. on Sleep Research, Koella, W. P. and Levin, P. Eds., Karger, Basel, 510-13, 1975.

2778. Mayron, R., Ruiz, E., Phenytoin: does it reverse tricyclic-antidepressant-induced cardiac conduction abnormalities?, Ann. Emerg. Med., 14(5): 505, 1985.

2779. McClanahan, J. S., Maguire, J. H., Human stereoselective production of phenytoin (5,5-diphenylhydantoin) dihydrodiol and phenol metabolites, Pharmacologist, 27(3): 148, 1985.

2780. McGuire, S. A., Tomasovic, J. J., Ackerman, N., Hereditary continuous muscle fiber activity, Arch. Neurol., 41: 395-6, 1984.

2781. McKinney, L. C., Diphenylhydantoin reduces veratridine-induced sodium permeability in frog skeletal muscle, Neurosci. Lett., 55(2): 173-8, 1985.

2782. McLean, M., Carbamazepine and phenytoin limit rapid firing of action potentials of dorsal root ganglion neurons in cell culture, Soc. Neurosci. Abstr., 12 (Pt 2): 1015, 1986.

2783. McLean, M. J., Macdonald, R. L., Multiple actions of phenytoin on mouse spinal cord neurons in cell culture, Pharmacol. Exp. Ther., 227(3): 779-89, 1983.

2784. Mehta, M., Chronic pain, Recent Advances in Anaesthesia and Analgesia, Atkinson, R. S. and Hewer, L. C., Eds., Churchill Livingstone, New York, 157-77, 1982.

2785. Meldrum, B., Griffiths, T., Evans, M., Hypoxia and neuronal hyperexcitability-a clue to mechanisms of brain protection, Protection of Tissues Against Hypoxia, Wauquier, A., et al., Eds., Elsevier Biomedical Press, New York, 275-86, 1982.

2786. Meldrum, B. S., Anlezark, G. M., Ashton, C. G., Horton, R. W., Sawaya, C. B., Neurotransmitters and anticonvulsant drug action, Post-Traumatic Epilepsy and Pharmacological Prophylaxis, Majokowski, J., Ed., Polish Chapter of the Int. League Against Epilepsy, 139-53, 1977.

2787. Melten, J. W., Wittebrood, A. J., Willems, H. J., Faber, C. H., Werner, J., Faber, D. B., Comparison of equilibrium dialysis, ultrafiltration, and gel permeation chromatography for the determinations of free fractions of phenobarbital and phenytoin, J. Pharm. Sci., 74(6): 692-694, 1985.

2788. Mendiola-Gonzalez, J. F., Espejo-Plascencia, I., Chapa-Alvarez, J. R., Rodriguez-Noriega, E. Sodium diphenylhydantoin in burns: effects of pain and healing, Invest. Med. Int., 10: 443-7, 1983.

2789. Mercer, H. P., McGill, J. J., Ibrahim, R. A., Envenomation by sea snake in Queensland, Med. J. Aust., 1: 130-2, 1981.

2790. Messing, B. O., Carpenter, C. L., Greenberg, D. A., Mechanism of calcium channel inhibition by phenytoin: comparison with classical calcium channel antagonists, J. Pharmacol. Exp. Ther., 235(2): 407-1 1, 1985.

2791. Messing, R. O., Carpenter, C. L., Greenberg, D. A., Phenytoin (DPH) inhibits calcium flux through voltage-gated calcium channels in cultured cells, Neurology, 35(sup 1): 157, 1985.

2792. Meuienhoff, J. S., Phenytoin and the liver, Pharin. Weekbi., 117(39): 916-17,1982.

2793. Meyer, J., Epidermolysis Bullosa - Phenytoin, Schweiz. Med. Wochensch., 111(4): 1662-3, 1981.

2794. Michenfelder, J. D., Barbiturates for brain resuscitation: yes and no, Anesthesiology, 57(2); 74-75, 1982.

2795. Miller, J. A., Richter, J. A., Effects of anticonvulsants in vivo on high affinity choline uptake in vitro in mouse hippocampal synaptosomes, Br. J. Pharmacol., 84(l): 19-25, 1985.

2796. Miller, T. D., Pinkerton, T. C., Determinations of free phenytoin in plasma by ultra-filtration and high-performance liquid chromatography, Anal. Chim. Acta, 170(2): 295-300, 1985.

2797. Mimaki, T., Deshmukh, P. P., Yamamura, H. I., Effect of phenytoin on benzodiazepine receptors in rat brain, Advances in Epileptology: 12th Epilepsy International Symposium, Dam, M., et al., Eds., Raven Press, New York, 73-9, 1981.

2798. Minchin, M. C., Iversen, L. L., Release of [3H] gamma-aminobutyric acid from glial cells in rat dorsal root ganglia, J. Neurochem., 23: 533-40,1974.

2799. Missri, J. C., Shubrooks, S. J., Torsade de pointes: an atypical form of ventricular tachyeardia, Conn. Med., 46: 6970, 1982.

2800. Mitchell, J. E., Pyle, R. L., Eckert, E. D., Bulimia, American Psychiatric Association Annual Review, vol. 4, Hales, R. E. and Frances, A. J., Eds., American Psychiatric Press, Washington, D. C., 464-80, 1985.

2801. Mohr, J. P., Facial pain, Manual of Clinical Problems in Neurology, Little, Brown and Co., Boston, 97-8, 1984.

2802. Monroe, R. R., Episodic Behavioral Disorders, a Psychodynamic and Neurophysiologic Analysis, Harvard University Press, Cambridge, 1-517,1970.

2803. Monson, R. R., Heinonen, 0. P., Shapiro, S., Slone, D., Diphenylhydantoin and epilepsy in relation to congenital malformations and mental development, Am. J. Epidemiol., 100(6): 509,1974.

2804. Moore, S. L., Rakes, S. M., Binge eating-therapeutic response to diphenylhydantoin; case report, J. Clin. Psychiatry, 43: 385-6, 1982.

2805. Morello, R. S., Begenisich, T., Form and site of action of diphenylhydantoin on the sodium channel of squid axons, Biophys. J., 25: 135a, 1979.

2806. Morganroth, J., Comparative evaluation of antiarrhythmic agents, Drugs, 29 (Sup 4): 14-20, 1985.

2807. Moss, A. J., Schwarz, P. J., Delayed repolarization (QT or QTU prolongation) and malignant ventricular arrhythmias, Mod. Concepts Cardiovase. Dis., 5 1: 85-90, 1982.

2808. Moss, G., Stein, A. A., Cerebral etiology of the acute respiratory distress syndrome: diphenylhydantoin prophylaxis, J. Trauma, 15(1): 39-41, 1975.

2809. Mount, L. A., Reback, S., Familial paroxysmal choreoathetosis, Arch. Neurol. Psychiatry, 44: 841-7, 1940.

2810. Moustafa, M. A., Claesen, M., Adline, J., Vandervorst, D., Poupaert, J. H., Evidence for an arene-3,4-oxide as a metabolic intermediate in the meta- and para-hydroxylation of phenytoin in the dog, Drug Metab. Dispos., 11(6): 574-80, 1983.

2811. Moy, L. S., Tan, E. M., Holness, R., Uitto, J., Effects of phenytoin on collagen metabolism and growth of skin fibroblasts in culture, Clin. Res., 31(l): 22A, 1983.

2812. Mullen, P. W., Queiroz, M. L., The humoral immunotoxicological effects of phenytoin, an anticonvulsant drug with nonlinear pbarmacokineties, Immunotoxicology, NATO ASI Ser., Vol. G2, Mullen, P. W., Ed., Springer-Veriag, Berlin, 89-95,1984.

2813. Murphy, J. V., Reddy, M. N., Marquardt, K., High-density lipoprotein cholesterol concentrations in the plasma of children receiving anticonvulsants, Ann. Neurol., 10(3): 292, 1981.

2814. Muuronen, A., Kaste, M., Nikkila, E. A., Tolppanen, E. M., Mortality from ischaemic heart disease among patients using anticonvulsive drugs: a case-control study, Br. Med. J., 291: 1481-3, 1985.

2815. Naptomo, T., Effects of spartein and diphenylhydantoin on the sarcolemmal (Na+ K+)-ATPase activity of rat skeletal muscle, Niigata Yakka Daigaku Kenkyu Hokoku, 2: 1-4, 1982.

2816. Nakamura, H., Kadokawa, T., Nakatsuji, K., Nakamura, K., Pharmacological studies of a new anti-inflammatory drug, I-pbenyisulfony 1-5,5-diphenylhydantoin (PC-796) in experimental animals, Arzneim. Forsch., 20(8): 1032-46, 1970.

2817. Nakayama, K., Nakagawa, S., Sato, J., Kasahara, H., Sasaki, M., Mori, A., A clinicopharmaeological study on a seizure-controlled group with low serum concentrations of dipbenylhydantoin, Acta Neurol. Scand. suppl 79, 62; 103, 1980.

2818. Narr, H., New aspects in the treatment of dermatogenous contractures of the hand in epidermolysis bullosa, Handchir. Mikrochir. Plast. Chir., 16: 48-51, 1984.

2819. Nau, H., Kuhnz, W., Egger, H. J., Anticonvulsants during pregnancy and lactation. Transplacental, maternal and neonatal pharmacokineties, Clin. Pharmacokinet., 7: 508-43, 1982.

2820. Nemoto, E. M., Shin, G. K., Nemmer, J. P., Bleyaert, A. L., Pharmacologic attenuation of brain free fatty acid liberation during complete global ischemia as a measure of therapeutic efficacy, Protection of Tissues Against Hypoxia, Wauquier, A., Borgers, M., Eds., Elsevier Biomedical Press, New York, 211-21, 1982.

2821. Nencini, P., Phenytoin induces cyclic-AMP accumulation and free fatty acids release in rat brown adipose tissue, Pharmacol. Res. Commun., 14(7): 593-604, 1982.

2822. Neppe, V. M., The neuroleptic malignant syndrome, S. Afr. Med. J., 65: 523-5, 1984.

2823. Nicoletti, I., Mariotti, G., Filipponi, P., Serena Lungarotti, M., Hydantoin-induced fetopathy: description of one case, Minerva Pediatr., 32: 61-4,1980.

2824. Niedermeyer, E., Interactions of anticonvulsant drugs, Epilepsy Guide, Diagnosis and Treatment of Epileptic Seizure Disorders, Niedemeyer, E., Ed., Urban & Schwarzenberg, Baltimore, 208-11, 1983.

2825. Niedermeyer, E., Prevention of epileptic seizures, Epilepsy Guide, Diagnosis and Treatment of Epileptic Seizure Disorders, Niedenneyer, E., Ed., Urban & Sebwarzenberg, Baltimore, 199-202,1983.

2826. Niewiadomski, J. S., The hypothalamic and neurohypophysial vasopressin content as influenced by dipbenylhydantoin in dehydrated rats, Acta Physiol. Pol., 30(3): 351-8, 1979.

2827. Nikkila, E. A., Kaste, M., Ehnhoirn, C., Viikari, J., Increase of serum high-density lipoprotein in phenytoin users, Br. Med. J., 99, 1978.

2828. Nishikawa, T., Kubo, H., Saito, M., Competitive nephelometric immunoassay method for antiepileptic drugs in patient blood, J. Immunol. Methods, 29(l): 85-9, 1979.

2829. Nishimura, S., Imazawa, M., Miyamoto, K., Possible existence of loosely membrane-bound specific binding sites for phenytoin, Folia Psychiatr. Neurol. Jpn., 37(3): 303-5, 1983.

2830. Nissimov, B., Weiss, S., Zaavi, I., Mozes, K., Cardiac arrhythmias and electrocardiographic abnormalities in amitriptyline poisoning, Harefuah, 105-8 142-43, 1981.

2831. Noachtar, S., Roder, U. U., Wolf, P., The influence of long-term medication with diphenylhydantoin (DPH) on polygraphic sleep of epileptic patients, 16th Epilepsy International Congress, Abstracts, Hamburg, Sept. 6-9, Ciba-Geigy, Basel, 1, 1985.

2832. Norris, B., Saez, C., Comparison of the effects of carbamazepine and of diphenylhydantoin on the electrical properties of isolated toad skin, IRCS Med. Sci., 12: 164-5, 1984.

2833. North, J. B., Penhall, R. K., Hanieh, A., Frewin, D. B., Taylor, W. B., Phenytoin and postoperative epilepsy-a double-blind study, J. Neurosurg., 58: 672-7, 1983.

2834. Nosek, T. M., The effects of valproate and phenytoin on the cAMP and cGMP levels in nervous tissue, Proc. Soc. Exp. Biol. Med., 178(2): 196-9, 1985.

2835. Nosek, T. M., Crosland, M. B., Csukas, S., Calciumactivated neutral pirotease: activation and inhibition in striated muscle, Fed. Proc., 42(4): 1088,1983.

2836. Notani, M., Kawamura, H., Amano, K., Tanikawa, T., Kawabatake, H., Iseki, H., Shiwaku, T., Naga-o, T., Kakinoki, Y., Kitamura, K., The incidence of postoperative epilepsy and prophylactic anticonvulsants in patients with intracranial aneurysm, No Shinkei Geka, 12(3): 269-74, 1984.

2837. O’Callaghan, A. C., Nonnandale, J. P., Morgan, M., The prolonged Q-T syndrome. A review with anaesthetic irnplications and a report of two cases, Anaesth. Intensive Care, 10: 50-5, 1982.

2838. O’Neill, B., Callaghan, N., Stapleton, M., Molloy, W., Serum elevation of high density lipoprotein (HDL) cholesterol in epileptic patients taking carbamazepine or phenytoin, Acta Neurol. Scand., 65: 104-9,1982.

2839. Oellerich, M., Muller Vahl, H., The EMIT free level (TM) ultrafiltration technique compared with equilibrium dialysis and ultracentrifugation to determine protein binding of phenytoin, Clin. Pharmacokin., 9 (Sup. 1) 61-70, 1984.

2840. Ogura, C., Kunimoto, N., Kishirnoto, A., Takeshita, H., Mizukawa, R., Tsutsui, T., Hazama, H., Ryoke, K., Kurooka, S., Diphenylhydantoin concentrations in whole saliva, parotid saliva and plasma measured by enzyme immunoassay kit, Markit, Yonago Acta Med., 26(2-3): 55-64, IW.

2841. Okabe, H., Lebrei-, M., Karmen, A., Effects ofanticonvulsants on fatty acid metabolism in human serum, Tohoku Exp. Med., 148: 267-73,1986.

2842, Oldenkott, P., Lehr, H. A., Raisbeek, A. P., Ungerechtfe-tigter aussehlub von spendemieren nach phenytoin behandlung?, Dtsch. Med. Wschr., 110: 1834-5, 1985.

2843. Oneal, J. S., Sloan, K. B., Schulman, S. C., Substrate-labelled fluorescence immunoassay of phenytoin, J. Pharm. Biomed. Anal., 4(l): 103-6, 1986.

2844. Osawa, Y., The protective action of diphenylhydantoin (DPH) on the brain, J. Tokyo Med. Coll., 41(1): 3-14, 1983. 2845. Oxley, J., janz, D., Mcinardi, H., Chronic Toxicity of Antiepileptic Drugs, Raven Press, New York, 1983.

2846. Oyama, Y., Minagawa, K., Miura, H., Koshimizu, T., Effects of long-term administration of antiepileptic drugs on the pituitary-thyroid system in children, Acta Paediatr. Jpn., 21(l): 68-9, 1979.

2847. Pagni, C. A., Trigeminal neuralgia, Panminerva Med., 24:113-36, 1982.

2848. Painter, M. J., David, R., Alvin, J., The use of a stable isotope to study phenytoin metabolism in the newborn, Ann. Neurol., 16(3): 379,1984.

2849. Parsons, J. M., Sapse, A. T., Significance of hypercortisolism in anorexia nervosa, J. Orthomol. Psychiatry, 14(l): 13-18,1985.

2850. Partanen, V. S., Soininen, H., Saksa, M., Riekkinen, P., Electromyographic and nerve conduction findings in a patient with neurornyotonia, normocalcemic tetany and small cell lung cancer, Acta Neurol. Scand., 61: 216-26, 1980.

2851. Patsalos, P. N., Lascelles, P. T., Changes in regional brain levels of amino acid putative neurotransmitters after prolonged treatment with the anticonvulsant drugs diphenylhydantoin, phenobarbitone, sodium valproate, ethosuximide, and sulthiame in the rat, J. Neurochem., 36(2): 688-95, 1981.

2852. Paule, M. C., Killam, E. K., The effects of chronic phenytoin administration on incremental repeated acquisition (learning) tasks in the epileptic baboon, papio papio, Fed. Proc., 43(4): 1035, 1984.

2853. Paule, M. C., Killam, E. K., Serum anticonvulsant levels during chronic administration in the immature epileptic baboon, Papio papio, Proc. West. Pharmacol. Soc., 38: 169-72, 1985.

2854. Pedersen, J. C., An evaluation of the changes in bone turnover in an in vitro system: the direct effect on bone turnover of diphenylhydantoin, Acta Orthop. Scand., 53 (4): 703, 1981.

2855. Pedersen, J. G., Lund, B. J., Reimann, I., Influence of diphenylhydantoin on isotope release and bone enzymes in vitro, Acta Orthop. Scand., 53: 885-88, 1982.

2856. Peerless, S. J., Preand postoperative management of cerebral aneurysms, Clin. Neurosurg., 26: 209-30,-1979.

2857. Pei, Y. Q., Development and clinical application of antiepileptic drugs, Sheng Li Ka Hsueh Chin Chan, 12: 22833,1981.

2858. Perez-Ruvalcabaga, J. A., Quintero-Perez, N. P., Campa-Uribe, G., Chapa-Alvarez, R., Rodriquez-Noriega, E., The multiple uses of phenytoin in a general hospital setting, Eur. J. Clin. Invest., 14: 37, 1984.

2859. Perucca, E., Anticonvulsant drug interactions, Psychopharmacology of Anticonvulsants, Sandler, M., Ed., Oxford University Press, New York, 122-28, 1982.

2860. Perucca, E., Crema, A., Therapeutic monitoring of serum antiepileptic drug levels, Epilepsy: An Update on Research and Therapy, Nistico, G., et al., eds., Alan R. Liss, Inc., New York, 267-83, 1983.

2861. Perucca, E., Hichens, A., Drug interactions with phenytoin, Epilepsy Abstracts, 15(5); 189, 1982.

2862. Perucca, E., Hichens, A., Antiepileptic drug interactions, Handbook of Experimental Pharmacology, Antiepileptic Drugs, Frey, H. H. and Janz, D., Eds., Springer-Vertag, Berlin, 831-855, 1985.

2863. Perwein, E., Diphenylhydantoin therapy of a Gedde-Dahl Inverse (recessive) hereditary dystrophic bullous epidermolysis, Hautarzt., 34(4): 188, 1983.

2864. Petersen, E. N., DMCM: a potent convulsive benzodiazepine receptor ligand, Europ. J. Pharmacol., 94: 117-24, 1983.

2865. Peterson, D. I., Phenytoin absorption following jejunoileal bypass, Bull. Clin. Neurosci., 48: 148-9, 1983.

2866. Peterson, C. M., McLean, S., Monitoring free plasma concentrations of phenytoin, Br. J. Clin. Pharmacol., 18(6): 971-2, 1984.

2867. Pettengell, K. E., Spitaels, J. M., Sirnjee, A. E., Dysphagia and dystrophia myotonica: a case report, S. Afr. Med. J., 68: 113-14, 1985.

2868. Phillips, T. L., Wasserman, T. H., Johnson, R. J., Levin, V. A., Vanraalte, G., Final report on the United States phase 1 clinical trial of the hypoxic cell radiosensitizer, misonidazole (Ro-07-0582; NSC 261037), Cancer, 48: 1697-1704, 1981.

2869. Phillis, J. W., Wu, P. H., The effect of various centrally active drugs on adenosine uptake by the central nervous system, Comp. Biochem. Physiol., 72c: 179-87, 1982.

2870. Pincus, J. H., Weinfeld, H. M., Acetylcholine release from synaptosomes and phenytoin action, Brain Res., 296: 313-17, 1984.

2871. Pippenger, C. E., Bastiani, R. J., Schneider, R. S., Evaluation of an experimental homogeneous enzyme immunoassay for the quantitation of phenytoin and phenobarbitone in serum or plasma, Clinical Pharmacology of Anti-epileptic Drugs, Schneider, H., et al., Eds., Springer-Verlag, New York, 331-41, 1975.

2872. Piredda, S., Yonekawa, W., Whittingham, T. S., Kapferberg, H. J., Potassium, pentylenetetrazol, and anticonvulsants in mouse hippocampal slices, Epilepsia, 26(2): 167-74, 1985.

2873. Pirttiaho, H. I., Sotaniemi, E. A., Pelkonen, R. O., Pitkanen, U., Hepatic blood flow and drug metabolism in patients on enzyme-inducing anticonvulsants, Eur. J. Clin. Pharmacol., 22: 441-5, 1982.

2874. Pisciotta, A. V., Phenytoin: hematological toxicity, Antiepileptic Drugs, D. M. Woodbury, J. K. Penry, C. E. Pippenger, Eds., Raven Press, New York, 257-8, 1982.

2875. Plant, G., Focal paroxysmal kinesigenic choreoathetosis, J. Neurol. Neurosurg. Psychiatry, 46: 345-8, 1983.

2876. Pollack, S. V., Wound healing: a review - systemic medications affecting wound healing, J. Dermatol. Surg. Oncol., 8: 667-72, 1982.

2877. Pond, S. M., Pharmacokinetic drug interactions, Pharmacokinetic Basis for Drug Treatment, Benet, L. Z., et al., Eds., Raven Press, New York, 195-220, 1984.

2878. Pozdeev, V. K., The effect of diphenylhydantoin on the function of the brain transmitter systems, Mediator Processes in Epilepsy, Nauka, Leningrad, 85-92, 1983.

2879. Prasad, S., Kumari, P., Effect of diphenylhydantoin (DPH) sodium on some neurotransmitters of central nervous system, Indian J. Pharmacol., 14: 25, 1982.

2880. Pratt, J. A., Jenner, P., Marsden, C. D., Benzodiazepines, anticonvtxlsants, epilepsy and myocionus, Neurotransmitters, Seizures, and Epilepsy, Morselli, P. L., et al., Eds., Raven Press, New York, 227-38, 198 1.

2881. Pratt, J. A., Jenner, P., Marsden, C. D., Comparison of the effects of benzodiazepines and other anticonvulsant drugs on synthesis and utilization of 5-HT in mouse brain, Neuropharmacology, 24(l): 59-68, 1985.

2882. Pritchard, P. B., O’Neal, D. B., Nonconvulsive status epilepticus following metrizamide myelography, Ann. Neurol., 16: 252-4, 1984.

2883. Puceinelli, C., Ceccarelli, C., Mucci, G., Landucei, C., Phenytoin utilization as a possible treatment of torsade de pointe ventricular tachycardia, Minerva Cardioangiol., 29: 423-30, 1981.
2884. Quandt, F. N., Narahashi, T., Internal perfusion of neuroblastoma cells and the effects of diphenylhydantoin on voltage-dependent currents, Neurosci. Abstr., 6: 97, 1980.

2885. Quandt, F. N., Yeh, J. Z., Slow inactivation of single Na channels induced by diphenylhydantoin, Soc. Neurosci. Abstr., 12 (Pt 1): 45, 1986.

2886. Quattrone, A., Crunelli, V., Samanin, R., Seizure susceptibility and anticonvulsant activity of carbamazepine, diphenylhydantoin and phenobarbital in rats with selective depletions of brain monoamines, Neuropharmacology, 17: 643-7, 1978.

2887. Quest, J. A., Breed, C. R., Gillis, R. A., Effect of phenytoin on cardiac slowing induced by cholinergic stimulation, J.  Cardiovasc. Pharmacol., 4: 629-34, 1982.

2888. Rahwan, R. G., Piaseik, M. F., Witiak, D. T., The role of calcium antagonism in the therapeutic action of drugs, Can. J. Physiol. Pharmacol., 57(5): 443-60, 1979.

2889. Raines, A., Mahany, T. M., Baizer, L., Swope, S., Hershkowitz, N., Description and analysis of the myotonolytic effects of phenytoin in the decerebrate cat: implications for potential utility of phenytoin in spastic disorders, J. Pharmacol. Exp. Ther., 232(1): 283-94, 1985.

2890. Rall, T. W., Schleifer, L. S., Drugs effective in the therapy of the epilepsies, The Pharmacological Basis of Therapeutics, 7th edition, Gilman, A. G., et al., Eds., Macmillan Publishing Co., New York, 446-72, 1985.

2891. Rane, A., Peng, D., Phenytoin enhances epoxide metabolism in human fetal liver cultures, Drug Metab. Dispos., 13(3): 382-5, 1985.

2892. Rapport, R. L., Harris, A. B., Friel, P. N., Ojemann, G. A., Human epileptic brain: Na, K, ATPase activity and phenytoin concentrations, Arch. Neurol., 32(8); 549-54, 1975.

2893. Rashid, S., Waterfall, J. F., Effect of antiarrhythmic and analgesic drugs on the effective refractory period of guinea pig isolated atria and ventricular strips, J. Pharm. Pharmacol., 31: 411-2, 1979.

2894. Rating, D., Nau, H., Kuhnz, W., Antiepileptic drugs in the newborn clinical and pharmacological data, Monatsschr. Kinderheilkd., 131(1): 6-12,1983.

2895. Ratshin, B. A., Hunt, D., Russel, R. O., Rackley, C. E., QT-interval prolongation, paroxysmal ventricular arrhythmias, and convulsive syncope, Ann. Intern. Med., 75: 919-24, 1971.

2896. Rau, J. H., Struve, F. A., Green, R. S., Electroencephalographic correlates of compulsive eating, Clin. Electroencephalogr., 10: 180-9, 1979.

2897. Reddy, M. N., Effect of anticonvulsant drugs on plasma total cholesterol, high-density lipoprotein cholesterol, and apolipoproteins A and B in children with epilepsy, Proc. Soc. Exp. Biol. Med., 180(2): 354-63, 1985.

2898. Reeves, S. E., Hanyok, J. J., Amon, S. A., Cooley, P. J., Discrepancy in serum phenytoin concentrations determined by two immunoassay methods in uremic patients., Am. J. Hosp. Pharm., 42: 359-361, 1985.

2899. Reisecker, J., Markut, H., Tuizer, W., Problems with diagnosis and therapy of myotonia dystrophies, Wien. Med. Wochenschr., 133 (12): 319-21, 1983.

2900. Requena, R., Forte, R., Knopf, M., Scherrer, J., Kirschner, J., Levowitz, B. S., Intracellular potassium and vitamin A in the prevention of stress ulcers. Surg. Forum, 23: 388-9, 1972.

2901. Resnekov, L., Das Gupta, D. S., Prevention of ventricular rhythm disturbances in patients with acute myocardial infarction, Am. Heart J., 98(5): 653-9, 1979.

2902. Reynolds, E. H., Travers, R. D., Serum anticonvulsant concentrations in epileptic patients with mental symptoms, Br. J. Psychiat., 124: 440-5, 1974.

2903. Reynolds, E. H., Adverse haematological effect of antiepileptic drugs, Chronic Toxicity of Antiepileptic Drugs, Oxley, J., et al., Eds., Raven Press, New York, 91-99, 1983.

2904. Rhee, H. M., Effects of some antiarrhythmic agents on 45Ca++ transport in dog heart membrane vesicles and 86Rb+ transport in specialized cardiac tissues, Calcium-Binding Proteins 1983, DeBernard, B., et al., Eds., Elsevier Science Publishers, Amsterdam, 293-5, 1983.

2905. Rhee, H. M., Evidence against an involvement of Na+, K+-ATPase in antiarrhythmic mechanism of phenytoin, Naunyn. Schmiedebergs. Arch. Pharmacol., 323(1): 78-84, 1983.

2906. Ribares, R. G., Miller, R. J., Phenytoin inhibits voltage-dependent and dihydropyridine-stimulated calcium uptake by NGlO8ccl5, Soc. Neurosci. Abstr., II: 596, 1985.

2907. Ricevuti, G., Mazzone, A., Danesino, M., Toscano, M., Rizzo, S. C., Phenytoin to prevent or control granulocyte transfusion reactions, Lancet, 37, Jul 7, 1984.

2908. Rimmer, E. M., Buss, D. C., Routledge, P. A., Richen, A., Should we routinely measure free plasma phenytoin concentration?, Br. J. Clin. Pharmacol., 17(l): 99-102, 1984.

2909. Rodenkirchen, R., Bayer, R., Mannhold, R., Specific and non-specific Ca antagonists. A structure-activity analysis of cardiodepressive drugs, Prog. Pharmacol., 5(l): 9-23, 1982.

2910. Rodin, E., Subramanian, M. G., Gilroy, J., Investigation of sex hormones in male epileptic patients, Epilepsia, 25(6): 690-4, 1984.

2911. Rodriguez-Noriega, E., Esparza-Ahumada, S., Andrade-Perez, J. S., Espejo-Plascencia, I., Chapa-Alvarez, R., Treatment of ulcerations in soft tissues with topical diphenylhydantoin, Invest. Med. Int., 10: 184-6, 1983.

2912. Rodriguez-Noriega, E., Chapa-Alvarez, R., Perez-Ruvalcaba, J. A., The many in-hospital indications of diphenylhydantoinate, Invest. Med. Int., 10: 443-7,1983.

2913. Rodriguez-Noriega, E., Perez-Ruvalcaba, J. A., Quintero-Perez, N. P., Hernandez-Bugarin, O., Macias-Hernandez, O., Chapa-Alvarez, J. R., Andrade-Perez, J. S., The effect of phenytoin on muscle spasms and the hyperactive sympathetic syndrome of tetanus, Eur. J. Clin. Invest., 14; 36, 1984.

2914. Rosen, T., Schimmel, M. S., A short review of perinatal pharmacology, Bull. N.Y. Acad. Med., 59(7): 669-77, 1983.

2915. Rosman, N. P., Oppenheimer, E. Y., O’Connor, J. F., Emergency management of pediatric head injuries, Emerg. Med. Clin. North Am., 1: 141-74, IW.

2916. Rothstein, P., Dornbusch, J., Shaywitz, B. A., Prolonged seizures associated with the use of viscous lidocaine, J. Pediatr., 101: 461-3, 1982.

2917. Rousso, I., Pharmakiotis, A., Gatzola, M., Karatza, E., Tourkantonis, A., Sklavounou-Tsouroutsoglou, S., Effects of phenobarbital, diphenylhydantoin and carbamazepine on thyroid function in epileptic children, Acta Endocrinol., 107(265); 48-9,1984.

2918. Rowe, D. J., Harris, M., Effects of anticonvulsant drugs on bone resorption induced by parathyroid extract in vitro, Anticonvulsant Drugs and Enzyme Induction, Richens, A. et al., Eds., Associated Scientific Publ., Amsterdam, 113121,1976.

2919. Russel, J. M., Harvey, S. C., Effects of diphenylhydantoin on canine atria and A-V conduction system, Arch. Int. Pharmacyodyn., 182(i): 219-31, 1969.

2920. Sakai, T., Hosokawa, S., Shibasaki, H., Goto, I., Kuroiwa, Y., Sonoda, H., Murai, Y., Syndrome of continuous muscle-fiber activity: increased CSF GABA and effect of dantrolene, Neurology, 33: 495-8, 1983.

2921. Saladini, M., Gabana, M. A., Bracco, F., Effect of antiepileptic drugs on the cerebral amino acid uptake in vitro, Ital. J. Neurol. Sci., 2(4): 351-9, 1981.

2922. Sanchez-Chapula, J., Josephson, 1. R., Effect of phenytoin on the sodium current in isolated rat ventricular cells, J. Mol. Cell. Cardiol., 58(8): 515-22, 1983.

2923. Satoskar, R. S., Bhandakar, S. D., Pharmacotherapy of cardiac arrhythmias, Pharmacology and Pharmacotherapeutics, Bombay Popular Prakashan, Bombay, 316-30, 1983.

2924. Sayk, J., Kmietzyk, H. J., Survival time of glioma/glioblastoma patients under antiepileptic medication, Nervenarzt, 52: 611-15, 1981.

2925. Scandellari, C., Zaccaria, M., Sicolo, N., Casara, D., Erle, G., Federspil, G., Medical treatment of endogenous organic hyperinsulinism, Horm. Metab. Res., 6: 46-54, 1976.

2926. Schachner, E. ]R., Oster, Z. H., Cicale, N. R., The effect of diphenylhydantoin (Dilantin) on thallium-201 chloride uptake, Epilepsy Abstracts, 15(6): 202, 1982.

2927. Schaerrer, W. C., The use of Dilantin in the treatment of chronic ulcerative colitis, Personal Communication, 1-3, 1963.

2928. Schaffler, L., Karbowski, K., Relapsing paroxysmal abdominal pains of cerebral origin, Schweiz. Med. Wochenschr., 111(37): 1352-60,1981.

2929. Scheinberg, L., Giesser, B. S., Drug therapy, Multiple Sclerosis a Guide for Patients and Their Families, Scheinberg, L., Ed., Raven Press, New York, 45-55, 1984.

2930. Scherber, A., Richter, K., Schaps, P., Distribution of antiepileptic drugs between plasma, plasma water, cerebrospinal fluid, saliva and brain, Epilepsy: a Clinical and Experimental Research, Majkowski, J., Ed., Karger, Basel, 208-12, 1980.

2931. Scheuer, T., Kass, R. S., Phenytoin reduces calcium current in the cardiac Purkinje fiber, Cir. Res., 53: 16-23, 1983. 2932. Schless, G. L., Functional hypoglycemia: diagnosis and treatment, Diabetes, 31(2): 167a, 1982.

2933. Schmidt, D., Phenytoin, Adverse Effects of Antiepileptic Drugs, Raven Press, New York, 134-40, 1982.

2934. Schmidt, D., Adverse effects, Handbook of Experimental Pharmacology, Antiepileptic Drugs, Springer-Verlag, Berlin, 791-829, 1985.

2935. Schmidt, D., Seldon, L., Adverse Effects of Antiepileptic Drugs, Raven Press, New York, 1982.

2936. Schorer, R., Brain protection, Anaesthesiol. lntensivmed., 23(8): 3, 1982.

2937. Schottelius, D. D., Homogeneous immunoassay systern [EMIT] for quantitation of antiepileptic drugs in biological fluids, Antiepileptic Drugs: Quantitative Analysis and Interpretation, Pippenger, C. E., et al., Eds., Raven Press, New York, 95-108, 1978.

2938. Schreiner, C. A., Holden, H. E., Mutagens as teratogens: a correlative approach, Teratogenesis and Reproductive Toxicology, Johnson E. M. and Kochhar D. M., Eds., SpringerVeriag, Berlin, 135-68,1983.

2939. Schwarz, M., Sontag, K. H., Phenytoin potentiates the antispastic action of diazepam in spastic Han-Wistar mutant rats, Naunyn-Schmied. Arch. Pharmacol., 321: r42, 1982.

2940. Sechi, C. P., Traccis, S., Durelli, L., Monaco, F., Mutani, R., Carbamazepine versus diphenylhydantoin in the treatment of myotonia, Eur. Neurol.., 22: 113-18, 1983.

2941. Seeman, P., The membrane actions of anesthetics and tranquilizers, Pharamacol. Rev., 24(4): 583-655, 1972.

2942. Seipel, L., Breithardt, G., Medical treatment of sinus node disease: antiarrhythmic drugs and sinoatrial conduction, International Symposium on Diagnosis and Treatment of cardiac Arrhythmias, Bayes, A., and Cosin, J., Eds., Pergamon Press, New York, 636-61, 1980.

2943. Selby, G., Diseases of the fifth cranial nerve, Peripheral Neuropathy, Vol. 1, Dyck, P. J., et al., Eds., W. B. Saunders Co., Philadelphia, 533-69, 1975.

2944. Selzer, M. E., David, G., Yaari, Y., Phenytoin reduces frequency potentiation of synaptic potentials at the frog neuromuscular junction, Brain Res., 304(1): 149-53, 1984.

2945. Selzer, M. E., David, C., Yaari, Y., On the mechanism by which phenytoin blocks post-tetanic potentiation at the frog neuromuscular junction, J. Neurosci., 4(11): 2894-9, 1985.

2946. Serra, S., Callito, G., DeDomenico, P., Morgante, L., Bianchi, L., Ajello, L., Musolino, R., Arena, A., DiPerri, R., Influence of antiepileptic drugs on plasma lipid levels, Acta Neurol., 38(3): 190-7, 1983.

2947. Shah, D. S., Chambon, P., Guidotti, A., Binding of [3H]-5,5 Diphenythydantoin in rat brain membranes, Neuropharmacology, 20; 1115-9, 198 1.

2948. Sheppard, M. C., Davis, J. R., Lynam, T. C., Franklyn, J. A., Docherty, K., Phenytoin effects on prolactin release and synthesis, J. Endocrinol., 107 sup:abs 113, 1985.

2949. Shiba, D. A., Weinkam, B. J., The in vivo cytotoxic activity of procarbazine and procarbazine metabolites against L1210 ascites leukemia cells in CDF-1 mice and the effects of pretreatment with procarbazine phenobarbital, diphenylhydantoin and methylprednisolone, Cancer Chemother. Pharmacol., 11(2): 124-9, 1983.

2950. Shibuya, T., Hashimoto, K., Imai, S., Effective plasma concentrations of antiarrhymic drugs against sustained halothane-adrenaline arrhythmia in dogs, J. Cardiovasc. Pharmacol., 5(4): 538-45, 1983.

2951. Shrivastava, S., Tandon, R., The long QT interval: clinical significance and therapeutic implications, Indian J. Chest Dis. Allied Sci., 25: 60-8, 1983.

2952. Seigel, E. G., Janjic, D., Wollheim, C. B., Phenytoin inhibition of insulin release: studies on the involvement of Ca+ fluxes in rat pancreatic islets, Diabetes, 31: 265-9, 1982.

2953. Siegel, R. C., Scleroderma (systemic sclerosis), Conn’s Current Therapy, Rakel, R. E., Ed., W. B. Saunders Co., Philadelphia, 627-30, 1986.

2954. Simmonds, M. S., Distinction between the effects of barbiturates, benzodiazepines and phenytoin on responses to gamma-aminobutyric acid receptor activation and antagonism by bicuculline and picrotoxin. Br. J. Pharmacol., 73(3): 739-47,1981.

2955. Simpson, C. F., Taylor, J., Neurotoxic and antihypertensive effects of phenytoin in turkeys, J. Pharmacol. Exp. Ther., 233(3): 853-6, 1985.

2956. Singer, H. S., Slesinger, P., Effect of anticonvulsants on a neuroblastoma X glioma hybrid cell line: cell growth and synaptic neurochemistry, Epilepsia, 26(5): 519, 1985.

2957. Singer, P. A., Crarnpton, R. S., Bass, N. H., Familial Q-T prolongation syndrome, Arch. Neurol., 31: 64-6, 1974.

2958. Sirgo, M. A., Green, P. J., Rocei, M. L., Vlasses, P. H., Interpretation of serum phenytoin concentrations in uremia is assay-dependent, Neurology, 34: 1250-1, 1984.

2959. Sironi, V. A., Ravagnati, L., Ettorre, C., Cabrini, G. P., Marossero, F., Differences between the concentrations of antiepileptic drugs in normal and pathological human brain, Eur. J. Clin. Pharmacol., 22; 447-9, 1982.

2960. Skerritt, J. H., Davies, L. P., Johnston, C. A., A Purinergic component in the anticonvulsant action of carbamazepine?, Europ. J. Pharmacol., 82: 195-7, 1982.

2961. Skerritt, J. H., Johnston, G. A., Inhibition of amino acid transmitter release from rat slices by phenytoin and related anticonvulsants, Clin. Exp. Pharmacol. Physiol., 10: 527-33, 1983.

2962. Skerritt, J. H., Johnston, G. A. Modulation of excitant amino acid release by convulsant and anticonvulsant drugs, Neurotransmitters, Seizures, and Epilepsy II, Fariello, R. G. et al., Eds., Raven Press, New York, 215-26, 1984.

2963. Skillrud, D. M., Goldstein, N. P., Paroxysmal limb hemiataxia with crossed facial paresthesias in multiple sclerosis, JAMA, 250(20): 2843-4, 1983.

2964. Smith, P. J., Surks, M. I., Multiple effects of 5,5-diphenylhydantoin on the thyroid hormone system, Endocr. Rev., 5(4): 514-24, 1984.

2965. Smith, R. C., Daves, G. D., Lynn, R. K., Gerber, N., Hydantoin ring glucuronidation: characterization of a new metabolite of 5,5-diphenylhydantoin in man and the rat, Biomed. Mass Spectrom., 4(4): 275-9, 1977.

2966. Snow, R. W., Hasan, Z., Dudek, F. E., Effects of phenytoin on field bursts of rat hippocampal slices in low calcium solutions, Neuropharmacology, 24(9): 915-17, 1985.

2967. Snyder, C. H., Epileptic equivalents in children, Pediatrics, 21: 308-18, 1958.

2968. Solomon, G. E., Kutt, H., Plum, F., Special management problems. Complications of anti-epileptic drug therapy, Clinical Management of Seizures. A guide for the Physician, 2nd edition, W. B. Saunders Co., Philadelphia, 292-304, 1983.

2969. Solomon, G. E., Plum, F., Seizure types, Clinical Management of Seizures: A Guide for the Physician, W. B., Saunders Co., Philadelphia, 20-53,1976.

2970. Sonnenfeld, G., Harned, C. L., Nerland, D. E., Effects of interferon on drug metabolism, Tex. Rep. Biol. Med., 41: 363-9, 1981.

2971. Sordillo, P., Matarese, R. A., Novich, R. K., Zabetakis, P. M., Michelis, M. F., Specific modalities of therapy for inappropriate antidiuretic hormone secretion, Clin. Nephrol., 15(3): 107-10, 1981.

2972. Spark, R. F., Wills, C. A., Royal, H., Hypogonadism, hyperprolactinaemia, and temporal lobe epilepsy in hyposexual men, Lancet, 413-7 Feb. 25, 1984.

2973. Spiehler, V., Sun, L., Miyada, D. S., Sarandis, S. G., Walwick, E. R., Klein, M. W., Jordan, D. B., Jessen, B., Radioimmunoassay, enzyme immunoassay, spectrophotometry and gas-liquid chromatography compared for determination of phenobarbital and diphenylhydantoin, Clin. Chem., 22(6): 749-53, 1976.

2974. Spielberg, S. P., Gordon, G. B., Blake, D. A., Goldstein, D. A., Predisposition to phenytoin hepatotoxicity assessed in vitro, N. Eng. J. Med., 305(13): 722-27, 1981.

2975. Spinelli, W., Rosen, M., Developmental and use-dependent effects of phenytoin on neonatal and adult Purkinje fibers, J. Am. College Cardiol., 7(2): 123A, 1986.

2976. Spinelli, W., Rosen, M. R., Frequency-dependent actions of phenytoin in adult and young canine Purkinje fibers, Pharmacol. Exp. Ther., 238(3): 794-801, 1986.

2977. Sprague, G. L., Craigmill, A. L., Control of ethanol withdrawal symptoms in mice by phenytoin, Res. Commun. Chem. Pathol. Pharmacol., 15: 721-31, 1976.

2978. St. John, J. N., Glossopharyngeal neuralgia associated with syncope and seizures, Neurosurgery, 10: W-3, 1982.

2979. Staple, P. H., Eisenberg, C. M., Slosey, J. L., Waterhouse, J., Schofield, J., Patel, M., Effect of phenytoin on adjuvant arthritis (AA) in the rat, Arthritis Rheum., 24(4): s98, 1982.

2980. Staple, P. H., Wigdor, H. A., Phonytoin and proteoglycans of rabbit cartilage, J. Dent. Res., 63; 269, 1984.

2981. Steen, B., Rane, A., Lonnerholm, G., Phenytoin excretion in human breast milk and plasma levels in nursed infants, Ther. Drug. Monit., 4(4); 331-4, 1982.

2982. Stein, E., Kleinfeld, M., Diphenylhydantoin on sinoatrial pacemaker cells, Circulation, 35,36: 242, 1967.

2983. Stone, T. W., Studies with excitatory amino acid antagonists in rat CNS: 2-amino-5-phosphonovaleric acid, phenytoin, and benzodiazepines, Adv. Biochem. Psychopharmacol., 23: 223-30, 198 1.

2984. Stone, W. E., Javid, M. J., Effects of anticonvulsants and other agents on seizures induced by intracerebral L-glutamate, Brain Res., 264(1): 165-67, 1983.

2985. Stopfkuchen, H., Gilfrich, H. J., Jungst, B. K., Gempp, W., Massive digoxin intoxication in childhood, Intensive Care Med., 4:199-201, 1978.

2986. Striano, S., Meo, R., Bilo, L., Vitolo, S., Sleep apnea syndrome in Thomsen’s disease. A case report, Electroencephalogr. Clin. Neurophysiol., 56: 323-5, 1983.

2987. Strickler, S., Dansky, L., Andermann, E., Spielberg, S., Pharmacogenetic predisposition to phenytoin-induced birth defects, Pediatr. Res., 19(4 pt. 2): 180a, 1985.

2988. Strickler, S. M., Miller, M.A., Andermann E., Dansky, L. V., Seni, M. H., Spielberg, S. P., Genetic predisposition to phenytoin-induced birth defects, Lancet, 746-9, Oct. 5, 1985.

2989. Subik, M., Robinson, O. S., Phenytoin overdose with high plasma levels (case report), W. Va. Med. J., 78(11): 281-2, 1982.

2990. Sugaya, E., Matsuo, T., Takagi, T., Kajiwara, K., Kidokoro, Y., Phenytoin inhibition of hyperexcitability induced by low calcium in frog nerves, IRCS Med. Sci., 12: 1109-10, 1984.

2991. Sugaya, E., Onozuka, M., Furuichi, H. A., Kishii, K., Imai, S., Sugaya, A., Effect of phenytoin on intracellular calcium and intracellular protein changes during pentylenetetrazole-induced bursting activity in snail neurons, Brain Res., 327(1985) 161-8, 1985.

2992. Sung, M. L., Liang, Y. H., Wang, C. S., Shieh, C. C., Lu, S. A., Torsade de pointes—an unusual multiform ventricular tachycardia: a case report, Chin. Med. J., 29(6): 455-8, 1982.

2993. Surawicz, B., Pharmacologic treatment of cardiac arrhythmias: 25 years of progress, J. Am. Coll. Cardiol., 1: 36581, 1983.

2994. Surks, M. I., Ordene, K. W., Mann, D. N., Kumara-Siri, M. H., Diphenylhydantoin inhibits the thyrotropin response to thyrotropin-releasing hormone in man and rat, J. Clin. Endocrinol. Metab., 56: 940-5, 1983.

2995. Surman, 0. S., Parker, S. W., Complex partial seizures and psychiatric disturbance in end-stage renal disease, Psychosomatics, 22; 1077-80, 1981.

2996. Suzuki, H., Yamazake, N., Suzuki, Y., Hiraiwa, M., Shimoda, S., Mori, K., Miyasaka, M., Lowering effect of diphenylhydantoin on serum free thyroxine and thyroxine binding globulin (TBG), Acta Endocrinol., 105 (4): 477-81, 1984.

2997. Swerdlow, M., Anticonvulsant drugs and chronic pain, Clin. Neuropharmacol., 7 (1): 51-82, 1984.

2998. Taguchi, K., Watanabe, M., Ioku, M., A case of syringomyelia: electrophysiological analysis and treatment for attacks of periodical spasms and intractable pain, Neurol. Med. Chir., 21: 135-42, 1981.

2999. Takagi, T., Kajiwara, K., Komatsubara, J., Sugaya, E., Inhibitory effect of phenytoin on hyperexcitability induced by low calcium in frog nerves, Kanagawa Shigaku., 20(3): 394401, 1985.

3000. Takayasu, S., Maeda, M., Tsuji, A., Chemiluminescent enzyme immunoassay using .²-D-galactosidase as the label and the bis(2,4,6-trichlorophenyl)oxalate-fluoreseent dye system, J. Immunol. Methods, 83(2): 317-25, 1985.

3001. Takeya, K., Hotta, Y., Yajima, M., Effect of phenytoin on the positive inotropic actions of grayanotoxin-I and C-strophanthin in the isolated guinea pig atria under contraction-frequency change, J. Aichi Med., Univ. Assoc., 8(2): 96-104, 1980.

3002. Talesnik, E. G., Rivero, S. D., Gonzalez, B. M., Low serum concentrations of IgA and IgM in epileptic children treated with phenytoin, Rev. Chil. Pediatr., 56(2): 76-80,1985.

3003. Tang, X., Isaacs syndrome: report of a Chinese case with clinical and electrophysiologic study, China Med., Abstr., 2(3): 183, 1985.

3004. Tappaz, M., Pacheco, H., Effects of convulsant and anticonvulsant drugs on the spontaneous and induced release of GABA (14C) from slices of rat cerebral cortex, J. Pharmacol., 4:433-52,1973.

3005. Tasse, D. P., Protective value of diphenylhydantoin and vitamin A against stress ulcer, Can. J. Surg., 25(2): 194-5, 1982.

3006. Taylor, J. W., Murphy, M. J., Rivey, M. P., Clinical and electrophysiologic evaluation of peripheral nerve function in chronic phenytoin therapy, Epilepsia, 26(5): 416-20, 1985.

3007. Taylor, R. G., Layzer, B. B., Davis, H. S., Fowler, W. M., Continuous muscle fiber activity in the Schwartz-Jampel syndrome, Electroencephalogr. Clin. Neurophysiol., 33: 497509,1972.

3008. Teasdale, E., Macpherson, P., Guidelines for cervical myelography: lumbar versus cervical puncture technique, Br. Radiol., 57: 789-93, 1984.

3009. Tesseraud, F., Puissant, A., Epidermolysis bullosa, Rev. Prat., 33(15): 751-8, 1983.

3010. Theodore, W. H., Bairamian, D., Newmark, M. E., DiChiro, G., Porter, R. J., Larson, T., Fishbein, D., Effect of phenytoin on human cerebral glucose metabolism, J. Cereb. Blood Flow Metab., 6(3): 315-20, 1986.

3011. Theodore, W. H., Yu, L., Price, B., Yonekawa, W., Porter, R. J., Kapetanovic, I., Moore, H., Kupferberg, H., The clinical value of free phenytoin levels, Ann. Neurol., 18: 90-3, 1985.

3012. Thomas, M., Verges, B., Treatment of diabetic diarrhoea with phenytoin, Presse Med., 15: 11-14, 1986.

3013. Thompson, P. J., Phenytoin and psychosocial development, Antiepileptic Drug Therapy in Pediatrics, Morselli, P. L., Pippinger, C. E., Penry, J. K., Eds., Raven Press, New York, 193-200, 1983.

3014. Thompson, P. J., Huppert, F. A., Trimble, M. R., Phenytoin and cognitive function; effects on normal volunteers and implications for epilepsy, Br. J. Clin. Psychol., 20: 155-62,1981.

3015. Thompson, P. J., Trimble, M. R., Comparative effects of anticonvulsant drugs on cognitive functioning, Br. J. Clin. Pract., 154-6,1981.

3016. Thompson, P. J., Trimble, M. R., Anticonvulsant drugs and cognitive functions, Epilepsia, 23: 531-44, 1982.

3017. Tilson, H. A., Hong, J. S., Mactutus, C. F., Effects of 5,5-diphenylhydantoin (phenytoin) on neurobehavioral toxicity of organochlorine insecticides and permethrin, J. Pharmacol. Exp. Ther., 233(2): 285-9, 1985.

3018. Timiras, P. S., Hill, H. F., Hormones and epilepsy, Antiepileptic Drugs: Mechanisms of Action, Glaser, G. H., et al., Eds., Raven Press, New York, 655-66, 1980.

3019. Todd, M. M., Chadwick, H. S., Shapiro, H. M., Dunlop, B. J., Marshall, L. F. Dueek, R., The neurologic effects of thiopental therapy following experimental cardiac arrest in cats, Anesthesiology, 57: 76-86,1982.

3020. Tongia, S. K., Antagonism of frusemide diuresis by diphenylbydantoin sodium, Indian J. Med. Res., 74: 572-4, 1981. 3021. Toone, B., Wheeler, M., Fenwick, P., Effects of anticonvulsant drugs on male sex hormones and sexual arousal, Psychopharmacology of Anticonvulsants, Sandler, M., Ed., Oxford University Press, New York, 136-42, 1982.

3022. Toone, B. K., Wheeler, M., Nanjee, M., Fenwick, P., Grant, R., Sex hormones, sexual activity and plasma anticonvulsant levels in male epileptics, J. Neurol. Neurosurg. Psychiatry, 46; 824-6, 1983. ,

3023. Trimble, M., Anticonvulsant drugs, behavior, and cognitive abilities, Curr. Dev. Psychopharmacol., 65-91, 1981.

3024. Trimble, M. R., Corbett, J. A., Behavioural and cognitive disturbances in epileptic children, Irish Med. J., 73(10): 21-8, 1980.

3025. Trimble, M. R., Thompson, P., Corbett, J., Anticonvulsant drugs, cognitive function, and behavior, Psychopharmacology of Anticonvulsants, Sandler, M., Ed., Oxford University Press, New York, 106-21, 1982.

3026. Trimble, M. R., Thompson, P. J., Anticonvulsant drugs, cognitive function and behavior, Epilepsia, s55-s63, 1983.

3027. Troupin, A. S., Shaw, L. M., A new centrifugal filtration device for free drug separation, Epilepsia, 26(5): 455-9, 1985.

3028. Tsuchiya, J., Experimental studies on stress ulcer pathogenically related to subarachnoid hemorrhage, Gifu Daigaku Igakubu Kiyo, 29(5): 929-72, 1981.

3029. Tsuru, M., Erickson, R. R., Holtzman, J. L., The metabolism of phenytoin by isolated hepatocytes and hepatic microsomes from male rats, J. Pharmacol. Exp. Ther., 222(3): 658-61, 1982.

3030. Tuffanelli, D. L., Scleroderma (systemic sclerosis), Conn’s Current Therapy, Rakel, R. E., Ed., W. B. Saunders Co., Philadelphia, 681-83, 1984. .

3031. Tunnicliff, C., Smith, J. A., Ngo, T. T., Competition for diazepam receptor binding by diphenylhydantoin and its enhancement by gamma-aminobutyric acid, Biochem. Biophy. Res. Commun., 91: 1018-24, 1979.

3032. Turk, J. W., Ladenson, J. H., Phenytoin and phenobarbital concentrations in renal insufficiency, Ann. Intern. Med., 101(4): 568-9,1984.

3033. Turley, C. P., Milligan, T., Rapid protein determinations on ultrafiltrates prepared for free phenytoin quantification, Ther. Drug. Monit., 7(3): 313-14, 1985.

3034. Turnbull, D. M., Rawlins, M. D., Weightrnan, D., Chadwick, D. W., “Therapeutic” serum concentration of phenytoin: the influence of seizure type, J. Neurol. Neurosurg. Psychiatry, 47(3): 231-4, 1984.

3035. Twombly, D., Narahasbi, T., Phenytoin suppresses calcium channel currents in neuroblastoma cells, Soc. Neurosci. Abstr., 11: 518, 1985.

3036. Twombly, D. A., Narahashi, T., Phenytoin block of low threshold calcium channels is voltage and frequency-dependent, Soc. Neurosci. Abstr., 12 (Pt 2): 1193, 1986.

3037. Uhl, H. A., Phenytoin: the drug choice in tricyclic antidepressant overdose?, Ann. Emerg. Med., 10(5): 270-4, 1981.

3038. Umstead, C. S., McKernan, T. M., Salivary phenytoin concentrations in geriatric patients, Epilepsy Abstracts, 15(9): 340, 1982.

3039. Uram, M., Nemoto, E. M., Winter, P. M., A comparison of the effects of cerebral protective drugs and nonprotective drugs on monolayers of phospholipids, Anesthesiology, 59(3): A301, 1983.

3040. Urbaniak, J. R., Roth, J. H., Office diagnosis and treatment of hand pain, Orthop. Clin. North Am., 13: 477-95, 1982.

3041. U.S. Pharmacopeia Drug Information, Drug Information for the Health Care Provider, U.S. Pharmacopeial Convention, Inc., Rockville.

3042. Valimaki, M., Effects of drugs and nonthyroid disorders on thyroid hormones, Duodecim., 98(17): 1247-56, 1982.

3043. Valli, G., Barbieri, S., Cappa, S., Pellegrini, G., Searlato, G., Syndromes of abnormal muscular activity: overlap between continuous muscle fiber activity and the stiff man syndrome, J. Neurol. Neurosurg. Psychiatry, 46: 241-7, 1983.

3044. Van der Molon, H. L., Pbenytoin: pharmacology of seizure control, Hormonal Factors in Fertility, Infertility and Contraception, Van der Molen, H. J., et al., Eds., Excerpta Medica, Princeton, 71-82,1982.

3045. Van Hoeck, G. M., Comparison study between anticonvulsants assays and their free fractions in serous blood, saliva and capillary blood in man, J. Pharmacol., 15(l): 27-35, 1984.

3046. Varotto, M., Roman, G., Battistin, L., Pharmacological influences on the cerebral level and transport of GABA. Effect of some antiepileptic drugs on the cerebral level of GABA, Boll. Soc. Ital. Biol. Sper., 57(8): 904-8, 1981.

3047. Vasilescu, C., Florescu, A., Peripheral neuropathy with a syndrome of continuous motor unit activity, J. Neurol., 226: 275-82, 1982.

3048. Vernadakis, A., Neurotoxic effects of phenytoin: the developing organism, Mechanisms of Actions of Neurotoxic Substances, Prasad, K. N., Vernadakis, A., Eds., Haven Press, New York, 155-79, 1982.

3049. Vincent, P. C., Drug-induced aplastic anaemia and agranulocytosis, incidence and mechanisms, Drugs, 31: 52-63, 1986.

3050. Vizi, E. S., Pasztor, E., Release of acetylcholine from isolated human cortical slices: inhibitory effect of norepinephrine and phenytoin, Exp. Neurol., 73: 114-53, 1981.

3051. Von Albert, H. H., Phenytoin infusion in the treatment of epilepsy, Advances in Epileptology: 14th Epilepsy International Symposium, Parsonage, M, Ed., Raven Press, New York, 307-12, 1983.

3052. Von Demers, H. G., Cardiac therapy in the intensive care unit, Intensivbehandlung, 6(1): 28-33, 1981.

3053. Wada, A., Izumi, F., Yanagihara, N., Kobayashi, H., Modulation by ouabain and diphenylhydantoin of veratridine-induced 22 Na influx and its relation to 46 Ca influx and the secretion of catecholamines in cultured bovine adrenal medullary cells, Arch. Pharmacol., 328(3): 273-8, 1985.

3054. Wagner, J. H., Another report of nonconvulsive status epilepticus after metrizamide myelography, Ann. Neurol., 18(3): 369-70, 1985.

3055. Wald, R. W., Waxman, M. B., Downar, E., The effect of antiarrhythmic drugs on depressed conduction and undirectional block in sheep Purkinje fibers, Circ. Res., 46: 612-9, 1980.

3056. Wallin, B. G., Westerberg, C. E., Sundlof, C., Syncope induced by glossopharyngeal neuralgia: sympathetic outflow to muscle, Neurology, 34: 522-4, 1984.

3057. Walsh, J. C., Neuromyotonia: an unusual presentation of intrathoracic malignancy, J. Neurol. Neurosurg. Psychiatr., 39: 1086-91, 1976.

3058. Wang., B. J., Chang, Y. C., Therapeutic blood levels of phenytoin in treatment of paroxysmal choreaoathetosis, Ther. Drug. Monit., 7(l): 81-2, 1985.

3059. Wang, S. T., Peter, F., The Abbott TDx fluorescence polarization immunoassay and liquid chromatography compared for five anticonvulsant drug serum, Clin. Chem., 31(3): 493-4, 1985.

3060. Wasserman, T. H., Stetz, J., Phillips, T. L., Radiation therapy oncology group clinical trials with misonidazole, Cancer, 47: 2382-90, 1981.

3061. Wasserstrom, J. A., Ferrier, C. R., Effects of phenytoin on digitalis oscillatory after potentials, aftercontractions, and inotropy, Fed. Proc., 39: 1001, 1980.

3062. Wasserstrom, J. A., Ferrier, G. B., Effects of phenytoin and quinidine on digitalis-induced oscillatory afterpotentials, aftercontractions, and inotropy in canine ventricular tissues, Mol. Cell. Cardiol.., 14: 725-36, 1982.

3063. Watanabe, A. M., Bailey, J. C., The role of the autonomic central nervous system in mediating and modifying the action of cardiac antiarrhythmic drugs, Ann. N.Y. Acad. Sci., 432: 90-102, 1984.

3064. Wehrmann, W., Reichl, W., Bauer, R., Phenytoin treatment in hereditary bollous epidermolysis, Therapiewoche, 34(39): 5571-5, 1984.

3065. Weidauer, H., Feurie, G. E., Baldauf, G., Anton-Larnprecht, I., Therapy of esophageal stenoses in recessive epidermolysis bullosa dystrophies, Laryngol. Rhinol. Otol., 64: 5526,1985.

3066. Wellens, H. J., Brugada, P., Abdollah, H., Drug therapy of patients with arrhythmias associated with bypass tracts, Clinical Pharmacology of Cardiac Antiarrhythmic Agents: Classical and Current Concepts Reevaluated, Garfein, O. B., Ed., Ann. New York Academy of Science, 432: 272-8, 1984.

3067. Westveer, D. C., Gadowski, C. A., Gordon, S., Timmis, G. C., Amiodarone-induced ventricular tachycardia, Ann. Intern. Med., 97(4): 561-2, 1982.

3068. White, B. C., Penry, J. K., Bracket, C. F., Lisco, M., Art, D., Nemore, J., Mann, T., Mumaw, L., Whitley, L., Study on pharmacological prophylaxis of posttraumatic epilepsy in severely head injured patients utilizing therapeutic serum levels of antiepileptic drugs. NINCDS, Bethesda, Md. & Kansas Univ. Med, Center, Ka., 1982.

3069. White, H. S., Chen, C. F., Kemp, J. W., Woodbury, D. M., Effects of acute and chronic phenytoin on the electrolyte content and the activities of NA+, K+-, Ca2+, Mg2+-, and HCO3- - ATPases and carbonic anhydrase of neonatal and adult rat cerebral cortex, Epilepsia, 26(l): 43-57, 1985.

3070. White, H. S., Yen-Chow, Y. C., Chow, S. Y., Kemp, W., Woodbury, D. M., Effects of phenytoin on primary glial cell cultures, Epilepsia, 26(l): 58-68, 1985.

3071. White, J. C., Sweet, W. H., Trigeminal Neurolgia Tic Douloureux Pain and the Neurosurgeon. A Forty-year Experience, Charles C. Thomas, Springfield, 1969.

3072. Willow, M., Pharmacology of diphenylhydantoin and carbamazepine action on voltage-sensitive sodium channels, Trends in Neurosciences, 147-9, 1986.

3073. Willow, M., Gonoi, T., Catterall, W. A., Voltage clamp analysis of the inhibitory actions of diphenylhydantoin and carbamazepine on voltage-sensitive sodium channels in neuroblastoma cells, Mol. Pharmacol., 27(5): 549-58, 1985.

3074. Wilson, J. F., Marshall, R. W., Williams, J., Richens, A., Comparison of assay methods used to measure antiepileptic drugs in plasma, Ther. Drug. Monit., 5(4): 449-60, 1983.

3075. Wirth, H., Nesch, A., Ostapowicz, B., Anton-Lamprecht, I., Phenytoin therapy of recessive dystrophic epidermolysis bullosa hallopeau siemens and epidermolysis bullosa inversa, Z. Hautkr., 58(8): 555-74, 1983.

3076. Wit, A. L., Hoffman, B. F., Modification of the cardiac action potential by pharmacologic agents, Cell Pharmacol. Excitbl. Tiss., 408-84, 1975.

3077. Witchitz, S., Giudicelli, J. F., Diphenylhydantoin, International Symposium on Diagnosis and Treatment of Cardiac Arrhythmias, Bayes A., and Cosin, J., Eds., Pergamon Press, New York, 871-7,1980.

3078. Wohns, N. W., Colpitts, M., Clement, T., Karuza, A., Blackett, W. B., Foutch, R., Larson, E., Phenytoin and acute mountain sickness on Mount Everest, Am. J. Med., 80: 32-36, 1986.

3079. Wolf, P., Influence of the anti-epileptic drugs on sleep, 16th Epilepsy Congress, Abstracts, Hamburg, Ciba-Geigy, 1985.

3080. Wolf, P., Roder-Wanner, U. U., Brede, M., Influence of therapeutic phenobarbital and phenytoin medication on the polygraphic sleep of patients with epilepsy, Epilepsia, 25(4); 467-75, 1984.

3081. Woodbury, D. M., Metabolites and the mechanisms of action of antiepileptic drugs, Advances in Epileptology, Meinardi, H., Rowan, A. J., Eds., Swets & Zeitlinger, Amsterdam, 134-50, 1978.

3082. Woodbury, D. M., Antiepileptic drugs—phenytoin: introduction and history, Antiepileptic Drugs—Mechanisms of Action, Glaser, G. H., Penry, J. K., Woodbury, D. M., Eds., Raven Press, New York, 305-13, 1980.

3083. Woodbury, D. M., Phenytoin: Mechanisms of Action, Antiepileptic Drugs, Woodbury, D. M., Penry, J. K., Pippinger, C. E., Eds., Raven Press, New York, 269-81, 1982.

3084. Woodbury, D. M., Engstrom, F. L., White, H. S., Chen, C. F., Kemp, J. W., Chow, S. Y., Ionic and acid-base regulation of neurons and glia during seizures, Ann. Neurol., 16:sl35-sl44, 1984.

3085. Woodbury, D. M., Kemp, J. W., Chow, S. Y., Mechanism of action of antiepileptic drugs, Epilepsy, Ward, A. A., et al., Eds., Raven Press, New York, 179-223, 1983.

3086. Woolhouse, N. M., Adjepon-Yamoah, K. K., Critchley, A., Prescott, L. F., Reduced capacity for diphenylhydantoin hydroxylation in Ghanaians, Br. J. Clin. Pharmacol. 18(2): 287p-8p, 1984.

3087. Woscoff, A., Paz, A., Abulafia, J., Jaimovich, L., Grinspan, D., Dystrophic epidermolysis bullosa. Urogenital manifestation and phenytoin treatment, Med. Cutan. lber. Lat. Am., 12(2): 129-35, 1984.

3088. Yaari, Y., Carbone, E., Phenytoin reduces the number of Na channel openings in inside-out patches of avian sensory neurons, Pflugers. Arch., 405 (sup 2): 47, 1985.

3089. Yaari, Y., David, G., Selzer, M. E., Use- and frequency-dependent depression of nerve action potentials by phenytoin, Personal Communication, 1985.

3090. Yaari, Y., Devor, M., Phenytoin suppresses spontaneous ectopic discharge in rat sciatic nerve neuromas, Neurosci. Lett., 58(1): 117-22, 1985.

3091. Yaari, Y., Pincus, J. H., Argov, Z., Depression of synaptic transmission by diphenylhydantoin, Ann. Neurol., 1: 334-8,1977.

3092. Yaari, Y., Selzer, M. E., David, G., Frequency-dependent effects of phenytoin on frog junctional transmission, Brain Res., 345(1): 102-110, 1985.

3093. Yaari, Y., Selzer, M. E., Pincus, J. H., Phenytoin: mechanisms of its anticonvulsant action, Ann. Neurol., 20: 171-84, 1986.

3094. Yatani, A., Hamilton, S. L., Brown, A. M., Diphenylhydantoin blocks cardiac calcium channels and binds to the dihydropyridine receptor, Circ. Res., 59: 356-61, 1986.

3095. Yi, S. J., Seitz, P. K., Cooper, C. W., Inhibition of in vitro secretion of rat calcitonin by phenytoin, Fed. Proc, 46(3): 393, 1987.

3096. Young, H. C., Becker, D. P., Treatment of tic douloureux: current concepts, Va. Med., 108: 718-20,1981.

3097. Younger, L. E., Silverman, H., Chronic phenytoin administration alters the metabolic profile of superficial gastrocnemius muscle fibers in dystrophic mice, Exp. Neurol., 84: 140-52,1984.

3098. Zacchetti, O., Sozzi, G., Zarnpollo, A., Paroxysmal kinesigenic choreoathetosis. Case report, ltal. J. Neurol. Sci., 3: 345-7, 1983.

3099. Zimmer, J. P., Lehr, H. A., Kornhuber, M. E., Breitig, D., Montagnier, L., Gietzeri, K., Diphenylhydantoin (DPH) blocks HIV-receptor on lymphocyte surface, Blut, 53: 447-50, 1986.

3100. Zisfein, J., Sivak, M., Aron, A. M., Bender, A. N., Isaac’s syndrome with muscle hypertrophy reversed by phenytoin therapy, Arch. Neurol., 40: 241-2, 1983.